| 1 |
Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol 2023;11:480-9. [PMID: 36643046 DOI: 10.14218/JCTH.2022.00293] [Reference Citation Analysis]
|
| 2 |
Coffman-D'Annibale KL, Greten TF. Top advances of the year: Hepatobiliary cancers. Cancer 2023;129:1149-55. [PMID: 36692965 DOI: 10.1002/cncr.34652] [Reference Citation Analysis]
|
| 3 |
Da Fonseca LG, Uratani LF, Soares GF, Do Amaral PS, De Souza Melo Alencar RS, Chagas AL, Alves VAF, Carrilho FJ. Early variation of inflammatory indexes refines prognostic prediction in patients with hepatocellular carcinoma under systemic treatment. Mol Clin Oncol 2023;18:29. [PMID: 36908977 DOI: 10.3892/mco.2023.2625] [Reference Citation Analysis]
|
| 4 |
Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, Sun L, Liu Y, Du Y, Guo X, Cui T, Zhou H, Wang J, Yin D, Song R, Zhang S, Cai W, Meng F, Guo H, Zhang B, Yang D, Bao R, Hu Q, Wang J, Ye Y, Liu L. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 2023;78:770-82. [PMID: 36708811 DOI: 10.1016/j.jhep.2023.01.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Wei AC. Practice-Changing Evidence in Surgical Oncology 2021: Hepatobiliary Articles. Ann Surg Oncol 2023;30:1960-5. [PMID: 36745257 DOI: 10.1245/s10434-023-13132-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Wang CC, Kao JH. Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Hepatology 2023;77:E82-3. [PMID: 36626618 DOI: 10.1097/HEP.0000000000000009] [Reference Citation Analysis]
|
| 7 |
Jia J, Luo J, Zou B, Feng M, Liu L, Yu S, Zheng S, Yu J. Non-iatrogenic implantation of cutaneous metastasis from hepatocellular carcinoma. J Cancer Res Clin Oncol 2023;149:1513-9. [PMID: 35536361 DOI: 10.1007/s00432-022-04030-0] [Reference Citation Analysis]
|
| 8 |
Cabibbo G, Celsa C, Alimenti E, Iavarone M. Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon. Hepatology 2023;77:1074-7. [PMID: 36626617 DOI: 10.1097/HEP.0000000000000205] [Reference Citation Analysis]
|
| 9 |
El Hajra I, Sanduzzi-Zamparelli M, Sapena V, Muñoz-Martínez S, Mauro E, Llarch N, Iserte G, Forner A, Rios J, Bruix J, Reig M. Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis. Hepatology 2023;77:1139-49. [PMID: 36632997 DOI: 10.1097/HEP.0000000000000030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Yang Y, Chen D, Zhao B, Ren L, Huang R, Feng B, Chen H. The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis. Cancer Med 2023. [PMID: 36965092 DOI: 10.1002/cam4.5676] [Reference Citation Analysis]
|
| 11 |
Legros L, Pascale A, Guettier C, Eftekhari P, Merabet YB, Stang M, Bossevot R, Goldschmidt E, Ulusakarya A, Morisset S, Lewin M, Samuel D, Rosmorduc O. Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2023. [PMID: 36961524 DOI: 10.1007/s00280-023-04519-6] [Reference Citation Analysis]
|
| 12 |
Ippolito D, Maino C, Gatti M, Marra P, Faletti R, Cortese F, Inchingolo R, Sironi S. Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy. World J Gastroenterol 2023; 29(11): 1669-1684 [DOI: 10.3748/wjg.v29.i11.1669] [Reference Citation Analysis]
|
| 13 |
Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. J Clin Oncol 2023;41:1747-57. [PMID: 36512738 DOI: 10.1200/JCO.22.00972] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Yu SJ. Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. Pharmacol Ther 2023;:108387. [PMID: 36948423 DOI: 10.1016/j.pharmthera.2023.108387] [Reference Citation Analysis]
|
| 15 |
Chen Y, Hong H, Fang W, Zhang X, Luo H, Chen Z, Yu J, Fan W, Chi X, Peng Y. Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1113389] [Reference Citation Analysis]
|
| 16 |
van den Heuvel R. IMbrave 151 missed primary endpoint in advanced BTC. Medicom Conference Report ASCO GI 2023 2023. [DOI: 10.55788/f37566dc] [Reference Citation Analysis]
|
| 17 |
Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS, Friedman SL. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol 2023. [PMID: 36932227 DOI: 10.1038/s41575-023-00754-7] [Reference Citation Analysis]
|
| 18 |
Yu S, Zhang S, Xu H, Yang G, Xu F, Yang L, Chen D, An G, Wang Y. Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis. BMJ Open 2023;13:e059457. [PMID: 36931679 DOI: 10.1136/bmjopen-2021-059457] [Reference Citation Analysis]
|
| 19 |
Metwalli ZA, Davis RM, Tewari SO. Drug-Eluting Microspheres and Hepatocellular Carcinoma: Improving Outcomes Related to Drug or Better Practice? Cardiovasc Intervent Radiol 2023. [PMID: 36930286 DOI: 10.1007/s00270-023-03409-x] [Reference Citation Analysis]
|
| 20 |
Assaf ZJF, Zou W, Fine AD, Socinski MA, Young A, Lipson D, Freidin JF, Kennedy M, Polisecki E, Nishio M, Fabrizio D, Oxnard GR, Cummings C, Rode A, Reck M, Patil NS, Lee M, Shames DS, Schulze K. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med 2023. [PMID: 36928816 DOI: 10.1038/s41591-023-02226-6] [Reference Citation Analysis]
|
| 21 |
Han R, Li J, Hony J, Xiao Z, wang J, Yao M, Liang S, Lu L. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1052657] [Reference Citation Analysis]
|
| 22 |
Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol 2023:S0168-8278(23)00178-2. [PMID: 36933770 DOI: 10.1016/j.jhep.2023.03.003] [Reference Citation Analysis]
|
| 23 |
Ozer M, Goksu SY, Akagunduz B, George A, Sahin I. Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials. Cancers 2023;15:1808. [DOI: 10.3390/cancers15061808] [Reference Citation Analysis]
|
| 24 |
Yin Z, Ma T, Chen S, Yu M. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment. Cancer Biomark 2023. [PMID: 36938723 DOI: 10.3233/CBM-210300] [Reference Citation Analysis]
|
| 25 |
Hatanaka T, Yata Y, Naganuma A, Kakizaki S. Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy. Cancers 2023;15:1798. [DOI: 10.3390/cancers15061798] [Reference Citation Analysis]
|
| 26 |
Zhang L, Feng J, Kuang T, Chai D, Qiu Z, Deng W, Dong K, Zhao K, Wang W. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies. Int Immunopharmacol 2023;118:110019. [PMID: 36933492 DOI: 10.1016/j.intimp.2023.110019] [Reference Citation Analysis]
|
| 27 |
He M, Liu S, Lai Z, Du Z, Li Q, Xu L, Kan A, Shen J, Shi M. Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Curr Opin Pharmacol 2023;70:102362. [PMID: 36931163 DOI: 10.1016/j.coph.2023.102362] [Reference Citation Analysis]
|
| 28 |
Deng M, Li S, Wei W, Guo R. Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut Liver 2023;17:339-40. [PMID: 36789573 DOI: 10.5009/gnl220249] [Reference Citation Analysis]
|
| 29 |
Luo YZ, Zhu H. Immunotherapy for advanced or recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(3): 405-424 [DOI: 10.4251/wjgo.v15.i3.405] [Reference Citation Analysis]
|
| 30 |
Zou Y, Chen Z, Chen Z, Zhang Y, Zheng Z, Wu F, Xu L, Li Q, Lin Y, Shi N, Jin H. Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma. Clin Immunol 2023;:109290. [PMID: 36931486 DOI: 10.1016/j.clim.2023.109290] [Reference Citation Analysis]
|
| 31 |
Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? Target Oncol 2023. [PMID: 36920648 DOI: 10.1007/s11523-023-00953-x] [Reference Citation Analysis]
|
| 32 |
Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1407-1424 [DOI: 10.3748/wjg.v29.i10.1407] [Reference Citation Analysis]
|
| 33 |
Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1551-1568 [DOI: 10.3748/wjg.v29.i10.1551] [Reference Citation Analysis]
|
| 34 |
Chami P, Jarnagin W, Abou-alfa GK, Harding J, Kim N, Lin H, El Homsi M, Crane C, Hajj C. Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma. Cancers 2023;15:1748. [DOI: 10.3390/cancers15061748] [Reference Citation Analysis]
|
| 35 |
Wang Z, Pan B, Qiu J, Zhang X, Ke X, Shen S, Wu X, Yao Y, Tang N. SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape. Sci Signal 2023;16:eabq3362. [PMID: 36917642 DOI: 10.1126/scisignal.abq3362] [Reference Citation Analysis]
|
| 36 |
Mahmood S, Li D, Lee A, Rowe J, Beg M, Kasturi V, Iyer R, Abrams T, Dayyani F. A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). Future Oncol 2023. [PMID: 36912078 DOI: 10.2217/fon-2022-0844] [Reference Citation Analysis]
|
| 37 |
Yang M, Pan Y, Wang W. Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis. BMC Cancer 2023;23:236. [PMID: 36915049 DOI: 10.1186/s12885-023-10686-9] [Reference Citation Analysis]
|
| 38 |
Laumont CM, Nelson BH. B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 2023;41:466-89. [PMID: 36917951 DOI: 10.1016/j.ccell.2023.02.017] [Reference Citation Analysis]
|
| 39 |
Tang M, Li W, Li J, Lv J, Chen F, Zhu J, Liu P. Analysis of factors influencing the distribution of 131-I in combined treatment of Licartin with transcatheter arterial chemoembolization in primary hepatic carcinoma. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.993948] [Reference Citation Analysis]
|
| 40 |
Farasati Far B, Rabie D, Hemati P, Fooladpanjeh P, Faal Hamedanchi N, Broomand Lomer N, Karimi Rouzbahani A, Naimi-jamal MR. Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. Livers 2023;3:121-160. [DOI: 10.3390/livers3010011] [Reference Citation Analysis]
|
| 41 |
Ding L, Wang N, Wang Q, Fan X, Xin Y, Wang S. Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration. Cell Death Discov 2023;9:92. [PMID: 36906597 DOI: 10.1038/s41420-023-01392-3] [Reference Citation Analysis]
|
| 42 |
Kanogawa N, Ogasawara S, Maruta S, Iino Y, Obu M, Ishino T, Ogawa K, Yumita S, Iwanaga T, Unozawa H, Nakagawa M, Fujiwara K, Sakuma T, Fujita N, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Inoue M, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Koma Y, Azemoto R, Kato J, Kato N. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma. BMC Gastroenterol 2023;23:70. [PMID: 36906542 DOI: 10.1186/s12876-023-02674-x] [Reference Citation Analysis]
|
| 43 |
Xie M, Lin Z, Ji X, Luo X, Zhang Z, Sun M, Chen X, Zhang B, Liang H, Liu D, Feng Y, Wang Y, Li Y, Liu B, Huang W, Xia L. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol 2023:S0168-8278(23)00172-1. [PMID: 36907560 DOI: 10.1016/j.jhep.2023.02.036] [Reference Citation Analysis]
|
| 44 |
Xu L, Zhang S, Feng J, Tan D, Sun H, Guo H. ncRNAs-mediated overexpression of STIL predict unfavorable prognosis and correlated with the efficacy of immunotherapy of hepatocellular carcinoma. Cancer Cell Int 2023;23:44. [PMID: 36899391 DOI: 10.1186/s12935-023-02869-y] [Reference Citation Analysis]
|
| 45 |
Girardi DM, Sousa LP, Miranda TA, Haum FNC, Pereira GCB, Pereira AAL. Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. Cancers 2023;15:1680. [DOI: 10.3390/cancers15061680] [Reference Citation Analysis]
|
| 46 |
Yuanren G, Yin L, Liu R, Cui Y. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1054072] [Reference Citation Analysis]
|
| 47 |
Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol 2023;:175586. [PMID: 36906141 DOI: 10.1016/j.ejphar.2023.175586] [Reference Citation Analysis]
|
| 48 |
Fu Y, Peng W, Zhang W, Yang Z, Hu Z, Pang Y, Hu D, Chen J, Wang J, Zhou Z, Xu L, Chen M, Zhang Y. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol 2023. [PMID: 36894804 DOI: 10.1007/s00535-023-01976-x] [Reference Citation Analysis]
|
| 49 |
Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K, Kogure T, Yumita S, Ishino T, Ogawa K, Iwanaga T, Nakagawa M, Fujiwara K, Kojima R, Koroki K, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Kato J, Kato N. Exploration of new positions for cabozantinib for advanced hepatocellular carcinoma in the latest real-world practice.. [DOI: 10.21203/rs.3.rs-2655181/v1] [Reference Citation Analysis]
|
| 50 |
Xiao L, Liao Y, Wang J, Li Q, Zhu H, Hong C, Li R, He J, Cui H, Dong H, Zeng L, Liu L. Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study. Cancer Immunol Immunother 2023. [PMID: 36884079 DOI: 10.1007/s00262-023-03417-3] [Reference Citation Analysis]
|
| 51 |
Giovannini C, Suzzi F, Tovoli F, Bruccoleri M, Marseglia M, Alimenti E, Fornari F, Iavarone M, Piscaglia F, Gramantieri L. Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma. Cancers 2023;15:1661. [DOI: 10.3390/cancers15061661] [Reference Citation Analysis]
|
| 52 |
Zhang J, Hu C, Xie X, Qi L, Li C, Li S. Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. Vaccines 2023;11:614. [DOI: 10.3390/vaccines11030614] [Reference Citation Analysis]
|
| 53 |
Yen Y, Kuo F, Eng H, Liu Y, Lin C, Yong C, Li W, Wang C, Lin C. Tumor necrosis as a predictor of early tumor recurrence after liver resection in patients with hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2649058/v1] [Reference Citation Analysis]
|
| 54 |
Jost-Brinkmann F, Demir M, Wree A, Luedde T, Loosen SH, Müller T, Tacke F, Roderburg C, Mohr R. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort. Aliment Pharmacol Ther 2023. [PMID: 36883351 DOI: 10.1111/apt.17441] [Reference Citation Analysis]
|
| 55 |
Yahoo N, Dudek M, Knolle P, Heikenwälder M. Role of immune responses for development of NAFLD-associated liver cancer and prospects for therapeutic modulation. J Hepatol 2023:S0168-8278(23)00165-4. [PMID: 36893854 DOI: 10.1016/j.jhep.2023.02.033] [Reference Citation Analysis]
|
| 56 |
Lee SK, Choi JY, Jung ES, Kwon JH, Jang JW, Bae SH, Yoon SK. An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. Int J Mol Sci 2023;24. [PMID: 36902432 DOI: 10.3390/ijms24055002] [Reference Citation Analysis]
|
| 57 |
Qiu Z, Yu C, Qiu X, Li Q, Li J, Chen Z, Chang S, Zhang S, Fan G, Wang S. Safety and Efficacy of CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma. Acad Radiol 2023:S1076-6332(23)00063-6. [PMID: 36882354 DOI: 10.1016/j.acra.2023.02.006] [Reference Citation Analysis]
|
| 58 |
Scagliola A, Miluzio A, Biffo S. Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36902316 DOI: 10.3390/ijms24054885] [Reference Citation Analysis]
|
| 59 |
Tokunaga T, Tateyama M, Kondo Y, Miuma S, Miyase S, Tanaka K, Narahara S, Inada H, Kurano S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Fukubayashi K, Tanaka M, Tanaka Y. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36900359 DOI: 10.3390/cancers15051568] [Reference Citation Analysis]
|
| 60 |
Wong JK, Lim HJ, Tam VC, Burak KW, Dawson LA, Chaudhury P, Abraham RJ, Meyers BM, Sapisochin G, Valenti D, Samimi S, Ramjeesingh R, Mujoomdar A, Martins I, Dixon E, Segedi M, Liu DM. Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treat Rev 2023;115:102526. [PMID: 36924644 DOI: 10.1016/j.ctrv.2023.102526] [Reference Citation Analysis]
|
| 61 |
Brown TJ, Mamtani R, Gimotty PA, Karasic TB, Yang YX. Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. J Cancer Res Clin Oncol 2023. [PMID: 36862158 DOI: 10.1007/s00432-023-04590-9] [Reference Citation Analysis]
|
| 62 |
Hofmann I, Baum A, Hofmann MH, Trapani F, Reichel-Voda C, Ehrensperger D, Aichinger M, Ebner F, Budano N, Schweifer N, Sykora M, Depla E, Boucneau J, Gschwind A, Kraut N, Hilberg F, Künkele KP. Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition. J Pharmacol Exp Ther 2023;384:331-42. [PMID: 36241203 DOI: 10.1124/jpet.122.001255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 63 |
Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Mohamed YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver Int 2023;43:695-707. [PMID: 36577703 DOI: 10.1111/liv.15502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 64 |
Chan CY, Yuen VW, Chiu DK, Goh CC, Thu KL, Cescon DW, Soria-Bretones I, Law CT, Cheu JW, Lee D, Tse AP, Tan KV, Zhang MS, Wong BP, Wong CM, Khong PL, Ng IO, Bray MR, Mak TW, Yau TC, Wong CC. Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity. Hepatology 2023;77:729-44. [PMID: 35302667 DOI: 10.1002/hep.32461] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 65 |
Provencio M, Ortega AL, Coves-Sarto J, Calvo V, Marsé-Fabregat R, Dómine M, Guirado M, Carcereny E, Fernández N, Álvarez R, Blanco R, León-Mateos L, Sánchez-Torres JM, Sullivan IG, Cobo M, Sánchez-Hernández A, Massuti B, Sierra-Rodero B, Mártinez-Toledo C, Serna-Blasco R, Romero A, Cruz-Bermúdez A. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncol 2023;9:344-53. [PMID: 36520426 DOI: 10.1001/jamaoncol.2022.5959] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 66 |
Chen YL, Hsieh CC, Chu PM, Chen JY, Huang YC, Chen CY. Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review). Oncol Rep 2023;49:48. [PMID: 36660927 DOI: 10.3892/or.2023.8485] [Reference Citation Analysis]
|
| 67 |
Allignet B, Pradat P, Mornex F, Izarn F, Rode A, Mabrut JY, Mohkam K, Merle P. Surgical resection versus transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma. Strahlenther Onkol 2023;199:293-303. [PMID: 36441171 DOI: 10.1007/s00066-022-02022-0] [Reference Citation Analysis]
|
| 68 |
Agarwal PD, Lucey MR, Said A, Kratz J. Immunotherapy for HCC: limitations in patients with NASH. Ann Hepatol 2023;28:100886. [PMID: 36925208 DOI: 10.1016/j.aohep.2022.100886] [Reference Citation Analysis]
|
| 69 |
Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, Meng Z, Bai Y, Chen X, Liu X, Xiao J, Ho GF, Mao Y, Wang X, Ying J, Li J, Zhong W, Zhou Y, Siegel AB, Hao C. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2023;41:1434-43. [PMID: 36455168 DOI: 10.1200/JCO.22.00620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 70 |
Akce M, El-Rayes BF, Wajapeyee N. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. Oncogene 2023. [PMID: 36854723 DOI: 10.1038/s41388-023-02646-1] [Reference Citation Analysis]
|
| 71 |
Wheless M, Das S. Systemic Therapy for Pancreatic Neuroendocrine Tumors. Clin Colorectal Cancer 2023;22:34-44. [PMID: 36114085 DOI: 10.1016/j.clcc.2022.08.003] [Reference Citation Analysis]
|
| 72 |
Wang XH, Liu CJ, Wen HQ, Duan XH, Jiao YQ, Liu YJ, Chen MS, Zhu KS, Mao XH, Zhou QF. Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. Clin Transl Med 2023;13:e1214. [PMID: 36855781 DOI: 10.1002/ctm2.1214] [Reference Citation Analysis]
|
| 73 |
Roth GS, Villeret F, Decaens T, Merle P, Nahon P. Immunotherapy in hepatocellular carcinoma: How does underlying liver disease influence therapeutic strategy and outcomes? Liver Int 2023;43:546-57. [PMID: 36571256 DOI: 10.1111/liv.15504] [Reference Citation Analysis]
|
| 74 |
Komatsu S, Ueshima K, Kido M, Kuramitsu K, Tsugawa D, Yanagimoto H, Toyama H, Ku Y, Kudo M, Fukumoto T. Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi-institutional propensity-matched cohort study. J Hepatobiliary Pancreat Sci 2023;30:303-14. [PMID: 36047804 DOI: 10.1002/jhbp.1236] [Reference Citation Analysis]
|
| 75 |
Stefanini B, Ielasi L, Chen R, Abbati C, Tonnini M, Tovoli F, Granito A. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 2023;23:279-91. [PMID: 36794716 DOI: 10.1080/14737140.2023.2181162] [Reference Citation Analysis]
|
| 76 |
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study. Cancer Med 2023;12:5293-303. [PMID: 36226511 DOI: 10.1002/cam4.5337] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 77 |
Thabut D, Kudo M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. J Hepatol 2023;78:658-62. [PMID: 36460163 DOI: 10.1016/j.jhep.2022.11.019] [Reference Citation Analysis]
|
| 78 |
Wen W, Zhang Y, Zhang H, Chen Y. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2023;149:969-978. [DOI: 10.1007/s00432-022-04057-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 79 |
Cramer T. Impact of dietary carbohydrate restriction on the pathobiology of Hepatocellular Carcinoma: The gut-liver axis and beyond. Semin Immunol 2023;66:101736. [PMID: 36857893 DOI: 10.1016/j.smim.2023.101736] [Reference Citation Analysis]
|
| 80 |
Kawashima S, Togashi Y. Resistance to immune checkpoint inhibitors and the tumor microenvironment. Exp Dermatol 2023;32:240-9. [PMID: 36437644 DOI: 10.1111/exd.14716] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 81 |
Tomonari T, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Kawano Y, Okamoto K, Miyamoto H, Sato Y, Takayama T. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments. Clin J Gastroenterol 2023. [PMID: 36856957 DOI: 10.1007/s12328-023-01777-y] [Reference Citation Analysis]
|
| 82 |
Lin ZZ, Hu MC, Hsu C, Wu YM, Lu YS, Ho JA, Yeh SH, Chen PJ, Cheng AL. Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Cancer Lett 2023;556:216063. [PMID: 36669725 DOI: 10.1016/j.canlet.2023.216063] [Reference Citation Analysis]
|
| 83 |
Rho S, Wang C, Hosseini Dehkordi SH, Sears JJ, Hu ZI. Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications. American Heart Journal Plus: Cardiology Research and Practice 2023;27:100283. [DOI: 10.1016/j.ahjo.2023.100283] [Reference Citation Analysis]
|
| 84 |
Zhang P, Wang T, Liu H, She X, Chen K, Zhao Y, Ming Y. Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review. iLIVER 2023. [DOI: 10.1016/j.iliver.2023.03.001] [Reference Citation Analysis]
|
| 85 |
Wächter S, Knauff F, Roth S, Keber C, Holzer K, Manoharan J, Maurer E, Bartsch DK, Di Fazio P. Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma. Cancer Invest 2023;:1-17. [PMID: 36811581 DOI: 10.1080/07357907.2023.2183027] [Reference Citation Analysis]
|
| 86 |
Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 2023;22:213-34. [PMID: 36509911 DOI: 10.1038/s41573-022-00615-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 87 |
Cabibbo G, Edeline J. The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma. Liver Int 2023;43:528-30. [PMID: 36808694 DOI: 10.1111/liv.15513] [Reference Citation Analysis]
|
| 88 |
Gao X, Xu M, Wang H, Xia Z, Sun H, Liu M, Zhao S, Yang F, Niu Z, Gao H, Zhu H, Lu J, Zhou X. Development and validation of a mitochondrial energy metabolism-related risk model in hepatocellular carcinoma. Gene 2023;855:147133. [PMID: 36565797 DOI: 10.1016/j.gene.2022.147133] [Reference Citation Analysis]
|
| 89 |
Guven DC, Yildirim HC, Chalabiyev E, Kus F, Yilmaz F, Yasar S, Akyildiz A, Aktas BY, Yalcin S, Dizdar O. Emerging treatment strategies in hepatobiliary cancer. Expert Rev Anticancer Ther 2023;23:243-56. [PMID: 36803258 DOI: 10.1080/14737140.2023.2183844] [Reference Citation Analysis]
|
| 90 |
Campani C, Bamba-Funck J, Campion B, Sidali S, Blaise L, Ganne-Carrié N, Demory A, Sutter O, Larrey E, Evain M, Ghannouchi H, Wagner M, Marra F, Sutton A, Allaire M, Nault JC. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab. Liver Int 2023;43:708-17. [PMID: 36444741 DOI: 10.1111/liv.15487] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 91 |
Zhou C, Weng J, Liu C, Liu S, Hu Z, Xie X, Gao D, Zhou Q, Sun J, Xu R, Li H, Shen Y, Yi Y, Shi Y, Sheng X, Dong Q, Hung MC, Ren N. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma. Gastroenterology 2023:S0016-5085(23)00137-3. [PMID: 36863689 DOI: 10.1053/j.gastro.2023.02.005] [Reference Citation Analysis]
|
| 92 |
Wang Z, Wang Y, Gao P, Ding J. Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Lett 2023;555:216038. [PMID: 36529238 DOI: 10.1016/j.canlet.2022.216038] [Reference Citation Analysis]
|
| 93 |
Tang C, He Q, Feng J, Liao Z, Peng Y, Gao J. Portal vein tumor thrombus radiotherapy improves the outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: A multicenter real-world research of southwest China.. [DOI: 10.21203/rs.3.rs-2604867/v1] [Reference Citation Analysis]
|
| 94 |
Ielasi L, Tovoli F, Tonnini M, Stefanini B, Tortora R, Magini G, Sacco R, Pressiani T, Trevisani F, Garajová I, Piscaglia F, Granito A. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36900314 DOI: 10.3390/cancers15051523] [Reference Citation Analysis]
|
| 95 |
Mitsuhashi A, Koyama K, Ogino H, Afroj T, Nguyen NT, Yoneda H, Otsuka K, Sugimoto M, Kondoh O, Nokihara H, Hanibuchi M, Takizawa H, Shinohara T, Nishioka Y. Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. Cell Rep 2023;:112162. [PMID: 36870329 DOI: 10.1016/j.celrep.2023.112162] [Reference Citation Analysis]
|
| 96 |
Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment. Cancers (Basel) 2023;15. [PMID: 36900262 DOI: 10.3390/cancers15051470] [Reference Citation Analysis]
|
| 97 |
Yamauchi Y, Saeki I, Yamasaki T, Egusa M, Nishiyama N, Fujioka T, Kawamoto D, Nishimura T, Tanabe N, Oono T, Matsumoto T, Ishikawa T, Marumoto Y, Matsukuma S, Shindo Y, Tokumitsu Y, Yoshimine S, Murakami J, Tanaka T, Kimura S, Hoshii Y, Hamano K, Nagano H, Takami T. Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Hepatol Res 2023. [PMID: 36826420 DOI: 10.1111/hepr.13894] [Reference Citation Analysis]
|
| 98 |
Ye J, Wu J, Liu B. Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy. Biochim Biophys Acta Rev Cancer 2023;1878:188866. [PMID: 36842765 DOI: 10.1016/j.bbcan.2023.188866] [Reference Citation Analysis]
|
| 99 |
Ren Z, Zhang J, Zheng D, Luo Y, Song Z, Chen F, Li A, Liu X. Identification of Prognosis-Related Oxidative Stress Model with Immunosuppression in HCC. Biomedicines 2023;11:695. [DOI: 10.3390/biomedicines11030695] [Reference Citation Analysis]
|
| 100 |
Suzuki H, Iwamoto H, Seki T, Nakamura T, Masuda A, Sakaue T, Tanaka T, Imamura Y, Niizeki T, Nakano M, Shimose S, Shirono T, Noda Y, Kamachi N, Sakai M, Morita K, Nakayama M, Yoshizumi T, Kuromatsu R, Yano H, Cao Y, Koga H, Torimura T. Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors. Cancer Commun (Lond) 2023. [PMID: 36825684 DOI: 10.1002/cac2.12411] [Reference Citation Analysis]
|
| 101 |
Zhang F, Bi J, Liao J, Zhong W, Yu M, Lu X, Che J, Chen Z, Xu H, Hu S, Liu Y, Guo S. Molecular phenotypic linkage between N(6)-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. J Cancer Res Clin Oncol 2023. [PMID: 36826593 DOI: 10.1007/s00432-023-04589-2] [Reference Citation Analysis]
|
| 102 |
Tzeng HT, Huang YJ. Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity. Int J Mol Sci 2023;24. [PMID: 36901858 DOI: 10.3390/ijms24054422] [Reference Citation Analysis]
|
| 103 |
Furuichi N, Naganuma A, Kaburagi T, Suzuki Y, Hoshino T, Shibusawa N, Horiguchi S, Hatanaka T, Kakizaki S, Uraoka T. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Clin J Gastroenterol 2023. [PMID: 36821067 DOI: 10.1007/s12328-023-01775-0] [Reference Citation Analysis]
|
| 104 |
Chen K, Wu Y, Fan Q, Wang Y, Zhang X, Shi R, Chen C, Xia Z, Wu Y, Xia Y, Xu J, Zhao H. Molecular characterization of genes related with angiogenesis, cold- hot tumor, and tumor immunity interactions in patients with TACE resistance in hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2603521/v1] [Reference Citation Analysis]
|
| 105 |
D'Alessio A, Cammarota A, Rimassa L. Network meta-analysis: A map to navigate the maze of treatment for advanced hepatocellular carcinoma. Eur J Intern Med 2023:S0953-6205(23)00055-9. [PMID: 36828743 DOI: 10.1016/j.ejim.2023.02.015] [Reference Citation Analysis]
|
| 106 |
Su H, Liu Y, Huang J. Ferroptosis-Related Gene SLC1A5 Is a Novel Prognostic Biomarker and Correlates with Immune Microenvironment in HBV-Related HCC. J Clin Med 2023;12. [PMID: 36902506 DOI: 10.3390/jcm12051715] [Reference Citation Analysis]
|
| 107 |
Wu B, Shi X, Jiang M, Liu H. Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Mol Cancer 2023;22:38. [PMID: 36810098 DOI: 10.1186/s12943-023-01748-4] [Reference Citation Analysis]
|
| 108 |
Singal AG, Kudo M, Bruix J. Breakthroughs in Hepatocellular Carcinoma Therapies. Clin Gastroenterol Hepatol 2023:S1542-3565(23)00106-4. [PMID: 36813012 DOI: 10.1016/j.cgh.2023.01.039] [Reference Citation Analysis]
|
| 109 |
Fu X, Jiang W, Mu M, Wang G, Qi H, Chen Z, Zuo M, Gao F. Effect of percutaneous stenting strategy of unresectable malignant hilar biliary obstruction by three-dimensional reconstruction volumetry. Cancer Med 2023. [PMID: 36808263 DOI: 10.1002/cam4.5720] [Reference Citation Analysis]
|
| 110 |
Fu Y, Zeng CH, An C, Liu Y, Shin JH, Li X. How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. Cancers (Basel) 2023;15. [PMID: 36831664 DOI: 10.3390/cancers15041324] [Reference Citation Analysis]
|
| 111 |
van Son KC, Verschuren L, Hanemaaijer R, Reeves H, Takkenberg RB, Drenth JPH, Tushuizen ME, Holleboom AG. Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2023;15. [PMID: 36831649 DOI: 10.3390/cancers15041308] [Reference Citation Analysis]
|
| 112 |
Tampaki M, Papatheodoridis GV, Cholongitas E. Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview. Cancers (Basel) 2023;15. [PMID: 36831651 DOI: 10.3390/cancers15041310] [Reference Citation Analysis]
|
| 113 |
Zhang Z, Jiao T, Li J, Hu B, Zhang W, Wang Z, Wan T, Wang Y, Lu S. Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma. World J Surg Oncol 2023;21:53. [PMID: 36803872 DOI: 10.1186/s12957-023-02939-5] [Reference Citation Analysis]
|
| 114 |
Chan KM, Lai Y, Hung HC, Lee JC, Cheng CH, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Wang CT, Chai PM, Lien HY, Lee WC. Significance of Physical Status and Liver Function Reserve for Outcome of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib Treatment. J Hepatocell Carcinoma 2023;10:281-90. [PMID: 36845025 DOI: 10.2147/JHC.S393964] [Reference Citation Analysis]
|
| 115 |
Matsuo Y. Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview. Curr Oncol 2023;30:2493-500. [PMID: 36826151 DOI: 10.3390/curroncol30020190] [Reference Citation Analysis]
|
| 116 |
Hatanaka T, Yata Y, Saito N, Nakano S, Nakano Y, Hazama Y, Yoshida S, Hachisu Y, Tanaka Y, Yoshinaga T, Naganuma A, Kakizaki S. Relationship between Being Overweight and Clinical Outcomes of Ablation Therapy for Hepatocellular Carcinoma under Ultrasound Guidance: A Retrospective Analysis. Cancers (Basel) 2023;15. [PMID: 36831630 DOI: 10.3390/cancers15041289] [Reference Citation Analysis]
|
| 117 |
Merle P, Blanc JF, Edeline J, Le Malicot K, Allaire M, Assenat E, Guarssifi M, Bouattour M, Péron JM, Laurent-Puig P, Levrero M, Costentin C, Guiu B, Sokol H, Tougeron D, Aparicio T, Nault JC, Phelip JM. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. Dig Liver Dis 2023:S1590-8658(23)00191-3. [PMID: 36804053 DOI: 10.1016/j.dld.2023.01.161] [Reference Citation Analysis]
|
| 118 |
Zou X, Xu Q, You R, Yin G. Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. J Hepatocell Carcinoma 2023;10:267-79. [PMID: 36815093 DOI: 10.2147/JHC.S399874] [Reference Citation Analysis]
|
| 119 |
Xu B, Lu D, Liu K, Lv W, Xiao J, Zhang X, Zhang Z, Chai J, Wang L. Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy. Drug Des Devel Ther 2023;17:507-18. [PMID: 36814894 DOI: 10.2147/DDDT.S400533] [Reference Citation Analysis]
|
| 120 |
Ding ZN, Meng GX, Xue JS, Liu H, Yang LS, Li RZ, Mao XC, Yan YC, Wang DX, Dong ZR, Li T. Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis. Crit Rev Oncol Hematol 2023;184:103940. [PMID: 36805079 DOI: 10.1016/j.critrevonc.2023.103940] [Reference Citation Analysis]
|
| 121 |
Shigefuku R, Yoshikawa K, Tsukimoto M, Owa H, Tamai Y, Tameda M, Ogura S, Sugimoto R, Tanaka H, Eguchi A, Sugimoto K, Hasegawa H, Iwasa M, Nakagawa H. Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab. Intern Med 2023;62:539-43. [PMID: 35732454 DOI: 10.2169/internalmedicine.9701-22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 122 |
Avila MA. MicroRNA-223: a key regulator of liver tumour microenvironment. Gut 2023:gutjnl-2022-329322. [PMID: 36792357 DOI: 10.1136/gutjnl-2022-329322] [Reference Citation Analysis]
|
| 123 |
Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, Pawlik TM. Management of Hepatocellular Carcinoma: A Review. JAMA Surg 2023. [PMID: 36790767 DOI: 10.1001/jamasurg.2022.7989] [Reference Citation Analysis]
|
| 124 |
Akkız H. Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36835352 DOI: 10.3390/ijms24043941] [Reference Citation Analysis]
|
| 125 |
Xu MH, Huang C, Li ML, Zhu XD, Tan CJ, Zhou J, Fan J, Sun HC, Shen YH. Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study. Cancer Med 2023. [PMID: 36790032 DOI: 10.1002/cam4.5661] [Reference Citation Analysis]
|
| 126 |
Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kikuchi Y, Kogure T, Yumita S, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Taida T, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Shinozaki M, Kato J, Kato N. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. Cancer 2023;129:590-9. [PMID: 36426410 DOI: 10.1002/cncr.34559] [Reference Citation Analysis]
|
| 127 |
Miyazaki K, Morine Y, Xu C, Nakasu C, Wada Y, Teraoku H, Yamada S, Saito Y, Ikemoto T, Shimada M, Goel A. Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma. Cells 2023;12. [PMID: 36831279 DOI: 10.3390/cells12040612] [Reference Citation Analysis]
|
| 128 |
El-Khobar KE, Sukowati CHC. Updates on Organoid Model for the Study of Liver Cancer. Technol Cancer Res Treat 2023;22:15330338231154090. [PMID: 36788421 DOI: 10.1177/15330338231154090] [Reference Citation Analysis]
|
| 129 |
Solino GA, Ferreira RPCPC, D’albuquerque LAC, Farias AQ, Trindade LZ, Vasconcelos VFD, Pacheco MP. Atezolizumabe mais Bevacizumabe como Ponte para Transplante Hepático no Carcinoma Hepatocelular. BJT 2023;26. [DOI: 10.53855/bjt.v26i1.444_port] [Reference Citation Analysis]
|
| 130 |
Wu YL, van Hyfte G, Özbek U, Reincke M, Gampa A, Mohamed YI, Nishida N, Wietharn B, Amara S, Lee PC, Scheiner B, Balcar L, Pinter M, Vogel A, Weinmann A, Saeed A, Pillai A, Rimassa L, Naqash AR, Muzaffar M, Huang YH, Kaseb AO, Kudo M, Pinato DJ, Ang C. Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Front Oncol 2023;13:1128569. [PMID: 36865801 DOI: 10.3389/fonc.2023.1128569] [Reference Citation Analysis]
|
| 131 |
Zhao XH, Li HL, Guo CY, Yao QJ, Xia WL, Hu HT. Downstaging and Conversation Strategy for Advanced Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus: TACE, (125)I Seed Implantation, and RFA for Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus. J Hepatocell Carcinoma 2023;10:231-40. [PMID: 36819987 DOI: 10.2147/JHC.S392293] [Reference Citation Analysis]
|
| 132 |
Solino GA, Ferreira RPCPC, D’albuquerque LAC, Farias AQ, Trindade LZ, Vasconcelos VFD, Pacheco MP. Atezolizumab plus Bevacizumab as a Bridge for Liver Transplant in Hepatocellular Carcinoma. BJT 2023;26. [DOI: 10.53855/bjt.v26i1.444_eng] [Reference Citation Analysis]
|
| 133 |
Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2023; 29(6): 1054-1075 [DOI: 10.3748/wjg.v29.i6.1054] [Reference Citation Analysis]
|
| 134 |
Sun T, Guo Y, Sun B, Chen L, Ren Y, Zhu L, Zhang L, Liu Y, Zheng C. Association of the Pretreatment Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2083309/v3] [Reference Citation Analysis]
|
| 135 |
Suresh D, Srinivas AN, Prashant A, Harikumar KB, Kumar DP. Therapeutic options in hepatocellular carcinoma: a comprehensive review. Clin Exp Med 2023. [PMID: 36780119 DOI: 10.1007/s10238-023-01014-3] [Reference Citation Analysis]
|
| 136 |
Ielasi L, Stefanini B, Piscaglia F, Granito A, Tovoli F. A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival. Gastroenterology Insights 2023;14:38-44. [DOI: 10.3390/gastroent14010005] [Reference Citation Analysis]
|
| 137 |
Xu Z, Wu Y, Yang M, Wei H, Pu J. CBX2-mediated suppression of SIAH2 triggers WNK1 accumulations to promote glycolysis in hepatocellular carcinoma. Exp Cell Res 2023;426:113513. [PMID: 36780970 DOI: 10.1016/j.yexcr.2023.113513] [Reference Citation Analysis]
|
| 138 |
Shivapurkar N, Gay MD, He AR, Chen W, Golnazar S, Cao H, Duka T, Kallakury B, Vasudevan S, Smith JP. Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36835036 DOI: 10.3390/ijms24043625] [Reference Citation Analysis]
|
| 139 |
Nakamura A, Yamaguchi O, Mori K, Miura K, Tamiya M, Oba T, Yanagitani N, Mizutani H, Ninomiya T, Kajiwara T, Ito K, Miyanaga A, Arai D, Kodama H, Kobayashi K, Kaira K. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). Eur J Cancer 2023;184:62-72. [PMID: 36905770 DOI: 10.1016/j.ejca.2023.01.025] [Reference Citation Analysis]
|
| 140 |
Chen X, Sun M, Feng W, Chen J, Ji X, Xie M, Huang W, Chen X, Zhang B, Nie Y, Fan D, Wu K, Xia L. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. Front Genet 2023;14:1056000. [PMID: 36845390 DOI: 10.3389/fgene.2023.1056000] [Reference Citation Analysis]
|
| 141 |
Gong H, Ong SC, Li F, Zhao K, Weng Z, Jiang Z. Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China.. [DOI: 10.21203/rs.3.rs-2564957/v1] [Reference Citation Analysis]
|
| 142 |
Kohlhepp MS, Liu H, Tacke F, Guillot A. The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer-Challenges and opportunities. Front Mol Biosci 2023;10:1129831. [PMID: 36845555 DOI: 10.3389/fmolb.2023.1129831] [Reference Citation Analysis]
|
| 143 |
Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol 2023;14:1133308. [PMID: 36845131 DOI: 10.3389/fimmu.2023.1133308] [Reference Citation Analysis]
|
| 144 |
He F, Zeng P, Ma S, Yang X, Liu H, Liu Q, Zhou Y, Zhu H. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma. Front Pharmacol 2023;14:1088993. [PMID: 36843949 DOI: 10.3389/fphar.2023.1088993] [Reference Citation Analysis]
|
| 145 |
Di Marco L, Pivetti A, Foschi FG, D'Amico R, Schepis F, Caporali C, Casari F, Lasagni S, Critelli RM, Milosa F, Romanzi A, Marcelli G, De Maria N, Romagnoli D, Catellani B, Scianò F, Magistri P, Colecchia A, Sighinolfi P, Di Benedetto F, Martinez-Chantar ML, Villa E. Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma. Liver Transpl 2023. [PMID: 36747351 DOI: 10.1097/LVT.0000000000000087] [Reference Citation Analysis]
|
| 146 |
Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N, Xue J, Xun Z, Zhang L, Cheng J, Lei J, Sun H, Li Y, Lin J, Xie F, Wang D, Pan J, Hu K, Guan M, Huo L, Shi J, Yu L, Zhou L, Zhou J, Lu Z, Yang X, Mao Y, Sang X, Lu Y, Zhao H. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. Hepatol Int 2023;:1-11. [PMID: 36753026 DOI: 10.1007/s12072-022-10480-y] [Reference Citation Analysis]
|
| 147 |
Gabbia D, De Martin S. Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36834851 DOI: 10.3390/ijms24043441] [Reference Citation Analysis]
|
| 148 |
Morine Y, Saito Y, Yamada S, Teraoku H, Waki Y, Noma T, Ikemoto T, Shimada M. Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage hepatocellular carcinoma. Hepatol Res 2023. [PMID: 36755370 DOI: 10.1111/hepr.13887] [Reference Citation Analysis]
|
| 149 |
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, Ding WB, Li WH, Huang JH, Mu W, Gu SZ, Li JP, Zhao H, Wen SW, Lei YM, Song YS, Yuan CW, Wang WD, Huang M, Zhao W, Wu JB, Wang S, Zhu X, Han JJ, Ren WX, Lu ZM, Xing WG, Fan Y, Lin HL, Zhang ZS, Xu GH, Hu WH, Tu Q, Su HY, Zheng CS, Chen Y, Zhao XY, Fang ZT, Wang Q, Zhao JW, Xu AB, Xu J, Wu QH, Niu HZ, Wang J, Dai F, Feng DP, Li QD, Shi RS, Li JR, Yang G, Shi HB, Ji JS, Liu YE, Cai Z, Yang P, Zhao Y, Zhu XL, Lu LG, Teng GJ; CHANCE001 Investigators. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther 2023;8:58. [PMID: 36750721 DOI: 10.1038/s41392-022-01235-0] [Reference Citation Analysis]
|
| 150 |
Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Ohkawa K, Oshita M, Miyazaki M, Yakushijin T, Nozaki Y, Matsumoto K, Tanaka S, Kaneko A, Iio S, Nawa T, Yamada Y, Morishita N, Usui T, Hiramatsu N, Doi Y, Sakakibara M, Imanaka K, Yoshida Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. PLoS One 2023;18:e0281459. [PMID: 36749777 DOI: 10.1371/journal.pone.0281459] [Reference Citation Analysis]
|
| 151 |
Takakusagi S, Tanaka H, Naganuma A, Kakizaki S, Shibuya K, Ohno T, Takagi H, Uraoka T. Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment. Clin J Gastroenterol 2023. [PMID: 36750524 DOI: 10.1007/s12328-023-01768-z] [Reference Citation Analysis]
|
| 152 |
Xue J, Liu H, Li R, Tan S, Yan Y, Dong Z, Hong J, Liu E, Zhang Q, Chen Z, Wang D, Li T. Salvage surgery after combination immunotherapy for initially unresectable hepatocellular carcinoma: A retrospective clinical study.. [DOI: 10.21203/rs.3.rs-2546520/v1] [Reference Citation Analysis]
|
| 153 |
Vetrano E, Rinaldi L, Mormone A, Giorgione C, Galiero R, Caturano A, Nevola R, Marfella R, Sasso FC. Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. Biomedicines 2023;11. [PMID: 36831004 DOI: 10.3390/biomedicines11020468] [Reference Citation Analysis]
|
| 154 |
Xie X, Li L, Tao S, Chen M, Fei L, Yang Q, Huang C, Chen L. Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo. Int J Mol Sci 2023;24. [PMID: 36834630 DOI: 10.3390/ijms24043217] [Reference Citation Analysis]
|
| 155 |
Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, Bei R, Buonomo OC, Roselli M, Mauriello A, Barillari G. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. Int J Mol Sci 2023;24. [PMID: 36834641 DOI: 10.3390/ijms24043226] [Reference Citation Analysis]
|
| 156 |
Fukushima M, Tajima K, Sasaki R, Nakao Y, Takahashi K, Ozawa E, Miuma S, Kato T, Miyaaki H, Nakao K. Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma. Clin J Gastroenterol 2023. [PMID: 36746879 DOI: 10.1007/s12328-023-01767-0] [Reference Citation Analysis]
|
| 157 |
Okuno M, Ishii T, Ichida A, Soyama A, Takemura N, Hirono S, Eguchi S, Hasegawa K, Sasaki Y, Uemura K, Kokudo N, Hatano E. Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.. [DOI: 10.21203/rs.3.rs-2267674/v1] [Reference Citation Analysis]
|
| 158 |
Odagiri N, Tamori A, Kotani K, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Enomoto M, Kawada N. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab. Clin J Gastroenterol 2023. [PMID: 36739366 DOI: 10.1007/s12328-023-01761-6] [Reference Citation Analysis]
|
| 159 |
Peng Q, Li J, Wu Q, Wang P, Kang Z, Deng Y, Xiao Y, Zheng P, Ge F, Chen Y. ZNF385A and ZNF346 Serve as Prognostic Biomarkers Associated with an Inflamed Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36834567 DOI: 10.3390/ijms24043155] [Reference Citation Analysis]
|
| 160 |
Yin Y, Luo Y, He K. Landscape of immunocytes infiltration and prognostic immune-related genes in hepatocellular carcinoma. Asian J Surg 2023:S1015-9584(23)00087-8. [PMID: 36746728 DOI: 10.1016/j.asjsur.2023.01.032] [Reference Citation Analysis]
|
| 161 |
Jeon AJ, Teo YY, Sekar K, Chong SL, Wu L, Chew SC, Chen J, Kendarsari RI, Lai H, Ling WH, Kaya NA, Lim JQ, Ramasamy A, Oguz G, Chung AY, Chan CY, Cheow PC, Kam JH, Madhavan K, Kow A, Ganpathi IS, Lim TKH, Leow WQ, Loong S, Loh TJ, Wan WK, Soon GST, Pang YH, Yoong BK, Ong DB, Lim J, de Villa VH, Cruz RDD, Chanwat R, Thammasiri J, Bonney GK, Goh BKP, Tucker-Kellogg G, Foo RSY, Chow PKH. Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma. BMC Cancer 2023;23:118. [PMID: 36737737 DOI: 10.1186/s12885-022-10444-3] [Reference Citation Analysis]
|
| 162 |
Zhao J, Stephan-Falkenau S, Schuler M, Arndt B. Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2023;15. [PMID: 36765942 DOI: 10.3390/cancers15030988] [Reference Citation Analysis]
|
| 163 |
Frager SZ, Cooper W, Saenger Y, Schwartz JM. Treatment of recurrent hepatocellular carcinoma following liver resection, ablation or liver transplantation. World J Meta-Anal 2023; 11(2): 47-54 [DOI: 10.13105/wjma.v11.i2.47] [Reference Citation Analysis]
|
| 164 |
Ding X, Zhang WJ, You R, Zou X, Wang ZQ, Ouyang YF, Peng L, Liu YP, Duan CY, Yang Q, Lin C, Xie YL, Chen SY, Liu YL, Gu CM, Xie RQ, Huang PY, Hong MH, Hua YJ, Chen MY. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. J Clin Oncol 2023;:JCO2201450. [PMID: 36735896 DOI: 10.1200/JCO.22.01450] [Reference Citation Analysis]
|
| 165 |
Arakaki S, Ono S, Kawamata F, Ishino S, Uesato Y, Nakajima T, Nishi Y, Morishima S, Arakaki S, Maeshiro T, Souri M, Ichinose A, Masuzaki H, Takatsuki M. Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report. Surg Case Rep 2023;9:16. [PMID: 36729240 DOI: 10.1186/s40792-023-01601-2] [Reference Citation Analysis]
|
| 166 |
Liu Y, Pan J, Gao F, Xu W, Li H, Qi X. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Adv Ther 2023;40:521-49. [PMID: 36399316 DOI: 10.1007/s12325-022-02371-3] [Reference Citation Analysis]
|
| 167 |
Jiang C, Sun XD, Qiu W, Chen YG, Sun DW, Lv GY. Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy? Hepatobiliary Pancreat Dis Int 2023;22:7-13. [PMID: 36825482 DOI: 10.1016/j.hbpd.2022.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 168 |
Hasan I, Loho IM, Setiawan PB, Djumhana A, Purnomo HD, Siregar L, Gani RA, Sulaiman AS, Lesmana CRA. Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia Pac J Clin Oncol 2023;19:263-74. [PMID: 35599455 DOI: 10.1111/ajco.13768] [Reference Citation Analysis]
|
| 169 |
Pinter M, Pinato DJ, Ramadori P, Heikenwalder M. NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy. Clin Cancer Res 2023;29:513-20. [PMID: 36166660 DOI: 10.1158/1078-0432.CCR-21-1258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 170 |
Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data. Hepatol Res 2023;53:116-26. [PMID: 36316794 DOI: 10.1111/hepr.13852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 171 |
Aziz H, Brown ZJ, Panid Madani S, Kamel IR, Pawlik TM. Fibrolamellar Hepatocellular Carcinoma: Comprehensive Review of Diagnosis, Imaging, and Management. J Am Coll Surg 2023;236:399-410. [PMID: 36648268 DOI: 10.1097/XCS.0000000000000476] [Reference Citation Analysis]
|
| 172 |
Yuen VW, Chiu DK, Law CT, Cheu JW, Chan CY, Wong BP, Goh CC, Zhang MS, Xue HD, Tse AP, Zhang Y, Lau HY, Lee D, Au-Yeung RKH, Wong CM, Wong CC. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. J Hepatol 2023;78:376-89. [PMID: 36455783 DOI: 10.1016/j.jhep.2022.10.037] [Reference Citation Analysis]
|
| 173 |
Vivekanandhan S, Bahr D, Kothari A, Ashary MA, Baksh M, Gabriel E. Immunotherapies in rare cancers. Mol Cancer 2023;22:23. [PMID: 36726126 DOI: 10.1186/s12943-023-01720-2] [Reference Citation Analysis]
|
| 174 |
Magalhães D, Dos Santos J, Frutuoso A, Mesquita A. Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. Cureus 2023;15:e34724. [PMID: 36909127 DOI: 10.7759/cureus.34724] [Reference Citation Analysis]
|
| 175 |
Sun H, Shen Y, Huang C, Zhu X, Tan C, Tang Z, Fan J, Zhou J. The development and prospects of liver surgery. Clinical Surgical Oncology 2023. [DOI: 10.1016/j.cson.2023.100009] [Reference Citation Analysis]
|
| 176 |
Gu T, Jiang A, Zhou C, Lin A, Cheng Q, Liu Z, Zhang J, Luo P. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. Int J Cancer 2023;152:480-95. [PMID: 36274626 DOI: 10.1002/ijc.34332] [Reference Citation Analysis]
|
| 177 |
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer 2023;180:9-20. [PMID: 36527976 DOI: 10.1016/j.ejca.2022.11.017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 178 |
Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma. Hepatol Res 2023;53:104-15. [PMID: 36149726 DOI: 10.1111/hepr.13843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 179 |
Fung J, DiSabato D, Liao CY, Ahmed O, Pillai A. Perspective: Advances in liver transplantation for hepatocellular carcinoma - A prototype for transplant oncology. Hepatobiliary Pancreat Dis Int 2023;22:4-6. [PMID: 36163102 DOI: 10.1016/j.hbpd.2022.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 180 |
Tan J, Liu T, Fan W, Wei J, Zhu B, Liu Y, Liu L, Zhang X, Chen S, Lin H, Zhang Y, Li J. Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1(high)CD11b(+) cells elimination in hepatocellular carcinoma. Acta Pharm Sin B 2023;13:632-47. [PMID: 36873191 DOI: 10.1016/j.apsb.2022.08.006] [Reference Citation Analysis]
|
| 181 |
Oura K, Morishita A, Hamaya S, Fujita K, Masaki T. The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36769116 DOI: 10.3390/ijms24032805] [Reference Citation Analysis]
|
| 182 |
Matoya S, Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Kuroyanagi K, Kusakabe A, Koguchi H, Hasegawa I, Miyaki T, Tanaka Y, Kondo H, Kimura Y, Ozasa A, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group (SLSG). The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis. Hepatol Res 2023. [PMID: 36723964 DOI: 10.1111/hepr.13886] [Reference Citation Analysis]
|
| 183 |
Zheng Z, Ma M, Han X, Li X, Huang J, Zhao Y, Liu H, Kang J, Kong X, Sun G, Sun G, Kong J, Tang W, Shao G, Xiong F, Song J. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Biomater 2023;157:337-51. [PMID: 36509402 DOI: 10.1016/j.actbio.2022.12.004] [Reference Citation Analysis]
|
| 184 |
Roehlen N, Muller M, Nehme Z, Crouchet E, Jühling F, Del Zompo F, Cherradi S, Duong FHT, Almeida N, Saviano A, Fernández-Vaquero M, Riedl T, El Saghire H, Durand SC, Ponsolles C, Oudot MA, Martin R, Brignon N, Felli E, Pessaux P, Lallement A, Davidson I, Bandiera S, Thumann C, Marchand P, Moll S, Nicolay B, Bardeesy N, Hoshida Y, Heikenwälder M, Iacone R, Toso A, Meyer M, Elson G, Schweighoffer T, Teixeira G, Zeisel MB, Laquerriere P, Lupberger J, Schuster C, Mailly L, Baumert TF. Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment. J Hepatol 2023;78:343-55. [PMID: 36309131 DOI: 10.1016/j.jhep.2022.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 185 |
Ni JJ, Zhang ZZ, Ge MJ, Chen JY, Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. Acta Pharmacol Sin 2023;44:288-307. [PMID: 35927312 DOI: 10.1038/s41401-022-00953-z] [Reference Citation Analysis]
|
| 186 |
Tomonari T, Tani J, Ogawa C, Deguchi A, Senoh T, Moriya A, Shibata H, Fukuno H, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Kawano Y, Morishita A, Takaguchi K, Miyamoto H, Sato Y, Masaki T, Takayama T. Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma. Hepatol Res 2023;53:172-8. [PMID: 36214071 DOI: 10.1111/hepr.13845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 187 |
Elshami M, Ahmed FA, Kakish H, Hue JJ, Hoehn RS, Rothermel LD, Bajor D, Mohamed A, Selfridge JE, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Trends and disparities in the utilization of systemic chemotherapy in patients with metastatic hepato-pancreato-biliary cancers. HPB (Oxford) 2023;25:239-51. [PMID: 36411233 DOI: 10.1016/j.hpb.2022.11.003] [Reference Citation Analysis]
|
| 188 |
Zhang L, Liu R, Deng T, Ba Y. Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. Cancer Innovation 2023;2:36-51. [DOI: 10.1002/cai2.60] [Reference Citation Analysis]
|
| 189 |
Cui C, Zhang S, Ren X, Cui W, Wang Y. Immune-related interstitial lung disease induced by different immune checkpoint inhibitors regimens: A real-world study from 2014 to 2022 based on FAERS databases. Eur J Pharmacol 2023;946:175561. [PMID: 36736527 DOI: 10.1016/j.ejphar.2023.175561] [Reference Citation Analysis]
|
| 190 |
Wang XH, Duan WB, Liang W, Li H, Xie XY, Li SQ, Chen MS, Liang P, Mao XH, Zhou QF. Efficacy of radiofrequency ablation following transarterial chemoembolisation combined with sorafenib for intermediate stage recurrent hepatocellular carcinoma: a retrospective, multicentre, cohort study. EClinicalMedicine 2023;56:101816. [PMID: 36703645 DOI: 10.1016/j.eclinm.2022.101816] [Reference Citation Analysis]
|
| 191 |
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:169-78. [PMID: 36529152 DOI: 10.1016/S2468-1253(22)00339-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 192 |
Hatanaka T, Naganuma A, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Kakizaki S, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis. Cancer Med 2023;12:4259-69. [PMID: 36156452 DOI: 10.1002/cam4.5294] [Reference Citation Analysis]
|
| 193 |
Zhou XH, Li JR, Zheng TH, Chen H, Cai C, Ye SL, Gao B, Xue TC. Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy. Clin Exp Metastasis 2023;40:5-32. [PMID: 36318440 DOI: 10.1007/s10585-022-10188-1] [Reference Citation Analysis]
|
| 194 |
Allaire M, Manfredi S, Lerosey L, Ganne-Carrié N, Thabut D. Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey. Clin Res Hepatol Gastroenterol 2023;47:102059. [PMID: 36455860 DOI: 10.1016/j.clinre.2022.102059] [Reference Citation Analysis]
|
| 195 |
Wei Y, Ke W, Lu Z, Ren Y. PI3K δ inhibitor PI-3065 induces apoptosis in hepatocellular carcinoma cells by targeting survivin. Chem Biol Interact 2023;371:110343. [PMID: 36623716 DOI: 10.1016/j.cbi.2023.110343] [Reference Citation Analysis]
|
| 196 |
Nelson DW, Vauthey JN. Optimizing Treatment Strategies with Preoperative Assessment for Microvascular Invasion in Hepatocellular Carcinoma. Ann Surg Oncol 2023;30:660-2. [PMID: 36310312 DOI: 10.1245/s10434-022-12746-z] [Reference Citation Analysis]
|
| 197 |
Peng SW, Ngo MT, Kuo YC, Teng MH, Guo CL, Lai HC, Chang TS, Huang YH. Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765890 DOI: 10.3390/cancers15030931] [Reference Citation Analysis]
|
| 198 |
Psilopatis I, Damaskos C, Garmpi A, Sarantis P, Koustas E, Antoniou EA, Dimitroulis D, Kouraklis G, Karamouzis MV, Vrettou K, Marinos G, Kontzoglou K, Garmpis N. FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? Int J Mol Sci 2023;24. [PMID: 36769004 DOI: 10.3390/ijms24032685] [Reference Citation Analysis]
|
| 199 |
Iguchi K, Sada R, Matsumoto S, Kimura H, Zen Y, Akita M, Gon H, Fukumoto T, Kikuchi A. DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness. Cancer Sci 2023. [PMID: 36718957 DOI: 10.1111/cas.15743] [Reference Citation Analysis]
|
| 200 |
Yang J, Jiang S, Chen Y, Zhang J, Deng Y. Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence. Curr Oncol 2023;30:1708-19. [PMID: 36826093 DOI: 10.3390/curroncol30020132] [Reference Citation Analysis]
|
| 201 |
Chiang HC, Lee YC, Chang TT, Lin YJ, Wu HT, Wang CT, Chen CY, Chen PJ, Hsieh MT, Lin SH, Chen SH, Chuang CH, Wu IC, Hong TC, Wu JS, Han MZ, Chen WT, Chiang CM, Hung KK, Kuo HY. Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765812 DOI: 10.3390/cancers15030854] [Reference Citation Analysis]
|
| 202 |
Li J, Yang F, Li J, Huang ZY, Cheng Q, Zhang EL. Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World J Gastrointest Surg 2023; 15(1): 19-31 [DOI: 10.4240/wjgs.v15.i1.19] [Reference Citation Analysis]
|
| 203 |
Lominadze Z, Hill K, Shaik MR, Canakis JP, Bourmaf M, Adams-Mardi C, Abutaleb A, Mishra L, Shetty K. Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. Int J Mol Sci 2023;24. [PMID: 36768686 DOI: 10.3390/ijms24032358] [Reference Citation Analysis]
|
| 204 |
Rizzo A, Mollica V, Tateo V, Tassinari E, Marchetti A, Rosellini M, De Luca R, Santoni M, Massari F. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunol Immunother 2023. [PMID: 36695827 DOI: 10.1007/s00262-023-03366-x] [Reference Citation Analysis]
|
| 205 |
Wang C, Wu L, Yuan H, Yu H, Xu J, Chen S, Yan S, Wang X. A powerful antitumor "trident": the combination of radio-, immuno- and anti-angiogenesis therapy based on mesoporous silica single coated gold nanoparticles. J Mater Chem B 2023;11:879-89. [PMID: 36594928 DOI: 10.1039/d2tb02046g] [Reference Citation Analysis]
|
| 206 |
Ishido S, Tsuchiya K, Kano Y, Yasui Y, Takaura K, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Matsumoto H, Nobusawa T, Keitoku T, Tanaka S, Maeyashiki C, Tamaki N, Takahashi Y, Nakanishi H, Sakurai U, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765676 DOI: 10.3390/cancers15030719] [Reference Citation Analysis]
|
| 207 |
Yang X, Zhang N, Song Y, Yang X, Sang X, Zhao H. Immunotherapy prototype Mk. 3.0 model in primary liver cancer: adding locoregional stereotactic therapy and prognostic factors classification management. Medical Review 2023;0. [DOI: 10.1515/mr-2022-0045] [Reference Citation Analysis]
|
| 208 |
Ma X, Sun X, Xie F, Jian W, Wang Q, Xie Y, Li C, Kai Z. The influence of drug-eluting beads transarterial chemoembolization on serum levels of soluble programed cell death protein-1 in advanced hepatocellular carcinoma patients.. [DOI: 10.21203/rs.3.rs-2029599/v1] [Reference Citation Analysis]
|
| 209 |
Uchida Y, Yoh T, Fukui A, Takai A, Hatano E. Complete Metabolic Response by 18F-FDG PET/CT to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Clin Nucl Med 2023. [PMID: 36727879 DOI: 10.1097/RLU.0000000000004570] [Reference Citation Analysis]
|
| 210 |
Laface C, Ranieri G, Maselli FM, Ambrogio F, Foti C, Ammendola M, Laterza M, Cazzato G, Memeo R, Mastrandrea G, Lioce M, Fedele P. Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765612 DOI: 10.3390/cancers15030654] [Reference Citation Analysis]
|
| 211 |
Gao B, Wang Y, Lu S. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma. Sci Rep 2023;13:1137. [PMID: 36670201 DOI: 10.1038/s41598-023-28436-z] [Reference Citation Analysis]
|
| 212 |
Cassinotto C, Nogue E, Durand Q, Panaro F, Assenat E, Dohan A, Malafaye N, Guiu B, Molinari N. Life expectancy of patients with hepatocellular carcinoma according to the upfront treatment: A nationwide analysis. Diagn Interv Imaging 2023:S2211-5684(23)00002-5. [PMID: 36682959 DOI: 10.1016/j.diii.2023.01.002] [Reference Citation Analysis]
|
| 213 |
Steinmann SM, Sánchez-Martín A, Tanzer E, Cigliano A, Pes GM, Simile MM, Desaubry L, Marin JJG, Evert M, Calvisi DF. eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36768380 DOI: 10.3390/ijms24032055] [Reference Citation Analysis]
|
| 214 |
Zhang ZH, Hou SN, Yu JZ, Zhang W, Ma JQ, Yang MJ, Liu QX, Liu LX, Luo JJ, Qu XD, Yan ZP. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis. Front Oncol 2022;12:1086095. [PMID: 36741718 DOI: 10.3389/fonc.2022.1086095] [Reference Citation Analysis]
|
| 215 |
Yang Z, Suda G, Maehara O, Ohara M, Yoda T, Sasaki T, Kohya R, Yoshida S, Hosoda S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Sakamoto N. Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765554 DOI: 10.3390/cancers15030593] [Reference Citation Analysis]
|
| 216 |
Zhao M, Chen S, Li C, Du Y, Li P. Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2023;15. [PMID: 36765557 DOI: 10.3390/cancers15030600] [Reference Citation Analysis]
|
| 217 |
Jiang X, Deng W, Tao S, Tang Z, Chen Y, Tian M, Wang T, Tao C, Li Y, Fang Y, Pu C, Gao J, Wang X, Qu W, Gai X, Ding Z, Fu Y, Zheng Y, Cao S, Zhou J, Huang M, Liu W, Xu J, Fan J, Shi Y. A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinoma. Cell Discov 2023;9:7. [PMID: 36650126 DOI: 10.1038/s41421-022-00504-0] [Reference Citation Analysis]
|
| 218 |
Mao Z, Nie Y, Jia W, Wang Y, Li J, Zhang T, Lei X, Shi W, Song W, Zhang X. Revealing Prognostic and Immunotherapy-Sensitive Characteristics of a Novel Cuproptosis-Related LncRNA Model in Hepatocellular Carcinoma Patients by Genomic Analysis. Cancers (Basel) 2023;15. [PMID: 36672493 DOI: 10.3390/cancers15020544] [Reference Citation Analysis]
|
| 219 |
Gao X, Zhao R, Ma H, Zuo S. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a systematic review and single-arm meta-analysis.. [DOI: 10.21203/rs.3.rs-2445357/v1] [Reference Citation Analysis]
|
| 220 |
Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, Zheng L, Pan CX. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol 2023;12:10. [PMID: 36647169 DOI: 10.1186/s40164-023-00372-8] [Reference Citation Analysis]
|
| 221 |
Yang H, Kang B, Ha Y, Lee SH, Kim I, Kim H, Lee WS, Kim G, Jung S, Rha SY, Gaillard VE, Cheon J, Kim C, Chon HJ. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. JHEP Rep 2023;5:100672. [PMID: 36866388 DOI: 10.1016/j.jhepr.2023.100672] [Reference Citation Analysis]
|
| 222 |
Peng X, Gong C, Zhang W, Zhou A. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Front Oncol 2022;12:1091088. [PMID: 36727075 DOI: 10.3389/fonc.2022.1091088] [Reference Citation Analysis]
|
| 223 |
Tomiyama T, Itoh S, Iseda N, Toshida K, Kosai-Fujimoto Y, Tomino T, Kurihara T, Nagao Y, Morita K, Harada N, Liu YC, Ozaki D, Kohashi K, Oda Y, Mori M, Yoshizumi T. Clinical Significance of Signal Regulatory Protein Alpha (SIRPα) Expression in Hepatocellular Carcinoma. Ann Surg Oncol 2023. [PMID: 36641515 DOI: 10.1245/s10434-022-13058-y] [Reference Citation Analysis]
|
| 224 |
Teng PC, Huang DQ, Lin TY, Noureddin M, Yang JD. Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2023;17:24-33. [PMID: 36530125 DOI: 10.5009/gnl220357] [Reference Citation Analysis]
|
| 225 |
Su K, Huang W, Li X, Xu K, Gu T, Liu Y, Song J, Qian K, Xu Y, Zeng H, Yang Y, Guo L, Han Y. Evaluation of Lactate Dehydrogenase and Alkaline Phosphatase as Predictive Biomarkers in the Prognosis of Hepatocellular Carcinoma and Development of a New Nomogram. J Hepatocell Carcinoma 2023;10:69-79. [PMID: 36685113 DOI: 10.2147/JHC.S398632] [Reference Citation Analysis]
|
| 226 |
Lin CL, Liang KH, Hu CC, Chien CH, Chen LW, Chien RN, Lin YH, Yeh CT. A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36675198 DOI: 10.3390/ijms24021681] [Reference Citation Analysis]
|
| 227 |
Zhou Y, Li G, Wang J, Liu M, Wang Z, Song Y, Zhang X, Wang X. PD-L1: expression regulation. Blood Science 2023;Publish Ahead of Print. [DOI: 10.1097/bs9.0000000000000149] [Reference Citation Analysis]
|
| 228 |
Liu M, Xie L, Zhang Y, Chen J, Zhang X, Chen Y, Huang W, Cai M, Liang L, Lai M, Huang J, Guo Y, Lin L, Zhu K. Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases. Cell Death Dis 2023;14:25. [PMID: 36639658 DOI: 10.1038/s41419-023-05550-4] [Reference Citation Analysis]
|
| 229 |
Wei J, Jiang H, Zhou Y, Tian J, Furtado FS, Catalano OA. Radiomics: A radiological evidence-based artificial intelligence technique to facilitate personalized precision medicine in hepatocellular carcinoma. Dig Liver Dis 2023:S1590-8658(22)00863-5. [PMID: 36641292 DOI: 10.1016/j.dld.2022.12.015] [Reference Citation Analysis]
|
| 230 |
Wang Y, Ma L, Xue P, Qin B, Wang T, Li B, Wu L, Zhao L, Liu X. Construction and Analysis of Hepatocellular Carcinoma Prognostic Model Based on Random Forest. Can J Gastroenterol Hepatol 2023;2023:6707698. [PMID: 36685007 DOI: 10.1155/2023/6707698] [Reference Citation Analysis]
|
| 231 |
Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother 2023. [PMID: 36633661 DOI: 10.1007/s00262-022-03349-4] [Reference Citation Analysis]
|
| 232 |
Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, Bell ATF, Elisseeff J, Popel AS, Anders RA, Jaffee EM, Yarchoan M, Fertig EJ, Kagohara LT. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. bioRxiv 2023:2023. [PMID: 36712023 DOI: 10.1101/2023.01.10.523481] [Reference Citation Analysis]
|
| 233 |
Wen K, Yang F, Hu L, Shi J, Mui S, Wang W, Liao H, Li H, Xiao Z, Yan Y. Analysis of the potential association between ferroptosis and immune in hepatocellular carcinoma and their relationship with prognosis. Front Oncol 2022;12:1031156. [PMID: 36776357 DOI: 10.3389/fonc.2022.1031156] [Reference Citation Analysis]
|
| 234 |
Ji X, Xu Z, Sun J, Li W, Duan X, Wang Q. Lenvatinib with or without Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: a retrospective study.. [DOI: 10.21203/rs.3.rs-2452311/v1] [Reference Citation Analysis]
|
| 235 |
Ding Z, Pan Y, Shang T, Jiang T, Lin Y, Yang C, Pang S, Cui X, Wang Y, Feng X, Xu M, Pei M, Chen Y, Li X, Ding J, Tan Y, Wang H, Dong L, Wang L. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers.. [DOI: 10.21203/rs.3.rs-2341124/v1] [Reference Citation Analysis]
|
| 236 |
Mei H, Wen W, Fang K, Xiong Y, Liu W, Wang J, Wan R. Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review. Front Oncol 2022;12:1088659. [PMID: 36713559 DOI: 10.3389/fonc.2022.1088659] [Reference Citation Analysis]
|
| 237 |
Shi Q, Zhou X, Zhang Z, Zhang W, Ma J, Yang M, Yu J, Luo J, Liu L, Yan Z. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance. Front Immunol 2022;13:1097625. [PMID: 36703965 DOI: 10.3389/fimmu.2022.1097625] [Reference Citation Analysis]
|
| 238 |
Kaneko S, Asahina Y, Nakagawa M, Murakawa M, Miyazaki Y, Asakage T, Fukuda S, Namiki T, Kano Y, Nagata M, Tsuchiya J, Miyoshi M, Kitahata-Kawai F, Nitta S, Itsui Y, Kakinuma S, Okamoto R. Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatol Res 2023. [PMID: 36626292 DOI: 10.1111/hepr.13878] [Reference Citation Analysis]
|
| 239 |
Hayashi Y, Kaneko R, Ogino H, Uekusa T, Kitajima M, Ikehara T, Nagai H, Matsuda T. A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab-bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen. Clin J Gastroenterol 2023. [PMID: 36624210 DOI: 10.1007/s12328-023-01756-3] [Reference Citation Analysis]
|
| 240 |
Liu Z, Zhu Y, Xie H, Zou Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol 2022;13:1077468. [PMID: 36699050 DOI: 10.3389/fphar.2022.1077468] [Reference Citation Analysis]
|
| 241 |
Ben Khaled N, Reiter FP, Geier A, De Toni EN. Systemtherapie des hepatozellulären Karzinoms: mehr als eine „palliative“ Therapie? Gastroenterologie 2023. [DOI: 10.1007/s11377-022-00666-z] [Reference Citation Analysis]
|
| 242 |
Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, van der Burg SH, Ott PA, Bogaert C. Challenges in neoantigen-directed therapeutics. Cancer Cell 2023;41:15-40. [PMID: 36368320 DOI: 10.1016/j.ccell.2022.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 243 |
Wanting H, Jian Z, Chaoxin X, Cheng Y, Chengjian Z, Lin Z, Dan C. Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs. J Cancer Res Clin Oncol 2023. [PMID: 36609710 DOI: 10.1007/s00432-022-04560-7] [Reference Citation Analysis]
|
| 244 |
Ohm H, Abdel-Rahman O. Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors. Curr Oncol 2023;30:786-802. [PMID: 36661709 DOI: 10.3390/curroncol30010060] [Reference Citation Analysis]
|
| 245 |
Fu J, Liu G, Zhang X, Lei X, Liu Q, Qian K, Tong Q, Qin W, Li Z, Cao Z, Zhang J, Liu C, Wang Z, Liu Z, Liang XM, Yamamoto H, Xu X. TRPM8 promotes hepatocellular carcinoma progression by inducing SNORA55 mediated nuclear-mitochondrial communication. Cancer Gene Ther 2023. [PMID: 36609627 DOI: 10.1038/s41417-022-00583-x] [Reference Citation Analysis]
|
| 246 |
Yu J, Pajvani UB. Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma. Medical Review 2023;0. [DOI: 10.1515/mr-2022-0043] [Reference Citation Analysis]
|
| 247 |
Brackenier C, Kinget L, Cappuyns S, Verslype C, Beuselinck B, Dekervel J. Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36672297 DOI: 10.3390/cancers15020348] [Reference Citation Analysis]
|
| 248 |
Kato N, Kudo M, Tsuchiya K, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Okano N, Ikeda M, Morimoto M, Kuroda S, Kimura A. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study. Hepatol Res 2023. [PMID: 36601972 DOI: 10.1111/hepr.13876] [Reference Citation Analysis]
|
| 249 |
Rizzo A, Ricci AD, Fanizzi A, Massafra R, De Luca R, Brandi G. Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Curr Oncol 2023;30:749-57. [PMID: 36661706 DOI: 10.3390/curroncol30010057] [Reference Citation Analysis]
|
| 250 |
Li Z, Chen C, Si A, Qu W, Zhang J, Xia Z, Luo L, Zhang Y, Liu X. HBV integration affect the efficacy of systematic drug therapy after radical resection of liver cancer: a prospective cohort study.. [DOI: 10.21203/rs.3.rs-2423553/v1] [Reference Citation Analysis]
|
| 251 |
Hou G, Liu B, Fan ZQ, Li C, Zhang JP, Guo YH, Zhang RY, Zheng Y, Zhu H, Wang NY. Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. Front Oncol 2022;12:1094104. [PMID: 36686731 DOI: 10.3389/fonc.2022.1094104] [Reference Citation Analysis]
|
| 252 |
Tao S, Liang S, Zeng T, Yin D. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Front Immunol 2022;13:1043667. [PMID: 36685594 DOI: 10.3389/fimmu.2022.1043667] [Reference Citation Analysis]
|
| 253 |
Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Clin Cancer Res 2023;29:30-9. [PMID: 35969170 DOI: 10.1158/1078-0432.CCR-22-1366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 254 |
Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology 2023. [PMID: 36680397 DOI: 10.1097/HEP.0000000000000237] [Reference Citation Analysis]
|
| 255 |
Lu S, Qin S, Zhou Z, Chen J, Gu K, Sun P, Pan Y, Yu G, Ma K, Shi J, Sun Y, Yang L, Chen P, Liu A, He J. Bevacizumab biosimilar candidate TAB008 compared to Avastin(®) in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study. J Cancer Res Clin Oncol 2023. [PMID: 36595042 DOI: 10.1007/s00432-022-04563-4] [Reference Citation Analysis]
|
| 256 |
Zhang X, Xie J, He D, Yan X, Chen J. Cell Pair Algorithm-Based Immune Infiltrating Cell Signature for Improving Outcomes and Treatment Responses in Patients with Hepatocellular Carcinoma. Cells 2023;12. [PMID: 36611994 DOI: 10.3390/cells12010202] [Reference Citation Analysis]
|
| 257 |
Chen S, Huang C, Liao G, Sun H, Xie Y, Liao C, Wang J, He M, Hu H, Dai Z, Ren X, Zeng X, Lin Z, Zhang GP, Xie W, Shen S, Li S, Peng S, Kuang DM, Zhao Q, Duda DG, Kuang M. Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences. Gut 2023:gutjnl-2022-328428. [PMID: 36596711 DOI: 10.1136/gutjnl-2022-328428] [Reference Citation Analysis]
|
| 258 |
Fu Y, Mackowiak B, Feng D, Lu H, Guan Y, Lehner T, Pan H, Wang XW, He Y, Gao B. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Gut 2023:gutjnl-2022-327924. [PMID: 36593103 DOI: 10.1136/gutjnl-2022-327924] [Reference Citation Analysis]
|
| 259 |
Bowman KER, Ahne L, O'Brien L, Vander Mause ER, Lu P, Wallis B, Evason KJ, Lim CS. p53-Bad* Fusion Gene Therapy Induces Apoptosis In Vitro and Reduces Zebrafish Tumor Burden in Hepatocellular Carcinoma. Mol Pharm 2023;20:331-40. [PMID: 36490361 DOI: 10.1021/acs.molpharmaceut.2c00665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 260 |
Dai X, Li X, Du Y, Han M, Wang Z, Wang Y, Yan F, Liu Y. Gold Nanorod–Mesoporous Silica Core Shell Nanocomposites for NIR-II Photothermal Ablation and Dual PD-L1/VEGF Blockade Therapy in Hepatocellular Carcinoma. Chemical Engineering Journal 2023. [DOI: 10.1016/j.cej.2023.141426] [Reference Citation Analysis]
|
| 261 |
Li S, Wu J, Wu J, Fu Y, Zeng Z, Li Y, Li H, Liao W, Yan M. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study. Front Immunol 2023;14:1109771. [PMID: 36875116 DOI: 10.3389/fimmu.2023.1109771] [Reference Citation Analysis]
|
| 262 |
Cheon J, Kim H, Kim HS, Kim CG, Kim I, Kang B, Kim C, Jung S, Ha Y, Chon HJ. Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma. Ther Adv Med Oncol 2023;15:175883592211485. [DOI: 10.1177/17588359221148541] [Reference Citation Analysis]
|
| 263 |
Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehí M, Miho M, Radu P, Dufour JF, Verslype C, Zimpel C, Marquardt JU, Galle PR, Vogel A, Bathon M, Meyer T, Labgaa I, Digklia A, Roberts LR, Mohamed Ali MA, Mínguez B, Citterio D, Mazzaferro V, Finkelmeier F, Trojan J, Özdirik B, Müller T, Schmelzle M, Bejjani A, Sung MW, Schwartz ME, Finn RS, Thung S, Villanueva A, Sia D, Llovet JM. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology 2023;164:72-88.e18. [PMID: 36108710 DOI: 10.1053/j.gastro.2022.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 264 |
Wan S, Zhao E, Weissinger D, Krantz BA, Werba G, Freeman D, Khanna LG, Siolas D, Oberstein PE, Chattopadhyay PK, Simeone DM, Welling TH. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. Front Immunol 2023;14:1067352. [PMID: 36798126 DOI: 10.3389/fimmu.2023.1067352] [Reference Citation Analysis]
|
| 265 |
Liang L, Wang X, Huang S, Chen Y, Zhang P, Li L, Cui Y. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Front Immunol 2023;14:1046771. [PMID: 36936932 DOI: 10.3389/fimmu.2023.1046771] [Reference Citation Analysis]
|
| 266 |
Nota T, Kageyama K, Yamamoto A, Kakehashi A, Yonezawa H, Jogo A, Sohgawa E, Murai K, Ogawa S, Miki Y. Safety and Feasibility of Contrast-Enhanced Computed Tomography with a Nanoparticle Contrast Agent for Evaluation of Diethylnitrosamine-Induced Liver Tumors in a Rat Model. Acad Radiol 2023;30:30-9. [PMID: 35680546 DOI: 10.1016/j.acra.2022.03.027] [Reference Citation Analysis]
|
| 267 |
White SB, Maddirela DR. Fibrosis and Immunotherapy in Hepatocellular Carcinoma. Interdisciplinary Cancer Research 2023. [DOI: 10.1007/16833_2022_122] [Reference Citation Analysis]
|
| 268 |
Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol 2023;20:37-49. [PMID: 36258033 DOI: 10.1038/s41575-022-00688-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 269 |
Fang Y, Liu W, Tang Z, Ji X, Zhou Y, Song S, Tian M, Tao C, Huang R, Zhu G, Jiang X, Gao J, Qu W, Wang H, Zhou P, Wu X, Jin L, Sun H, Ding Z, Peng Y, Zhao S, Zhou J, Fan J, Xu W, Shi Y. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology 2023;77:109-23. [PMID: 35043976 DOI: 10.1002/hep.32348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 270 |
Bai J, Huang M, Song B, Luo W, Ding R. The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma. Technol Cancer Res Treat 2023;22:15330338231159718. [PMID: 36855803 DOI: 10.1177/15330338231159718] [Reference Citation Analysis]
|
| 271 |
DasGupta R, Yap A, Yaqing EY, Chia S. Evolution of precision oncology-guided treatment paradigms. WIREs Mech Dis 2023;15:e1585. [PMID: 36168283 DOI: 10.1002/wsbm.1585] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 272 |
Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, Fung J, Pillai A, Liao CY, Sharma M, Liauw SL. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2023;115:202-13. [PMID: 36108891 DOI: 10.1016/j.ijrobp.2022.09.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 273 |
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48. [PMID: 36633525 DOI: 10.3322/caac.21763] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 41.0] [Reference Citation Analysis]
|
| 274 |
Pugliese N, Alfarone L, Arcari I, Giugliano S, Parigi TL, Rescigno M, Lleo A, Aghemo A. Clinical features and management issues of NAFLD-related HCC: what we know so far. Expert Rev Gastroenterol Hepatol 2023;17:31-43. [PMID: 36576057 DOI: 10.1080/17474124.2023.2162503] [Reference Citation Analysis]
|
| 275 |
Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
|
| 276 |
Khalil DN, El Dika I, Azhari H, Harding JJ, O’reilly EM, Abou-alfa GK. Immune Strategies for Gastrointestinal Cancer: HCC. Cancer Immunotherapy 2023. [DOI: 10.1007/13905_2021_13] [Reference Citation Analysis]
|
| 277 |
Ota Y, Aso K, Otake S, Okada M, Shukuda K, Sawada K, Yokoo H, Tanino M, Fujiya M, Okumura T. Contrast-enhanced ultrasonography for the diagnosis of spontaneous necrosis of hepatocellular carcinoma: A report of 2 cases. Radiology Case Reports 2023;18:173-181. [DOI: 10.1016/j.radcr.2022.10.019] [Reference Citation Analysis]
|
| 278 |
Huang Y, Wang S, Ke A, Guo K. Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. Biochim Biophys Acta Rev Cancer 2023;1878:188848. [PMID: 36502929 DOI: 10.1016/j.bbcan.2022.188848] [Reference Citation Analysis]
|
| 279 |
Wu C, Tseng C. Microbiota and Liver Cancer. Microbiome in Gastrointestinal Cancer 2023. [DOI: 10.1007/978-981-19-4492-5_5] [Reference Citation Analysis]
|
| 280 |
Erol C, Sendur MAN. Pulmonary Side Effects of Immunotherapy. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_349-1] [Reference Citation Analysis]
|
| 281 |
Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt KH, Benckert J. Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma. Front Pharmacol 2023;14:1124214. [PMID: 36937889 DOI: 10.3389/fphar.2023.1124214] [Reference Citation Analysis]
|
| 282 |
Zheng SS, Wu YF, Zhang BH, Huang C, Xue TC. A novel myeloid cell marker genes related signature can indicate immune infiltration and predict prognosis of hepatocellular carcinoma: Integrated analysis of bulk and single-cell RNA sequencing. Front Mol Biosci 2023;10:1118377. [PMID: 36959981 DOI: 10.3389/fmolb.2023.1118377] [Reference Citation Analysis]
|
| 283 |
Brandi G, Tovoli F, Tavolari S. Have We Found the "Holy Grail" That May Predict Response to Immunotherapy in Hepatocellular Carcinoma? Gastroenterology 2023;164:15-8. [PMID: 36334819 DOI: 10.1053/j.gastro.2022.10.030] [Reference Citation Analysis]
|
| 284 |
Tefera J, Savic LJ, Gebauer B. Prinzipien der nicht-chirurgischen lokoregionären Therapie. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-46764-0_179-1] [Reference Citation Analysis]
|
| 285 |
Lindblad KE, Lujambio A. Imaging for better responses to immunotherapy in hepatocellular carcinoma. Hepatology 2023;77:6-9. [PMID: 35727179 DOI: 10.1002/hep.32627] [Reference Citation Analysis]
|
| 286 |
Zhou J, Sun Y, Zhang W, Yuan J, Peng Z, Wang W, Gong J, Yang L, Cao Y, Zhao H, Chen C, Wang W, Shen L, Zhou A. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Hepatology 2023;77:65-76. [PMID: 35491432 DOI: 10.1002/hep.32548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 287 |
Murai H, Kodama T, Maesaka K, Tange S, Motooka D, Suzuki Y, Shigematsu Y, Inamura K, Mise Y, Saiura A, Ono Y, Takahashi Y, Kawasaki Y, Iino S, Kobayashi S, Idogawa M, Tokino T, Hashidate-Yoshida T, Shindou H, Miyazaki M, Imai Y, Tanaka S, Mita E, Ohkawa K, Hikita H, Sakamori R, Tatsumi T, Eguchi H, Morii E, Takehara T. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology 2023;77:77-91. [PMID: 35567547 DOI: 10.1002/hep.32573] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 288 |
Kuzmanović A, Lin C, Bartneck M. Liver Cancer and the Curative Potential of Nanomedicine. Interdisciplinary Cancer Research 2023. [DOI: 10.1007/16833_2023_129] [Reference Citation Analysis]
|
| 289 |
Wang H, Zhang G, Yang X, Lu Z, Zhao H. Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. Biochim Biophys Acta Rev Cancer 2023;1878:188841. [PMID: 36423747 DOI: 10.1016/j.bbcan.2022.188841] [Reference Citation Analysis]
|
| 290 |
Chen L, Zhang R, Lin Z, Tan Q, Huang Z, Liang B. Radiation therapy in the era of immune treatment for hepatocellular carcinoma. Front Immunol 2023;14:1100079. [PMID: 36742293 DOI: 10.3389/fimmu.2023.1100079] [Reference Citation Analysis]
|
| 291 |
Cho Y, Kim BH, Park JW. The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea. Clin Mol Hepatol 2023;29:99-101. [PMID: 36300329 DOI: 10.3350/cmh.2022.0321] [Reference Citation Analysis]
|
| 292 |
Uchikawa S, Kawaoka T, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Miki D, Imamura M, Aikata H. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography. J Med Ultrason (2001) 2023;50:57-62. [PMID: 36169740 DOI: 10.1007/s10396-022-01260-0] [Reference Citation Analysis]
|
| 293 |
Tsuruoka M, Inoue J, Ouchi K, Uno K, Itami H, Ninomiya M, Iwata T, Sano A, Sato K, Onuki M, Sawahashi S, Koike T, Masamune A. A Case of Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma. Intern Med 2023. [DOI: 10.2169/internalmedicine.0629-22] [Reference Citation Analysis]
|
| 294 |
Kwee SA, Wong LL, Ludema C, Deng CK, Taira D, Seto T, Landsittel D. Target Trial Emulation: A Design Tool for Cancer Clinical Trials. JCO Clin Cancer Inform 2023;7:e2200140. [PMID: 36608311 DOI: 10.1200/CCI.22.00140] [Reference Citation Analysis]
|
| 295 |
Wang L, Wang H, Cui Y, Liu M, Jin K, Xu D, Wang K, Xing B. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study. Front Oncol 2023;13:1115109. [PMID: 36874115 DOI: 10.3389/fonc.2023.1115109] [Reference Citation Analysis]
|
| 296 |
Kotowski K, Kucharski D, Machura B, Adamski S, Gutierrez Becker B, Krason A, Zarudzki L, Tessier J, Nalepa J. Detecting liver cirrhosis in computed tomography scans using clinically-inspired and radiomic features. Comput Biol Med 2023;152:106378. [PMID: 36512877 DOI: 10.1016/j.compbiomed.2022.106378] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 297 |
Zhu J, Wu W. Clinical Analysis of Transcatheter Arterial Chemoembolization Sequential Microwave Ablation Combined with Targeted Therapy and Immunotherapy in the Treatment of Large Hepatocellular Carcinoma. JBM 2023;11:18-25. [DOI: 10.4236/jbm.2023.111003] [Reference Citation Analysis]
|
| 298 |
Heinrich B. [Innate and adaptive immunity in the context of non-alcoholic fatty liver disease]. Z Gastroenterol 2023;61:76-82. [PMID: 36623545 DOI: 10.1055/a-1993-3519] [Reference Citation Analysis]
|
| 299 |
Guo DZ, Zhang SY, Dong SY, Yan JY, Wang YP, Cao Y, Rao SX, Fan J, Yang XR, Huang A, Zhou J. Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. Front Oncol 2023;13:1109742. [PMID: 36910622 DOI: 10.3389/fonc.2023.1109742] [Reference Citation Analysis]
|
| 300 |
Zeng H, Xu Q, Wang J, Xu X, Luo J, Zhang L, Luo C, Ying J, Li J. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. Front Immunol 2023;14:1073133. [PMID: 36756114 DOI: 10.3389/fimmu.2023.1073133] [Reference Citation Analysis]
|
| 301 |
Jeon SH, Lee YJ, Kim HD, Nam H, Ryoo BY, Park SH, Yoo C, Shin EC. Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma. Cancer Immunol Immunother 2023;72:371-84. [PMID: 35902399 DOI: 10.1007/s00262-022-03258-6] [Reference Citation Analysis]
|
| 302 |
Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2023;72:129-40. [PMID: 35197323 DOI: 10.1136/gutjnl-2021-325918] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 303 |
Nevarez NM, Chang GY, Yopp AC. An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma. Surg Oncol Clin N Am 2023;32:101-17. [PMID: 36410911 DOI: 10.1016/j.soc.2022.07.008] [Reference Citation Analysis]
|
| 304 |
Baldwin XL, Spanheimer PM, Downs-Canner S. A Review of Immune Checkpoint Blockade for the General Surgeon. J Surg Res 2023;281:289-98. [PMID: 36228339 DOI: 10.1016/j.jss.2022.08.040] [Reference Citation Analysis]
|
| 305 |
Butt NU, Baytas SN. Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future. Curr Pharm Des 2023;29:2-14. [PMID: 36529919 DOI: 10.2174/1381612829666221216114350] [Reference Citation Analysis]
|
| 306 |
Persano M, Casadei-Gardini A, Burgio V, Scartozzi M, Cascinu S, Rimini M. Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors? Expert Rev Anticancer Ther 2023;23:19-27. [PMID: 36472371 DOI: 10.1080/14737140.2023.2156340] [Reference Citation Analysis]
|
| 307 |
Lengyel CG. Mechanisms of Resistance to Immunotherapies in Cancer. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_335-1] [Reference Citation Analysis]
|
| 308 |
Herrmann SM, Dobbin SJ, Herrmann J, Touyz RM, Lang NN. Hypertension and renal disease during anti-cancer therapies. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease 2023. [DOI: 10.1016/b978-0-323-68135-3.00029-5] [Reference Citation Analysis]
|
| 309 |
Yang Z, Yan C, Ma J, Peng P, Ren X, Cai S, Shen X, Wu Y, Zhang S, Wang X, Qiu S, Zhou J, Fan J, Huang H, Gao Q. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. Nat Metab 2023;5:61-79. [PMID: 36593272 DOI: 10.1038/s42255-022-00710-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 310 |
Gaugain L, Cawston H, Dubois de Gennes C, Sanchez Alvares J, Nahon P, Mazaleyrat B, Le Dissez C. Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. PLoS One 2023;18:e0280442. [PMID: 36652428 DOI: 10.1371/journal.pone.0280442] [Reference Citation Analysis]
|
| 311 |
Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Zhong JY, Feng S, Ni QZ, Zhu HF, Pan WW, Li JJ, Liang C, Zhou HK, Meng Y, Lau WY, Cheng SQ. Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study. Front Immunol 2023;14:1107542. [PMID: 36875125 DOI: 10.3389/fimmu.2023.1107542] [Reference Citation Analysis]
|
| 312 |
Jose A, Bavetta MG, Martinelli E, Bronte F, Giunta EF, Manu KA. Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease. J Oncol 2022;2022:3817724. [PMID: 36624801 DOI: 10.1155/2022/3817724] [Reference Citation Analysis]
|
| 313 |
Zhang B, Tao B, Li Y, Yi C, Lin Z, Ma Y, Han J, Shao W, Chen Z, Lin J, Chen J. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. Eur J Intern Med 2022:S0953-6205(22)00454-X. [PMID: 36588054 DOI: 10.1016/j.ejim.2022.12.025] [Reference Citation Analysis]
|
| 314 |
Barnestein R, Galland L, Kalfeist L, Ghiringhelli F, Ladoire S, Limagne E. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. OncoImmunology 2022;11:2120676. [DOI: 10.1080/2162402x.2022.2120676] [Reference Citation Analysis]
|
| 315 |
Kee KM, Chen CH, Hu JT, Huang YH, Wang TE, Chau GY, Chen KH, Chen YL, Lin CC, Hung CF, Huang SF, Liu TW, Ku HY, Huang BS, Wang YP, Tseng HP, Chiang CJ, Lu SN. Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. Viruses 2022;15. [PMID: 36680166 DOI: 10.3390/v15010126] [Reference Citation Analysis]
|
| 316 |
Noordam L, de Beijer MT, Mancham S, Vogler I, Boor PP, de Ruiter V, Luijten R, Ijzermans JN, Sahin U, Bruno MJ, Sprengers D, Buschow SI, Kwekkeboom J. Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients. OncoImmunology 2022;11:2131096. [DOI: 10.1080/2162402x.2022.2131096] [Reference Citation Analysis]
|
| 317 |
Mougel A, Méjean F, Tran T, Adimi Y, Galy-fauroux I, Kaboré C, Mercier E, Urquia P, Terme M, Tartour E, Tanchot C. Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling. OncoImmunology 2022;11:2110218. [DOI: 10.1080/2162402x.2022.2110218] [Reference Citation Analysis]
|
| 318 |
Toubert C, Guiu B, Al Taweel B, Assenat E, Panaro F, Souche FR, Ursic-Bedoya J, Navarro F, Herrero A. Prolonged Survival after Recurrence in HCC Resected Patients Using Repeated Curative Therapies: Never Give Up! Cancers (Basel) 2022;15. [PMID: 36612227 DOI: 10.3390/cancers15010232] [Reference Citation Analysis]
|
| 319 |
Minici R, Siciliano MA, Ammendola M, Santoro RC, Barbieri V, Ranieri G, Laganà D. Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. Cancers (Basel) 2022;15. [PMID: 36612251 DOI: 10.3390/cancers15010257] [Reference Citation Analysis]
|
| 320 |
Rennert C, Lang‐meli J, Gromak M, Hofmann M, Thimme R, Roehlen N. Perspectives for novel therapeutic concepts in hepatocellular carcinoma targeting the stromal and innate immune microenvironment. Liver Cancer International 2022. [DOI: 10.1002/lci2.70] [Reference Citation Analysis]
|
| 321 |
Ohama H, Hiraoka A, Tada F, Kato K, Fukunishi Y, Yanagihara E, Kato M, Saneto H, Izumoto H, Ueki H, Yoshino T, Kitahata S, Kawamura T, Kuroda T, Suga Y, Miyata H, Hanaoka J, Watanabe J, Ohtani H, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y. Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma. Cancers (Basel) 2022;15. [PMID: 36612233 DOI: 10.3390/cancers15010236] [Reference Citation Analysis]
|
| 322 |
Locke GE, Alrabiah K, Kim TK, Knox J, Jang R, Dawson LA. Very late local recurrences of hepatocellular carcinoma with macrovascular invasion treated with stereotactic body radiotherapy: Report of two cases. Liver Cancer International 2022. [DOI: 10.1002/lci2.69] [Reference Citation Analysis]
|
| 323 |
Zou H, Lei Q, Yan X, Lai Y, Ung COL, Hu H. Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis. Cancers (Basel) 2022;15. [PMID: 36612256 DOI: 10.3390/cancers15010260] [Reference Citation Analysis]
|
| 324 |
Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, Arora M, Brufsky A, Dees EC, Santa-Maria CA, Connolly RM, Force J, Moreno-Aspitia A, Herndon JM, Carmody M, Davies SR, Larson S, Pfaff KL, Jones SM, Weirather JL, Giobbie-Hurder A, Rodig SJ, Liu Z, Hagemann IS, Sharon E, Gillanders WE. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ Breast Cancer 2022;8:134. [PMID: 36585404 DOI: 10.1038/s41523-022-00500-3] [Reference Citation Analysis]
|
| 325 |
Long J, Chen P, Yang X, Bian J, Yang X, Wang A, Lin Y, Wang H, Sang X, Zhao H. Co-expression of receptor tyrosine kinases and CD8 T-lymphocyte genes is associated with distinct prognoses, immune cell infiltration patterns and immunogenicity in cancers. Transl Res 2022:S1931-5244(22)00318-8. [PMID: 36586534 DOI: 10.1016/j.trsl.2022.12.008] [Reference Citation Analysis]
|
| 326 |
Jung J, Park S, Jang Y, Lee SH, Jeong YS, Yim SY, Lee JS. Clinical Significance of Glycolytic Metabolic Activity in Hepatocellular Carcinoma. Cancers (Basel) 2022;15. [PMID: 36612182 DOI: 10.3390/cancers15010186] [Reference Citation Analysis]
|
| 327 |
Ganesan R, Yoon SJ, Suk KT. Microbiome and Metabolomics in Liver Cancer: Scientific Technology. Int J Mol Sci 2022;24. [PMID: 36613980 DOI: 10.3390/ijms24010537] [Reference Citation Analysis]
|
| 328 |
Basudan AM. The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clin Pract 2022;13:22-40. [PMID: 36648843 DOI: 10.3390/clinpract13010003] [Reference Citation Analysis]
|
| 329 |
Guo Y, Ren Y, Wu F, Dong X, Zheng C. Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor. Therap Adv Gastroenterol 2022;15:17562848221142417. [PMID: 36600683 DOI: 10.1177/17562848221142417] [Reference Citation Analysis]
|
| 330 |
Wang J, Wu R, Sun JY, Lei F, Tan H, Lu X. An overview: Management of patients with advanced hepatocellular carcinoma. Biosci Trends 2022;16:405-25. [PMID: 36476621 DOI: 10.5582/bst.2022.01109] [Reference Citation Analysis]
|
| 331 |
Hu T, Chen X, Lu S, Zeng H, Guo L, Han Y. Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer. Technol Cancer Res Treat 2022;21:15330338221140655. [PMID: 36567598 DOI: 10.1177/15330338221140655] [Reference Citation Analysis]
|
| 332 |
Shi H, Zhang W, Hu B, Wang Y, Zhang Z, Sun Y, Mao G, Li C, Lu S. Whole-exome sequencing identifies a set of genes as markers of hepatocellular carcinoma early recurrence. Hepatol Int 2022. [PMID: 36550350 DOI: 10.1007/s12072-022-10457-x] [Reference Citation Analysis]
|
| 333 |
Luo L, He Y, Zhu G, Xiao Y, Song S, Ge X, Wang T, Xie J, Deng W, Hu Z, Shan R. Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? J Hepatocell Carcinoma 2022;9:1353-68. [PMID: 36578526 DOI: 10.2147/JHC.S388965] [Reference Citation Analysis]
|
| 334 |
Hamad A, Aziz H, Kamel IR, Diaz DA, Pawlik TM. Yttrium-90 Radioembolization: Current Indications and Outcomes. J Gastrointest Surg 2022. [PMID: 36547759 DOI: 10.1007/s11605-022-05559-8] [Reference Citation Analysis]
|
| 335 |
Jiang J, Diaz DA, Nuguru SP, Mittra A, Manne A. Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers (Basel) 2022;15. [PMID: 36612046 DOI: 10.3390/cancers15010050] [Reference Citation Analysis]
|
| 336 |
Fencer MG, Davis CH, Liu J, Galan MA, Spencer KR. Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial. J Investig Med High Impact Case Rep 2022;10:23247096221129470. [PMID: 36541195 DOI: 10.1177/23247096221129470] [Reference Citation Analysis]
|
| 337 |
Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, Santos A, Armendariz-Borunda J. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers (Basel) 2022;15. [PMID: 36612019 DOI: 10.3390/cancers15010023] [Reference Citation Analysis]
|
| 338 |
Welty NE, Gill SI. Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2022;4:563-78. [PMID: 36636439 DOI: 10.1016/j.jaccao.2022.11.006] [Reference Citation Analysis]
|
| 339 |
Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2022;4:579-97. [PMID: 36636451 DOI: 10.1016/j.jaccao.2022.09.004] [Reference Citation Analysis]
|
| 340 |
Jin X, Ma X, Zhao D, Yang L, Ma N. Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation. Transl Oncol 2023;28:101603. [PMID: 36542991 DOI: 10.1016/j.tranon.2022.101603] [Reference Citation Analysis]
|
| 341 |
Kimura M, Asano H, Usami E, Teramachi H, Yoshimura T. Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma. J Oncol Pharm Pract 2022. [DOI: 10.1177/10781552221145475] [Reference Citation Analysis]
|
| 342 |
Negussie AH, Mikhail AS, Owen JW, Hong N, Carlson CJ, Tang Y, Carrow KP, Mauda-Havakuk M, Lewis AL, Karanian JW, Pritchard WF, Wood BJ. In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer. Sci Rep 2022;12:21886. [PMID: 36535979 DOI: 10.1038/s41598-022-26094-1] [Reference Citation Analysis]
|
| 343 |
Guven DC, Erul E, Sahin TK, Dizdar O, Yalcin S, Sahin IH. The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Future Oncology 2022. [DOI: 10.2217/fon-2022-0642] [Reference Citation Analysis]
|
| 344 |
Li Q, Han J, Yang Y, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol 2022;13:1070961. [PMID: 36601120 DOI: 10.3389/fimmu.2022.1070961] [Reference Citation Analysis]
|
| 345 |
Federico P, Giunta EF, Tufo A, Tovoli F, Petrillo A, Daniele B. Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact. Cancers (Basel) 2022;14. [PMID: 36551730 DOI: 10.3390/cancers14246245] [Reference Citation Analysis]
|
| 346 |
Huang Y, Zhang L, He M, Lai Z, Bu X, Wen D, Li Q, Xu L, Wei W, Zhang Y, Zhou Z, Chen M, Guo R, Shi M, Kan A. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. Technol Cancer Res Treat 2022;21:15330338221117389. [PMID: 36529949 DOI: 10.1177/15330338221117389] [Reference Citation Analysis]
|
| 347 |
Gao S, Li N, Zhang X, Chen J, Ko BCB, Zhao Y. An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET(+) hepatocellular carcinoma. Biochem Biophys Rep 2023;33:101412. [PMID: 36578529 DOI: 10.1016/j.bbrep.2022.101412] [Reference Citation Analysis]
|
| 348 |
wang L, Peng Y, Qin S, Wan X, Zeng X, Li S, Liu Q, Tan C. First-Line Systemic Treatment Strategies for unresectable hepatocellular carcinoma : a cost-effectiveness analysis.. [DOI: 10.1101/2022.12.15.22283549] [Reference Citation Analysis]
|
| 349 |
Li S, Mei J, Cheng Y, Li Q, Wang Q, Fang C, Lei Q, Huang H, Cao M, Luo R, Deng J, Jiang Y, Zhao R, Lu L, Zou J, Deng M, Lin W, Guan R, Wen Y, Li J, Zheng L, Guo Z, Ling Y, Chen H, Zhong C, Wei W, Guo R. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. JCO 2022. [DOI: 10.1200/jco.22.01142] [Reference Citation Analysis]
|
| 350 |
Wei B, Hao Z, Zheng H, Qin Y, Zhao F, Shi L. Brevilin A Inhibits VEGF-Induced Angiogenesis through ROS-Dependent Mitochondrial Dysfunction. Oxid Med Cell Longev 2022;2022:5888636. [PMID: 36567856 DOI: 10.1155/2022/5888636] [Reference Citation Analysis]
|
| 351 |
Matsuda K, Kurebayashi Y, Masugi Y, Yamazaki K, Ueno A, Tsujikawa H, Ojima H, Kitago M, Itano O, Shinoda M, Abe Y, Sakamoto M. Immunovascular microenvironment in relation to prognostic heterogeneity of WNT/β-catenin-activated hepatocellular carcinoma. Hepatol Res 2022. [PMID: 36517953 DOI: 10.1111/hepr.13869] [Reference Citation Analysis]
|
| 352 |
Long Y, Song X, Guan Y, Lan R, Huang Z, Li S, Zhang L. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022. [PMID: 36516040 DOI: 10.1111/jgh.16088] [Reference Citation Analysis]
|
| 353 |
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng. Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ Open 2022;12:e064688. [PMID: 36521893 DOI: 10.1136/bmjopen-2022-064688] [Reference Citation Analysis]
|
| 354 |
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Medicine 2022. [DOI: 10.1002/cam4.5535] [Reference Citation Analysis]
|
| 355 |
Volponi C, Gazzillo A, Bonavita E. The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. Cancers (Basel) 2022;14. [PMID: 36551635 DOI: 10.3390/cancers14246151] [Reference Citation Analysis]
|
| 356 |
Mawatari S, Tamai T, Kumagai K, Saisyoji A, Muromachi K, Toyodome A, Taniyama O, Sakae H, Ijuin S, Tabu K, Oda K, Hiramine Y, Moriuchi A, Sakurai K, Kanmura S, Ido A. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36551623 DOI: 10.3390/cancers14246139] [Reference Citation Analysis]
|
| 357 |
Woo SM, Kimchy AV, Sequeira LM, Dorris CS, He AR, Rangnekar AS. Immunotherapy Use Prior to Liver Transplant in Patients with Hepatocellular Carcinoma. Curr Oncol 2022;29:9813-25. [PMID: 36547185 DOI: 10.3390/curroncol29120771] [Reference Citation Analysis]
|
| 358 |
Da BL, He AR, Shetty K, Suchman KI, Yu H, Lau L, Wong LL, Rabiee A, Amdur RL, Crawford JM, Fox SS, Grimaldi GM, Shah PK, Weinstein J, Bernstein D, Satapathy SK, Chambwe N, Xiang X, Mishra L. Pathogenesis to management of hepatocellular carcinoma. Genes Cancer 2022;13:72-87. [DOI: 10.18632/genesandcancer.226] [Reference Citation Analysis]
|
| 359 |
Fahmy D, Alksas A, Elnakib A, Mahmoud A, Kandil H, Khalil A, Ghazal M, van Bogaert E, Contractor S, El-Baz A. The Role of Radiomics and AI Technologies in the Segmentation, Detection, and Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36551606 DOI: 10.3390/cancers14246123] [Reference Citation Analysis]
|
| 360 |
Fukunaga A, Takata K, Itoh S, Yamauchi R, Tanaka T, Yokoyama K, Shakado S, Kohashi K, Yoshizumi T, Hirai F. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab–bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis. Clin J Gastroenterol 2022. [DOI: 10.1007/s12328-022-01744-z] [Reference Citation Analysis]
|
| 361 |
Unome S, Imai K, Takai K, Miwa T, Hanai T, Nishigaki Y, Hayashi H, Kochi T, Shimizu S, Nagano J, Iritani S, Suetsugu A, Shimizu M. Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36551574 DOI: 10.3390/cancers14246089] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 362 |
Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa C, Toyoda H, Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouso K, Tsutsui A, Ohama H, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Kaibori M, Iijima H, Hiasa Y, the Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. Cancer Medicine 2022. [DOI: 10.1002/cam4.5495] [Reference Citation Analysis]
|
| 363 |
Finn RS, Yau T, Hsu CH, De Toni EN, Goyal L, Galle PR, Qin S, Rao S, Sun F, Wang C, Widau RC, Zhu AX. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2. Oncologist 2022;27:e938-48. [PMID: 36190331 DOI: 10.1093/oncolo/oyac183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 364 |
Sun KX, Cao SS, Shi FH, Guan Y, Tang M, Zhao MN, Jian YF, Cui B, Li ZY, Wang JW, Yu F, Ding Y. First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States. Therap Adv Gastroenterol 2022;15:17562848221140662. [PMID: 36518883 DOI: 10.1177/17562848221140662] [Reference Citation Analysis]
|
| 365 |
Tümen D, Heumann P, Gülow K, Demirci CN, Cosma LS, Müller M, Kandulski A. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines 2022;10. [PMID: 36551958 DOI: 10.3390/biomedicines10123202] [Reference Citation Analysis]
|
| 366 |
Xie F, Chen B, Yang X, Wang H, Zhang G, Wang Y, Wang Y, Zhang N, Xue J, Long J, Li Y, Sun H, Xun Z, Liu K, Chen X, Song Y, Yang X, Lu Z, Mao Y, Sang X, Lu Y, Zhao H. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma. Front Immunol 2022;13:1052937. [PMID: 36569829 DOI: 10.3389/fimmu.2022.1052937] [Reference Citation Analysis]
|
| 367 |
Stoehr F, Kloeckner R, Pinto Dos Santos D, Schnier M, Müller L, Mähringer-Kunz A, Dratsch T, Schotten S, Weinmann A, Galle PR, Mittler J, Düber C, Hahn F. Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC-A Proof-of-Concept Study. Cancers (Basel) 2022;14. [PMID: 36551521 DOI: 10.3390/cancers14246036] [Reference Citation Analysis]
|
| 368 |
Zhou Y, Wang S, Wu W, Ling J, Li H, Jia Q, Zheng J, Zheng X, Yu R, Wu Q, Shi Y, Lieftink C, Beijersbergen RL, Yuan S, Bernards R, Jin H, Qin W. Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. EBioMedicine 2023;87:104397. [PMID: 36502574 DOI: 10.1016/j.ebiom.2022.104397] [Reference Citation Analysis]
|
| 369 |
Martin C, Enrico D. Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. Front Oncol 2022;12:962947. [PMID: 36568253 DOI: 10.3389/fonc.2022.962947] [Reference Citation Analysis]
|
| 370 |
Eulberg D, Frömming A, Lapid K, Mangasarian A, Barak A. The prospect of tumor microenvironment-modulating therapeutical strategies. Front Oncol 2022;12:1070243. [PMID: 36568151 DOI: 10.3389/fonc.2022.1070243] [Reference Citation Analysis]
|
| 371 |
Shannon AH, Ruff SM, Pawlik TM. Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress. JHC 2022;Volume 9:1247-1261. [DOI: 10.2147/jhc.s383922] [Reference Citation Analysis]
|
| 372 |
Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget 2022;13:1314-21. [PMID: 36473155 DOI: 10.18632/oncotarget.28322] [Reference Citation Analysis]
|
| 373 |
Xiang L, Piao L, Wang D, Qi LF. Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma. Front Immunol 2022;13:974241. [PMID: 36544774 DOI: 10.3389/fimmu.2022.974241] [Reference Citation Analysis]
|
| 374 |
Su C, Teng W, Lin P, Jeng W, Chen K, Hsieh Y, Chen W, Ho M, Hsieh C, Wang C, Chai P, Lin C, Lin C, Lin S. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma. Cancer Medicine 2022. [DOI: 10.1002/cam4.5506] [Reference Citation Analysis]
|
| 375 |
Santarsiero A, Pappalardo I, Rosa GM, Pisano I, Superchi S, Convertini P, Todisco S, Scafato P, Infantino V. Mitochondrial Role in Intrinsic Apoptosis Induced by a New Synthesized Chalcone in Hepatocellular Carcinoma Cells. Biomedicines 2022;10. [PMID: 36551876 DOI: 10.3390/biomedicines10123120] [Reference Citation Analysis]
|
| 376 |
Sinner F, Pinter M, Scheiner B, Ettrich TJ, Sturm N, Gonzalez-Carmona MA, Waidmann O, Finkelmeier F, Himmelsbach V, De Toni EN, Ben Khaled N, Mohr R, Fründt TW, Kütting F, Bömmel FV, Lieb S, Krug S, Bettinger D, Schultheiß M, Jochheim LS, Best J, Müller C, Keitel V, Venerito M. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience. Cancers (Basel) 2022;14. [PMID: 36497447 DOI: 10.3390/cancers14235966] [Reference Citation Analysis]
|
| 377 |
Nowak-sliwinska P, van Beijnum JR, Griffioen CJ, Huinen ZR, Sopesens NG, Schulz R, Jenkins SV, Dings RPM, Groenendijk FH, Huijbers EJM, Thijssen VLJL, Jonasch E, Vyth-dreese FA, Jordanova ES, Bex A, Bernards R, de Gruijl TD, Griffioen AW. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis 2022. [DOI: 10.1007/s10456-022-09863-4] [Reference Citation Analysis]
|
| 378 |
Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 2022;310:121138. [DOI: 10.1016/j.lfs.2022.121138] [Reference Citation Analysis]
|
| 379 |
Bu MT, Chandrasekhar P, Ding L, Hugo W. The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. Pharmacol Ther 2022;240:108211. [PMID: 35577211 DOI: 10.1016/j.pharmthera.2022.108211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 380 |
Fornari F, Giovannini C, Piscaglia F, Gramantieri L. Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research. JHC 2022;Volume 9:1263-1278. [DOI: 10.2147/jhc.s347946] [Reference Citation Analysis]
|
| 381 |
Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T. Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data in Brief 2022;45:108558. [DOI: 10.1016/j.dib.2022.108558] [Reference Citation Analysis]
|
| 382 |
Chuah S, Tai D, Chew V. Reply to: "Challenges and issues in bivariate endpoints in study designs of translational medicine". J Hepatol 2022;77:1727-8. [PMID: 36028064 DOI: 10.1016/j.jhep.2022.08.017] [Reference Citation Analysis]
|
| 383 |
Deng M, Li S, Wang Q, Zhao R, Zou J, Lin W, Mei J, Wei W, Guo R. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann Med 2022;54:803-11. [PMID: 35272564 DOI: 10.1080/07853890.2022.2048416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 384 |
Reinders MTM, van Erpecum KJ, Smits MLJ, Braat AJAT, Bruijne J, Bruijnen R, Sprengers D, Man RA, Vegt E, IJzermans JNM, Moelker A, Lam MGEH. Safety and Efficacy of (166)Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study. J Nucl Med 2022;63:1891-8. [PMID: 35589409 DOI: 10.2967/jnumed.122.263823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 385 |
Yusa T, Yamashita YI, Okabe H, Nakao Y, Itoyama R, Kitano Y, Kaida T, Miyata T, Mima K, Imai K, Hayashi H, Baba H. Survival impact of immune cells infiltrating peritumoral area of hepatocellular carcinoma. Cancer Sci 2022;113:4048-58. [PMID: 35611468 DOI: 10.1111/cas.15437] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 386 |
Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, Tada T, Kumada T, Sho T, Lai E, Celsa C, Campani C, Tonnini M, Tamburini E, Hiraoka A, Takaguchi K, Nishida N, Iwamoto H, Itobayashi E, Tsuji K, Sakamoto N, Ishikawa T, Toyoda H, Kudo M, Kawaguchi T, Hatanaka T, Nouso K, Suda G, Cabibbo G, Marra F, Della Corte A, Ratti F, Pedica F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A. Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. Hepatol Res 2022;52:1050-9. [PMID: 35960789 DOI: 10.1111/hepr.13824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 387 |
Calderaro J, Di Tommaso L, Maillé P, Beaufrère A, Nguyen CT, Heij L, Gnemmi V, Graham RP, Charlotte F, Chartier S, Wendum D, Vij M, Allende D, Diaz A, Fuster C, Rivière B, Herrero A, Augustin J, Evert K, Calvisi DF, Leow WQ, Leung HHW, Bednarsch J, Boleslawski E, Rela M, Chan AW, Forner A, Reig M, Pujals A, Favre L, Allaire M, Scatton O, Uguen A, Trépo E, Sanchez LO, Chatelain D, Remmelink M, Boulagnon-Rombi C, Bazille C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Kather JN, Gouw ASH, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaiem R, Nault JC, Laurent A, Amaddeo G, Regnault H, de Martin E, Sempoux C, Navale P, Shinde J, Bacchuwar K, Westerhoff M, Lo RC, Sebbagh M, Guettier C, Lequoy M, Komuta M, Ziol M, Paradis V, Shen J, Caruso S. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. J Hepatol 2022;77:1586-97. [PMID: 35987274 DOI: 10.1016/j.jhep.2022.07.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 388 |
Lee SE, Kim K, Lee H, Park J. Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. Cancer Epidemiology 2022;81:102265. [DOI: 10.1016/j.canep.2022.102265] [Reference Citation Analysis]
|
| 389 |
Kim C, Yang H, Kim I, Kang B, Kim H, Kim H, Lee WS, Jung S, Lim HY, Cheon J, Chon HJ. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma. JAMA Oncol 2022;8:1825-9. [PMID: 36264560 DOI: 10.1001/jamaoncol.2022.4733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 390 |
Hayashi H, Sawada K, Hasebe T, Nakajima S, Sawada J, Takiyama Y, Takiyama Y, Okumura T, Fujiya M. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events. Intern Med 2022;61:3497-502. [PMID: 35491133 DOI: 10.2169/internalmedicine.9393-22] [Reference Citation Analysis]
|
| 391 |
Meier M, Nuciforo S, Coto-llerena M, Gallon J, Matter MS, Ercan C, Vosbeck J, Terracciano LM, Soysal SD, Boll D, Kollmar O, Delaloye R, Piscuoglio S, Heim MH. Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report. Commun Med 2022;2:80. [DOI: 10.1038/s43856-022-00150-3] [Reference Citation Analysis]
|
| 392 |
Ahn JC, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, Sundaram V, Kosari K, Nissen N, Gong J, Hendifar A, Roberts LR, Abou-Alfa GK, Singal AG, Yang JD. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology 2022;76:1649-59. [PMID: 35429171 DOI: 10.1002/hep.32527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 393 |
Lee S, Kim S, Song Y, Kim N, No J, Kim KM, Seo HR. Sorbitol dehydrogenase induction of cancer cell necroptosis and macrophage polarization in the HCC microenvironment suppresses tumor progression. Cancer Letters 2022;551:215960. [DOI: 10.1016/j.canlet.2022.215960] [Reference Citation Analysis]
|
| 394 |
Larrey E, Campion B, Evain M, Sultanik P, Blaise L, Giudicelli H, Wagner M, Cluzel P, Rudler M, Ganne-Carrié N, Thabut D, Allaire M. A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC. Liver Int 2022;42:2843-54. [PMID: 36254617 DOI: 10.1111/liv.15458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 395 |
Dong H, Jian Y, Wang M, Liu F, Zhang Q, Peng Z, Cheng N, Zhang W. Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04386-3] [Reference Citation Analysis]
|
| 396 |
Yang Q, Wu G. CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression. Gastroenterología y Hepatología (English Edition) 2022;45:742-752. [DOI: 10.1016/j.gastre.2021.11.004] [Reference Citation Analysis]
|
| 397 |
Li L, Zhang Y, Zhou Y, Hu H, Hu Y, Georgiades C, Mao HQ, Selaru FM. Quaternary nanoparticles enable sustained release of bortezomib for hepatocellular carcinoma. Hepatology 2022;76:1660-72. [PMID: 35596926 DOI: 10.1002/hep.32584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 398 |
Shao G, Bai Y, Yuan X, Chen X, Gu S, Gu K, Hu C, Liang H, Guo Y, Wang J, Yen CJ, Lee VH, Wang C, Widau RC, Zhang W, Liu J, Zhang Q, Qin S. Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study. EClinicalMedicine 2022;54:101679. [PMID: 36247923 DOI: 10.1016/j.eclinm.2022.101679] [Reference Citation Analysis]
|
| 399 |
Jaffe A, Taddei TH, Giannini EG, Ilagan-Ying YC, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver Int 2022;42:2607-19. [PMID: 36161463 DOI: 10.1111/liv.15432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 400 |
Li X, Sun W, Ding X, Li W, Chen J. Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma. Front Immunol 2022;13:1060051. [PMID: 36532029 DOI: 10.3389/fimmu.2022.1060051] [Reference Citation Analysis]
|
| 401 |
Fonseca LG, Uratani LF, Soares GF, Amaral PS, Alencar RSSM, Chagas AL, Alves VAF, Carrilho FJ. Early variation of inflammatory indexes refines prognostic prediction in patients with hepatocellular carcinoma under systemic treatment.. [DOI: 10.21203/rs.3.rs-2294812/v1] [Reference Citation Analysis]
|
| 402 |
Zhang Y, Zhang X, Kuang M, Yu J. Emerging Insights on Immunotherapy in Liver Cancer. Antioxid Redox Signal 2022;37:1325-38. [PMID: 35754339 DOI: 10.1089/ars.2022.0047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 403 |
Lin X. Development of PD-1 / PD-L1 in the treatment of liver cancer. IJBLS 2022;1:57-59. [DOI: 10.54097/ijbls.v1i1.3233] [Reference Citation Analysis]
|
| 404 |
Lu G, Du R, Feng B, Wang J, Zhang F, Pei J, Wang Y, Shang Y. A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC. JIR 2022;Volume 15:6729-6743. [DOI: 10.2147/jir.s390113] [Reference Citation Analysis]
|
| 405 |
Gao Y, Su Z, Wang C, Xu J, Hu S, Zhang C, Sun P, Zhou X, Wang W, Zou T, Yang B, Cheng X, Yi X, Zheng Q. Light-Triggered Polymeric Prodrug and Nano-assembly for Chemo-Photodynamic Therapy and Potentiate Immune Checkpoint Blockade Immunotherapy for Hepatocellular Carcinoma. Materials & Design 2022. [DOI: 10.1016/j.matdes.2022.111457] [Reference Citation Analysis]
|
| 406 |
Kao WY, Su CW. Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter? Liver Int 2022;42:2597-8. [PMID: 36415175 DOI: 10.1111/liv.15434] [Reference Citation Analysis]
|
| 407 |
Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, Feng M, Wang F, Cheng J, Li Z, Zhan Q, Deng M, Zhu J, Zhang Z, Zhang N. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 2022;612:141-7. [PMID: 36352227 DOI: 10.1038/s41586-022-05400-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 408 |
Alhaddad H, Wong W, Abou-Gharbia M, Childers W, Melenski E, Bell RL, Sari Y. Effects of a Novel Beta Lactam Compound, MC-100093, on the Expression of Glutamate Transporters/Receptors and Ethanol Drinking Behavior of Alcohol-Preferring Rats. J Pharmacol Exp Ther 2022;383:208-16. [PMID: 36153003 DOI: 10.1124/jpet.122.001147] [Reference Citation Analysis]
|
| 409 |
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2022;23:1126-240. [PMID: 36447411 DOI: 10.3348/kjr.2022.0822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 410 |
Berger PA, Freitag J, Linkenbach SC, Merz L, Schork M, Thevissen S, Yildiz I, Beck JD. CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy. Hum Vaccin Immunother 2022;18:2124785. [PMID: 36222759 DOI: 10.1080/21645515.2022.2124785] [Reference Citation Analysis]
|
| 411 |
Chen Y, Zeng L, Zhu H, Wu Q, Liu R, Liang Q, Chen B, Dai H, Tang K, Liao C, Huang Y, Yan X, Fan K, Du J, Lin R, Wang J. Ferritin Nanocaged Doxorubicin Potentiates Chemo‐Immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death. Small Methods 2022. [DOI: 10.1002/smtd.202201086] [Reference Citation Analysis]
|
| 412 |
Li X, Ding X, Li W, Chen J. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03324-z] [Reference Citation Analysis]
|
| 413 |
Edeline J, Meyer T, Blanc JF, Raoul JL. New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations. Cancers (Basel) 2022;14. [PMID: 36497349 DOI: 10.3390/cancers14235868] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 414 |
Wu YL, Fulgenzi CAM, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ, Ang C. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. Cancers (Basel) 2022;14. [PMID: 36497316 DOI: 10.3390/cancers14235834] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 415 |
Kolligs F, Arnold D, Golfieri R, Pech M, Peynircioglu B, Pfammatter T, Ronot M, Sangro B, Schaefer N, Maleux G, Munneke G, Pereira H, Zeka B, de Jong N, Helmberger T; CIRT Principal Investigators. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study. JHEP Rep 2023;5:100633. [PMID: 36593888 DOI: 10.1016/j.jhepr.2022.100633] [Reference Citation Analysis]
|
| 416 |
Rizzo A, Carloni R, Ricci AD, Cusmai A, Laforgia M, Calabrò C, Ungaro V, Oreste D, Sollitto M, Palmiotti G, Brandi G. Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis. Expert Opinion on Drug Safety 2022. [DOI: 10.1080/14740338.2023.2152793] [Reference Citation Analysis]
|
| 417 |
Venkatesh P, Yan KL, Bravo-Jaimes K, Yang EH, Lluri G. Outcomes of malignancy in adults with congenital heart disease: a single center experience. Cardiooncology 2022;8:20. [PMID: 36419184 DOI: 10.1186/s40959-022-00144-z] [Reference Citation Analysis]
|
| 418 |
Breder VV, Pokataev IA, Abdelgafur OAYMZ, Avramenko IV, Goryainova AY, Kiselyov NM. Hepatocellular cancer of non-viral etiology: more questions than answers? Medicinskij alfavit 2022. [DOI: 10.33667/2078-5631-2022-26-7-12] [Reference Citation Analysis]
|
| 419 |
Eltarhoni K, Kamel F, Ihebunezie K, Nisar P, Soloviev M. Therapeutic Antibodies in Cancer Treatment in the UK. Int J Mol Sci 2022;23. [PMID: 36498915 DOI: 10.3390/ijms232314589] [Reference Citation Analysis]
|
| 420 |
Morine Y, Utsunomiya T, Yamanaka-Okumura H, Saito Y, Yamada S, Ikemoto T, Imura S, Kinoshita S, Hirayama A, Tanaka Y, Shimada M. Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis. Oncotarget 2022;13:1286-98. [PMID: 36441784 DOI: 10.18632/oncotarget.28306] [Reference Citation Analysis]
|
| 421 |
He P, Wan H, Wan J, Jiang H, Yang Y, Xie K, Wu H. Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1015527] [Reference Citation Analysis]
|
| 422 |
Zheng X, Qian K. Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization combined with tyrosine kinase inhibitors plus programmed cell death ligand 1 antibody for unresectable hepatocellular carcinoma. Anticancer Drugs 2022. [PMID: 36730299 DOI: 10.1097/CAD.0000000000001458] [Reference Citation Analysis]
|
| 423 |
Ramnaraign BH, Lee J, Ali A, Rogers SC, Fabregas JC, Thomas RM, Allegra CJ, Sahin I, Deremer DL, George TJ, Chatzkel JA. Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial. Future Oncology 2022. [DOI: 10.2217/fon-2022-0392] [Reference Citation Analysis]
|
| 424 |
Chen J, Wu Z, He K, Guo L, Rao M, Zhang J, Li H, Su K, Xu K, Gu T, Wang P, Zeng H, Hu L, Han Y. A Potential Predictive Marker for Advanced Hepatocellular Carcinoma PD-1 Inhibitors Combined with Radiation: Expression of PD-L1 on Circulating Tumor Cells.. [DOI: 10.21203/rs.3.rs-2277477/v1] [Reference Citation Analysis]
|
| 425 |
Tang C, Qin S, Li Q, Huang Y. Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients. Medicine (Baltimore) 2022;101:e31665. [PMID: 36401404 DOI: 10.1097/MD.0000000000031665] [Reference Citation Analysis]
|
| 426 |
Ouranos K, Chatziioannou A, Goulis I, Sinakos E. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World J Transplant 2022; 12(11): 331-346 [DOI: 10.5500/wjt.v12.i11.331] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 427 |
Goswami P, Adeniran OR, K. Frantz S, Matsuoka L, Du L, Gandhi RT, Collins ZS, Matrana MR, Petroziello M, Brower JS, Sze DY, Kennedy AS, Golzarian J, Wang EA, Brown DB. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C). BMC Gastroenterol 2022;22:467. [DOI: 10.1186/s12876-022-02528-y] [Reference Citation Analysis]
|
| 428 |
Conway JW, Braden J, Wilmott JS, Scolyer RA, Long GV, Pires da Silva I. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1030147] [Reference Citation Analysis]
|
| 429 |
Qi X, Guo J, Chen G, Fang C, Hu L, Li J, Zhang C. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. J Immunol Res 2022;2022:3393027. [PMID: 36438201 DOI: 10.1155/2022/3393027] [Reference Citation Analysis]
|
| 430 |
Zhang L, Xu J, Chu X, Zhang H, Yao X, Zhang J, Guo Y. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma. BMC Bioinformatics 2022;23:485. [PMID: 36384423 DOI: 10.1186/s12859-022-04997-0] [Reference Citation Analysis]
|
| 431 |
Zhang Y, Li Y, Xia Q, Li Y, Jin S, Mao Q, Liu C, Fan X, Lin H. Cell membrane-coated human hair nanoparticles for precise disease therapies. J Nanobiotechnol 2022;20:480. [DOI: 10.1186/s12951-022-01673-6] [Reference Citation Analysis]
|
| 432 |
Hsu Y, Chen C, Huang H, Lee Y, Wu M, Su C, Chou H, Wang L, Lee H, Lin S, Hsu P, Wu Y, Sheu J, Weng M. Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus. Transplantation 2022;Publish Ahead of Print. [DOI: 10.1097/tp.0000000000004425] [Reference Citation Analysis]
|
| 433 |
Damaskos C, Garmpis N, Dimitroulis D, Garmpi A, Psilopatis I, Sarantis P, Koustas E, Kanavidis P, Prevezanos D, Kouraklis G, Karamouzis MV, Marinos G, Kontzoglou K, Antoniou EA. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review. Int J Mol Sci 2022;23. [PMID: 36430594 DOI: 10.3390/ijms232214117] [Reference Citation Analysis]
|
| 434 |
Zhang J, Han H, Wang L, Wang W, Yang M, Qin Y. Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.988956] [Reference Citation Analysis]
|
| 435 |
Li SQ, Yang Y, Ye LS. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World J Gastroenterol 2022; 28(42): 6034-6044 [DOI: 10.3748/wjg.v28.i42.6034] [Reference Citation Analysis]
|
| 436 |
Ruff SM, Shannon AH, Pawlik TM. Advances in Targeted Immunotherapy for Hepatobiliary Cancers. Int J Mol Sci 2022;23. [PMID: 36430440 DOI: 10.3390/ijms232213961] [Reference Citation Analysis]
|
| 437 |
Deichaite I, Sears TJ, Sutton L, Rebibo D, Morgan K, Nelson T, Rose B, Tamayo P, Ferrara N, Asimakopoulos F, Carter H. Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer. J Transl Med 2022;20:527. [PMID: 36371231 DOI: 10.1186/s12967-022-03731-x] [Reference Citation Analysis]
|
| 438 |
Tomiyama T, Itoh S, Toshida K, Morinaga A, Fujimoto-Kosai Y, Tomino T, Kurihara T, Nagao Y, Morita K, Harada N, Kohashi K, Eguchi Y, Oda Y, Mori M, Yoshizumi T. A rare case of unresectable, microsatellite instability-high hepatocellular carcinoma and an examination of the tumor microenvironment. Int Cancer Conf J 2023;12:81-6. [PMID: 36605838 DOI: 10.1007/s13691-022-00585-4] [Reference Citation Analysis]
|
| 439 |
Mena E, Shih J, Chung J, Jones J, Rabiee A, Monge C, Turkbey B, Lindenberg L, Salerno KE, Kassin M, Wood B, Hernandez J, Maass-moreno R, Saboury B, Jakhete N, Molitoris JK, Unger KR, Choyke PL, Escorcia FE. Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma. PLoS ONE 2022;17:e0277407. [DOI: 10.1371/journal.pone.0277407] [Reference Citation Analysis]
|
| 440 |
Gray S, Lamarca A, Mcnamara MG, Edeline J, Piper‐hanley K, Valle JW, Hubner RA. Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma. Liver Cancer International 2022. [DOI: 10.1002/lci2.62] [Reference Citation Analysis]
|
| 441 |
Liu J, Waugh MG. The regulation and functions of ACSL3 and ACSL4 in the liver and hepatocellular carcinoma. Liver Cancer International 2022. [DOI: 10.1002/lci2.68] [Reference Citation Analysis]
|
| 442 |
Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022. [PMID: 36369487 DOI: 10.1038/s41575-022-00704-9] [Reference Citation Analysis]
|
| 443 |
Tornesello ML, Tornesello AL, Starita N, Cerasuolo A, Izzo F, Buonaguro L, Buonaguro FM. Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data. Expert Opinion on Therapeutic Targets 2022. [DOI: 10.1080/14728222.2022.2147062] [Reference Citation Analysis]
|
| 444 |
Zhang Y, Huang H, Jin L, Lin S. Anticarcinogenic Effects of Isothiocyanates on Hepatocellular Carcinoma. Int J Mol Sci 2022;23. [PMID: 36430307 DOI: 10.3390/ijms232213834] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 445 |
Yang Y, Xiao W, Liu R, Gao L, Chen J, Kan H. A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-23. [DOI: 10.1155/2022/4983532] [Reference Citation Analysis]
|
| 446 |
Zheng W, Qian C, Tang Y, Yang C, Zhou Y, Shen P, Chen W, Yu S, Wei Z, Wang A, Lu Y, Zhao Y. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1035323] [Reference Citation Analysis]
|
| 447 |
Kirchhammer N, Trefny MP, Auf der Maur P, Läubli H, Zippelius A. Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment. Sci Transl Med 2022;14. [DOI: 10.1126/scitranslmed.abo3605] [Reference Citation Analysis]
|
| 448 |
Matteucci L, Rapposelli IG, Passardi A. Editorial: Identification of novel biomarkers for pancreatic and hepatocellular cancers. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1056002] [Reference Citation Analysis]
|
| 449 |
Lee J, Hung Y, Chou K, Lee C, Lin S, Tsai Y, Lai W, Shao Y, Hsu C, Hsu C, Chao Y. Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1008855] [Reference Citation Analysis]
|
| 450 |
Chen Y, Wang C, Chen Y, Wang J, Hung C, Kuo Y. Low-dose nivolumab in advanced hepatocellular carcinoma. BMC Cancer 2022;22:1153. [DOI: 10.1186/s12885-022-10271-6] [Reference Citation Analysis]
|
| 451 |
Li R, Jin C, Zhao W, Liang R, Xiong H. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. BMC Gastroenterol 2022;22:450. [DOI: 10.1186/s12876-022-02540-2] [Reference Citation Analysis]
|
| 452 |
Ji M, Zou H, Shu B, Liu G, Zhang B, Xu Z, Pang F, Cheng M, Sun Y, Du T, Sun C, Zhu C. Prognostic analysis of hepatocellular carcinoma with macrovascular invasion after liver resection and a successful case of conversion therapy. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.1042431] [Reference Citation Analysis]
|
| 453 |
Leung RWH, Lee TKW. Wnt/β-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers 2022;14:5468. [DOI: 10.3390/cancers14215468] [Reference Citation Analysis]
|
| 454 |
Xian F, Wu C, Zhang G, Xu G. Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2022;101:e31479. [PMID: 36343054 DOI: 10.1097/MD.0000000000031479] [Reference Citation Analysis]
|
| 455 |
Fukuchi K, Nanai K, Yuita H, Maru C, Tsukada J, Ishigami M, Nagai Y, Nakano Y, Yoshimura C, Yoneda K, Amano M, Nakamura K, Oda Y, Nishigohri H, Yamamoto S, Ohnishi-totoki Y, Inaki K, Komori H, Nakano R, Kanari Y, Nishida A, Matsui Y, Funo S, Takahashi S, Ohtsuka T, Agatsuma T. Novel Antibody Exerts Antitumor Effect through Downregulation of CD147 and Activation of Multiple Stress Signals. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/3552793] [Reference Citation Analysis]
|
| 456 |
Chung A, Nasralla D, Quaglia A. Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective. J Hepatocell Carcinoma 2022;9:1149-69. [PMID: 36349146 DOI: 10.2147/JHC.S382310] [Reference Citation Analysis]
|
| 457 |
Sové RJ, Verma BK, Wang H, Ho WJ, Yarchoan M, Popel AS. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. J Immunother Cancer 2022;10. [PMID: 36323435 DOI: 10.1136/jitc-2022-005414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 458 |
Piscaglia F, Ravaioli F. Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies. Dig Liver Dis 2022;54:1561-2. [PMID: 36127229 DOI: 10.1016/j.dld.2022.08.032] [Reference Citation Analysis]
|
| 459 |
Li L, Liu HT, Teng YX, Deng ZJ, Zhang GL, Su JY, Ma L, Zhong JH. Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. Expert Opin Investig Drugs 2022;31:1151-67. [PMID: 36437752 DOI: 10.1080/13543784.2022.2151891] [Reference Citation Analysis]
|
| 460 |
Ruff SM, Shannon AH, Beane JD, Pawlik TM. Highlighting novel targets in immunotherapy for liver cancer. Expert Rev Gastroenterol Hepatol 2022;16:1029-41. [PMID: 36404729 DOI: 10.1080/17474124.2022.2150841] [Reference Citation Analysis]
|
| 461 |
Huang J, Zhong B, Jiang N, Li W, Zhang S, Yin Y, Yang J, Shen J, Wang W, Zhu X. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma. JHC 2022;Volume 9:1217-1228. [DOI: 10.2147/jhc.s386672] [Reference Citation Analysis]
|
| 462 |
Knavel Koepsel EM, Smolock AR, Pinchot JW, Kim CY, Ahmed O, Chamarthy MRK, Hecht EM, Hwang GL, Kaplan DE, Luh JY, Marrero JA, Monroe EJ, Poultsides GA, Scheidt MJ, Hohenwalter EJ; Expert Panel on Interventional Radiology. ACR Appropriateness Criteria® Management of Liver Cancer: 2022 Update. J Am Coll Radiol 2022;19:S390-408. [PMID: 36436965 DOI: 10.1016/j.jacr.2022.09.005] [Reference Citation Analysis]
|
| 463 |
Storandt MH, Mahipal A, Tella SH, Kommalapati A, Jin Z. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations. JHC 2022;Volume 9:1187-1200. [DOI: 10.2147/jhc.s365002] [Reference Citation Analysis]
|
| 464 |
Prince DS, Schlaphoff G, Davison SA, Huo YR, Xiang H, Chan MV, Lee AU, Thailakanathan C, Jebeili H, Rogan C, Al-Omary A, Gupta S, Lockart I, Tiwari N, Clark-Dickson M, Hillhouse JW, Laube R, Chang J, Nguyen V, Danta M, Cheng R, Strasser SI, Zekry A, Levy MT, Chan C, Liu K. Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study. J Gastroenterol Hepatol 2022;37:2173-81. [PMID: 36031345 DOI: 10.1111/jgh.15986] [Reference Citation Analysis]
|
| 465 |
Iijima T, Obata S, Chuma M, Miyagi E, Aoki S. Rapid progression of hepatocellular carcinoma in a pregnant woman: A case report. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.6558] [Reference Citation Analysis]
|
| 466 |
Suthen S, Lim CJ, Nguyen PHD, Dutertre CA, Lai HLH, Wasser M, Chua C, Lim TKH, Leow WQ, Loh TJ, Wan WK, Pang YH, Soon G, Cheow PC, Kam JH, Iyer S, Kow A, Tam WL, Shuen TWH, Toh HC, Dan YY, Bonney GK, Chan CY, Chung A, Goh BKP, Zhai W, Ginhoux F, Chow PKH, Albani S, Chew V. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology 2022;76:1329-44. [PMID: 35184329 DOI: 10.1002/hep.32419] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 467 |
de la Torre-Aláez M, Matilla A, Varela M, Iñarrairaegui M, Reig M, Lledó JL, Arenas JI, Lorente S, Testillano M, Márquez L, Da Fonseca L, Argemí J, Gómez-Martin C, Rodriguez-Fraile M, Bilbao JI, Sangro B. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J Immunother Cancer 2022;10. [PMID: 36450386 DOI: 10.1136/jitc-2022-005457] [Reference Citation Analysis]
|
| 468 |
Mao L, Fang M, Chen Y, Wei X, Cao J, Lin J, Zhang P, Chen L, Cao X, Chen Y, Guo J, Si L. Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study. Clin Cancer Res 2022;28:4642-8. [PMID: 36044526 DOI: 10.1158/1078-0432.CCR-22-1528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 469 |
Harkus U, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Semin Cancer Biol 2022;86:799-815. [PMID: 35065242 DOI: 10.1016/j.semcancer.2022.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 470 |
Stefanini B, Bucci L, Santi V, Reggidori N, Rampoldi D, Lani L, Granito A, Sangiovanni A, Cabibbo G, Farinati F, Campani C, Foschi FG, Svegliati-Baroni G, Raimondo G, Gasbarrini A, Mega A, Biasini E, Sacco R, Morisco F, Caturelli E, Vidili G, Azzaroli F, Giannini EG, Rapaccini GL, Brunetto MR, Masotto A, Nardone G, Di Marco M, Magalotti D, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. Dig Liver Dis 2022;54:1563-72. [PMID: 35906166 DOI: 10.1016/j.dld.2022.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 471 |
Kandalaft LE, Dangaj Laniti D, Coukos G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer 2022;22:640-56. [PMID: 36109621 DOI: 10.1038/s41568-022-00503-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 472 |
Charonpongsuntorn C, Tanasanvimon S, Korphaisarn K, Payapwattanawong S, Siripoon T, Pakvisal N, Juengsamarn J, Phaibulvatanapong E, Chindaprasirt J, Prasongsook N, Udomdamrongkul K, Ngamphaiboon N, Sirachainan E. Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study. JCO Glob Oncol 2022;8:e2200205. [PMID: 36455172 DOI: 10.1200/GO.22.00205] [Reference Citation Analysis]
|
| 473 |
Anderson TS, Wooster AL, Piersall SL, Okpalanwaka IF, Lowe DB. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Semin Cancer Biol 2022;86:981-96. [PMID: 35149179 DOI: 10.1016/j.semcancer.2022.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 474 |
Zheng-Lin B, Faleck DM, Harding JJ. Subacute Abdominal Pain in a Patient With Chronic Liver Disease and Hepatocellular Carcinoma. JAMA Oncol 2022;8:1688-9. [PMID: 36136344 DOI: 10.1001/jamaoncol.2022.3888] [Reference Citation Analysis]
|
| 475 |
Testa U, Pelosi E, Castelli G. Clinical value of identifying genes that inhibit hepatocellular carcinomas. Expert Rev Mol Diagn 2022;22:1009-35. [PMID: 36459631 DOI: 10.1080/14737159.2022.2154658] [Reference Citation Analysis]
|
| 476 |
Miao K, Zhang L. Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. Cancer Pathogenesis and Therapy 2022. [DOI: 10.1016/j.cpt.2022.11.003] [Reference Citation Analysis]
|
| 477 |
Saghafian Larijani R, Shabani Ravari N, Goodarzi N, Akhlaghpour S, Saghafian Larijani S, Rouini MR, Dinarvand R. Current status of transarterial chemoembolization (TACE) agents in hepatocellular carcinoma treatment. Journal of Drug Delivery Science and Technology 2022;77:103905. [DOI: 10.1016/j.jddst.2022.103905] [Reference Citation Analysis]
|
| 478 |
Lai Z, Huang Y, Wen D, Lin X, Kan A, Li Q, Wei W, Chen M, Xu L, He M, Shi M. One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. BMC Med 2022;20:415. [PMID: 36310160 DOI: 10.1186/s12916-022-02608-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 479 |
Sung PS, Lee IK, Roh PR, Kang MW, Ahn J, Yoon SK. Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1028728] [Reference Citation Analysis]
|
| 480 |
Yang C, Lee D, Zhang MS, Tse AP, Wei L, Bao MH, Wong BP, Chan CY, Yuen VW, Chen Y, Wong CC. Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment. Adv Sci (Weinh) 2022;9:e2202104. [PMID: 36310121 DOI: 10.1002/advs.202202104] [Reference Citation Analysis]
|
| 481 |
Fujita M, Chen MM, Siwak DR, Sasagawa S, Oosawa-Tatsuguchi A, Arihiro K, Ono A, Miura R, Maejima K, Aikata H, Ueno M, Hayami S, Yamaue H, Chayama K, Lee JS, Lu Y, Mills GB, Liang H, Nishizuka SS, Nakagawa H. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nat Commun 2022;13:6481. [PMID: 36309506 DOI: 10.1038/s41467-022-34249-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 482 |
Rizzo A, Ricci AD, Brandi G. Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. J Pers Med 2022;12. [PMID: 36579504 DOI: 10.3390/jpm12111788] [Reference Citation Analysis]
|
| 483 |
Tong W, Cheng M, Lin M, Hu H, Pan J, Huang H, Wang Y, Xie X, Lu M, Kuang M, Huang Y, Wang W. Identification of the origin of tumor in vein: comparison between CEUS LI-RADS v2017 and v2016 for patients at high risk. BMC Med Imaging 2022;22:186. [DOI: 10.1186/s12880-022-00912-4] [Reference Citation Analysis]
|
| 484 |
Sun T, Guo Y, Sun B, Chen L, Ren Y, Zhu L, Zhang L, Liu Y, Zheng C. Association of the Pretreatment Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2083309/v2] [Reference Citation Analysis]
|
| 485 |
Chen Z, Wu H, Jiang S, Liu X, Luo M, Yuan Y. Serum SALL4 as a predictive biomarker for the prognosis of patients with hepatocellular carcinoma who underwent nonsurgical treatment. Medicine (Baltimore) 2022;101:e31200. [PMID: 36316931 DOI: 10.1097/MD.0000000000031200] [Reference Citation Analysis]
|
| 486 |
Wei Q, Taskén K. Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. Biochemical Journal 2022;479:2219-2260. [DOI: 10.1042/bcj20210233] [Reference Citation Analysis]
|
| 487 |
Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, Cammarota A, Fründt TW, von Felden J, Schulze K, Himmelsbach V, Finkelmeier F, Deibel A, Siebenhüner AR, Shmanko K, Radu P, Schwacha-Eipper B, Ebert MP, Teufel A, Djanani A, Hucke F, Balcar L, Philipp AB, Hsiehchen D, Venerito M, Sinner F, Trauner M, D'Alessio A, Fulgenzi CAM, Pinato DJ, Peck-Radosavljevic M, Dufour JF, Weinmann A, Kremer AE, Singal AG, De Toni EN, Rimassa L, Pinter M. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep 2023;5:100620. [PMID: 36578451 DOI: 10.1016/j.jhepr.2022.100620] [Reference Citation Analysis]
|
| 488 |
Cassese G, Han HS, Lee B, Lee HW, Cho JY, Panaro F, Troisi RI. Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. World J Hepatol 2022;14:1862-74. [PMID: 36340753 DOI: 10.4254/wjh.v14.i10.1862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 489 |
Feng H, Zhuo Y, Zhang X, Li Y, Li Y, Duan X, Shi J, Xu C, Gao Y, Yu Z. Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. J Hepatocell Carcinoma 2022;9:1109-25. [PMID: 36320666 DOI: 10.2147/JHC.S381764] [Reference Citation Analysis]
|
| 490 |
Dennis C, Prince DS, Moayed-alaei L, Remash D, Carr-boyd E, Bowen DG, Strasser SI, Crawford M, Pulitano C, Kench J, Mccaughan GW, Mckenzie C, Liu K. Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.997093] [Reference Citation Analysis]
|
| 491 |
Zhu AX, Lin Y, Ferry D, Widau RC, Saha A. Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Immunotherapy 2022. [DOI: 10.2217/imt-2022-0089] [Reference Citation Analysis]
|
| 492 |
Li X, Zhang Q, Lu Q, Cheng Z, Liu F, Han Z, Yu X, Yu J, Liang P. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1023983] [Reference Citation Analysis]
|
| 493 |
Lee IC, Lee PC, Chao Y, Chi CT, Wu CJ, Hung YP, Su CW, Hou MC, Huang YH. Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment. Viruses 2022;14. [PMID: 36366452 DOI: 10.3390/v14112355] [Reference Citation Analysis]
|
| 494 |
Bai J, Tang R, Zhou K, Chang J, Wang H, Zhang Q, Shi J, Sun C. An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma. BMC Med Genomics 2022;15:222. [PMID: 36284275 DOI: 10.1186/s12920-022-01380-z] [Reference Citation Analysis]
|
| 495 |
Augustine T, John P, Friedman T, Jiffry J, Guzik H, Mannan R, Gupta R, Delano C, Mariadason JM, Zang X, Maitra R, Goel S. Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1018767] [Reference Citation Analysis]
|
| 496 |
Storandt MH, Gile JJ, Palmer ME, Zemla TJ, Ahn DH, Bekaii-Saab TS, Jin Z, Tran NH, Mahipal A. Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36358592 DOI: 10.3390/cancers14215173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 497 |
Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M, Nakao K, Sasaki R, Hirai F, Shakado S, Yoshizumi T, Itoh S, Yatsuhashi H, Bekki S, Ido A, Mawatari S, Honda K, Sugimoto R, Senju T, Takahashi H, Kuwashiro T, Maeshiro T, Nakamuta M, Aratake Y, Yamashita T, Otsuka Y, Matsumoto S, Sohda T, Shimose S, Murotani K, Tanaka Y. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Targ Oncol. [DOI: 10.1007/s11523-022-00921-x] [Reference Citation Analysis]
|
| 498 |
Sharma P, Anandhan S, Siddiqui BA, Goswami S, Subudhi SK, Gao J, Peggs K, Quezada S, Allison JP. Cancer Immunotherapy. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm068.pub2] [Reference Citation Analysis]
|
| 499 |
Sterling C Jr, Márquez-Garbán D, Vadgama JV, Pietras RJ. Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. Cancers (Basel) 2022;14. [PMID: 36291938 DOI: 10.3390/cancers14205154] [Reference Citation Analysis]
|
| 500 |
Wang X, Wu L, Dou Q, Ai L, Lu Y, Deng S, Liu Q, Ji H, Zhang H. Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response. Front Mol Biosci 2022;9:1034928. [DOI: 10.3389/fmolb.2022.1034928] [Reference Citation Analysis]
|
| 501 |
Bast RC, Zalutsky MR. Monoclonal Antibody and Targeted Toxin Therapy. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm065.pub2] [Reference Citation Analysis]
|
| 502 |
Li Q, Su T, Zhang X, Pan Y, Ma S, Zhang L, Zhang X, Gao X. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma. Cancer Manag Res 2022;14:3037-46. [PMID: 36275784 DOI: 10.2147/CMAR.S379911] [Reference Citation Analysis]
|
| 503 |
Zhao S, Zhou M, Wang P, Yang J, Zhang D, Yin F, Song P. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis. Technol Cancer Res Treat 2022;21:15330338221133640. [PMID: 36259214 DOI: 10.1177/15330338221133640] [Reference Citation Analysis]
|
| 504 |
Hata H, Matsumura C, Chisaki Y, Nishioka K, Tokuda M, Miyagi K, Suizu T, Yano Y. A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. Cancer Control 2022;29:10732748221130576. [PMID: 36254804 DOI: 10.1177/10732748221130576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 505 |
Personeni N, Pressiani T, Zanuso V, Casadei-Gardini A, D'Alessio A, Valgiusti M, Dadduzio V, Bergamo F, Soldà C, Rizzato MD, Giordano L, Santoro A, Rimassa L. Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment. J Pers Med 2022;12. [PMID: 36294865 DOI: 10.3390/jpm12101726] [Reference Citation Analysis]
|
| 506 |
Amioka K, Kawaoka T, Kinami T, Yamasaki S, Kosaka M, Johira Y, Yano S, Naruto K, Ando Y, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Kosaka Y, Ohya K, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Morio K, Moriya T, Naeshiro N, Nonaka M, Aisaka Y, Azakami T, Hiramatsu A, Aikata H, Oka S. Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2022;14:5066. [PMID: 36291850 DOI: 10.3390/cancers14205066] [Reference Citation Analysis]
|
| 507 |
Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022;400:1345-62. [PMID: 36084663 DOI: 10.1016/S0140-6736(22)01200-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 508 |
Hagiwara S, Komeda Y, Nishida N, Yoshida A, Kudo M. A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy. Cancer Rep (Hoboken) 2022;5:e1721. [PMID: 36224043 DOI: 10.1002/cnr2.1721] [Reference Citation Analysis]
|
| 509 |
Pu Z, Liu J, Liu Z, Peng F, Zhu Y, Wang X, He J, Yi P, Hu X, Fan X, Chen J. STING pathway contributes to the prognosis of hepatocellular carcinoma and identification of prognostic gene signatures correlated to tumor microenvironment. Cancer Cell Int 2022;22:314. [PMID: 36224658 DOI: 10.1186/s12935-022-02734-4] [Reference Citation Analysis]
|
| 510 |
Mo Z, Liu D, Chen Y, Luo J, Li W, Liu J, Yu L, Huang B, Zhang S. Single-cell transcriptomics reveals the role of Macrophage-Naïve CD4 + T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma. J Transl Med 2022;20:466. [PMID: 36221095 DOI: 10.1186/s12967-022-03675-2] [Reference Citation Analysis]
|
| 511 |
Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:1065-79. [PMID: 36254201 DOI: 10.2147/JHC.S369951] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 512 |
Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, Aino H, Yamaguchi T, Itano S, Suga H, Niizeki T, Moriyama E, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Kawaguchi T, Kuromatsu R, Koga H, Torimura T. Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma. Sci Rep 2022;12:17018. [PMID: 36220865 DOI: 10.1038/s41598-022-21528-2] [Reference Citation Analysis]
|
| 513 |
Saoudi González N, Castet F, Élez E, Macarulla T, Tabernero J. Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. Front Oncol 2022;12:1021772. [DOI: 10.3389/fonc.2022.1021772] [Reference Citation Analysis]
|
| 514 |
Kondo Y, Morosawa T, Minami S, Tanaka Y. DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC. Sci Rep 2022;12:16868. [PMID: 36207618 DOI: 10.1038/s41598-022-21472-1] [Reference Citation Analysis]
|
| 515 |
Xu X, Liu L, Wang H, Li W, Zou Y, Zeng Y, Yang Q, Bai D, Dai D. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy. ACS Biomater Sci Eng 2022. [PMID: 36206367 DOI: 10.1021/acsbiomaterials.2c00639] [Reference Citation Analysis]
|
| 516 |
Sugimoto R, Satoh T, Ueda A, Senju T, Tanaka Y, Yamashita S, Koyanagi T, Kurashige T, Higuchi N, Nakamura T, Tanaka M, Azuma Y, Ohno A, Ooho A, Ooe M, Mutsuki T, Uchimura K, Kuniyoshi M, Tada S, Aratake Y, Yoshimoto T, Yamashita N, Harada S, Nakamuta M, Motomura K, Kohjima M; Liver disease Investigators’ Network of Kyushu University & Surrounding Hospitals (LINKS). Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study. Medicine (Baltimore) 2022;101:e30871. [PMID: 36221372 DOI: 10.1097/MD.0000000000030871] [Reference Citation Analysis]
|
| 517 |
Li W, Liu Y, Wang C, Yong C, Lin C, Yen Y. Radiographic tumor burden score is useful for stratifying the overall survival of hepatocellular carcinoma patients undergoing resection at different Barcelona Clinic Liver.. [DOI: 10.21203/rs.3.rs-2121956/v1] [Reference Citation Analysis]
|
| 518 |
Zhou X, Wang Y, Zheng J, Wang S, Liu C, Yao X, Ren Y, Wang X. Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer. Front Genet 2022;13:990301. [DOI: 10.3389/fgene.2022.990301] [Reference Citation Analysis]
|
| 519 |
Salani F, Genovesi V, Vivaldi C, Massa V, Cesario S, Bernardini L, Caccese M, Graziani J, Berra D, Fornaro L, Masi G. Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle. Cancers 2022;14:4896. [DOI: 10.3390/cancers14194896] [Reference Citation Analysis]
|
| 520 |
Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Aldrighetti L, Kudo M, Cascinu S, Casadei-Gardini A. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open 2022;7:100591. [PMID: 36208496 DOI: 10.1016/j.esmoop.2022.100591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 521 |
Zaemes J, Rehman M, Smith C, He R. Immunotherapy and Hepatocellular Carcinoma. Immune Checkpoint Inhibitors - New Insights and Recent Progress [Working Title] 2022. [DOI: 10.5772/intechopen.107097] [Reference Citation Analysis]
|
| 522 |
Kaseb AO, Haque A, Vishwamitra D, Hassan MM, Xiao L, George B, Sahu V, Mohamed YI, Carmagnani Pestana R, Lombardo JL, Avritscher R, Yao JC, Wolff RA, Rashid A, Morris JS, Amin HM. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol 2022;12:986305. [DOI: 10.3389/fonc.2022.986305] [Reference Citation Analysis]
|
| 523 |
Shetty VV, Kellarai A. Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions. JCO Glob Oncol 2022;8:e2200118. [PMID: 36198133 DOI: 10.1200/GO.22.00118] [Reference Citation Analysis]
|
| 524 |
Cong T, Luo Y, Liu Y, Yang C, Yang H, Li Y, Li J, Li X. Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma. Front Genet 2022;13:1000997. [DOI: 10.3389/fgene.2022.1000997] [Reference Citation Analysis]
|
| 525 |
Qu J, Sun F, Guan H, Hou Y, Qi H, Sun X, Xing L. The immune-related gene-based prognostic index predicts the prognosis and effect of immune checkpoint inhibitors in hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2092544/v1] [Reference Citation Analysis]
|
| 526 |
Fabritius MP, Ricke J. Overview of Ongoing Clinical Trials on Radioembolization. Cardiovasc Intervent Radiol 2022. [PMID: 36184696 DOI: 10.1007/s00270-022-03270-4] [Reference Citation Analysis]
|
| 527 |
Qin LX. Immunotherapy for hepatobiliary malignancies: Progress and prospective. Hepatobiliary Pancreat Dis Int 2022;21:409-12. [PMID: 36117110 DOI: 10.1016/j.hbpd.2022.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 528 |
Narita H, Kawaratani H, Shibamoto A, Takeda S, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Nishimura N, Hokuto D, Sho M, Yoshiji H. Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report. Clin J Gastroenterol 2022;15:953-959. [DOI: 10.1007/s12328-022-01667-9] [Reference Citation Analysis]
|
| 529 |
Tran NH, Muñoz S, Thompson S, Hallemeier CL, Bruix J. Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy. Hepatology 2022;76:1203-18. [PMID: 35765265 DOI: 10.1002/hep.32613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 530 |
de Castria TB, Khalil DN, Harding JJ, O'Reilly EM, Abou-Alfa GK. Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncol 2022;18:3769-82. [PMID: 36399155 DOI: 10.2217/fon-2022-0652] [Reference Citation Analysis]
|
| 531 |
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. [PMID: 36263666 DOI: 10.3350/cmh.2022.0294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 532 |
D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology 2022;76:1000-12. [PMID: 35313048 DOI: 10.1002/hep.32468] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 533 |
Suchman K, Da BL. Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC. Hepatology 2022;76:E78-9. [PMID: 35503724 DOI: 10.1002/hep.32556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 534 |
Zhu Y, Qin LX. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2022;21:420-9. [PMID: 35977874 DOI: 10.1016/j.hbpd.2022.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 535 |
D'Alessio A, Fulgenzi CAM, Pinato DJ. Reply. Hepatology 2022;76:E82-3. [PMID: 35503722 DOI: 10.1002/hep.32553] [Reference Citation Analysis]
|
| 536 |
Akutsu N, Kawakami Y, Numata Y, Hirano T, Wagatsuma K, Ishigami K, Sasaki S, Nakase H. A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases. Clin J Gastroenterol 2022;15:960-967. [DOI: 10.1007/s12328-022-01669-7] [Reference Citation Analysis]
|
| 537 |
Samadaei M, Senfter D, Madlener S, Uranowska K, Hafner C, Trauner M, Rohr-Udilova N, Pinter M. Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma. J Cell Biochem 2022;123:1663-73. [PMID: 36271841 DOI: 10.1002/jcb.30340] [Reference Citation Analysis]
|
| 538 |
Sharma A, Blériot C, Currenti J, Ginhoux F. Oncofetal reprogramming in tumour development and progression. Nat Rev Cancer 2022;22:593-602. [PMID: 35999292 DOI: 10.1038/s41568-022-00497-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 539 |
Xue JN, Wang YY, Wang YC, Zhang N, Zhang LH, Lu ZH, Zhao LJ, Zhao HT. Novel cellular therapies for hepatobiliary malignancies. Hepatobiliary Pancreat Dis Int 2022;21:450-4. [PMID: 36100543 DOI: 10.1016/j.hbpd.2022.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 540 |
Zhang J, Fang J, Xun Z, Xu Y, Lu X, Zhao H. Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world. Hepatology 2022;76:E84-5. [PMID: 35604038 DOI: 10.1002/hep.32588] [Reference Citation Analysis]
|
| 541 |
Xiong J, Wang QQ. Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies. Hepatobiliary Pancreat Dis Int 2022;21:430-9. [PMID: 35907687 DOI: 10.1016/j.hbpd.2022.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 542 |
Howell J, Samani A, Mannan B, Hajiev S, Motedayen Aval L, Abdelmalak R, Tam VC, Bettinger D, Thimme R, Taddei TH, Kaplan DE, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therap Adv Gastroenterol 2022;15:17562848221100106. [PMID: 36199289 DOI: 10.1177/17562848221100106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 543 |
Zhang L, Sun J, Wang K, Zhao H, Zhang X, Ren Z. First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review. Curr Oncol 2022;29:7305-26. [PMID: 36290852 DOI: 10.3390/curroncol29100575] [Reference Citation Analysis]
|
| 544 |
Xia W, Zhao X, Guo Y, Cao G, Wu G, Fan W, Yao Q, Xu S, Guo C, Hu H, Li H. Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study. Front Oncol 2022;12:961394. [DOI: 10.3389/fonc.2022.961394] [Reference Citation Analysis]
|
| 545 |
Zhu XD, Huang C, Shen YH, Xu B, Ge NL, Ji Y, Qu XD, Chen L, Chen Y, Li ML, Zhu JJ, Tang ZY, Zhou J, Fan J, Sun HC. Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma. Ann Surg Oncol 2022. [PMID: 36178565 DOI: 10.1245/s10434-022-12530-z] [Reference Citation Analysis]
|
| 546 |
Daly RJ, Scott AM, Klein O, Ernst M. Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. Mol Cancer 2022;21:189. [PMID: 36175961 DOI: 10.1186/s12943-022-01656-z] [Reference Citation Analysis]
|
| 547 |
Guo Z, Zhu H, Zhang X, Huang L, Wang X, Shi H, Yu L, Qiu Y, Tu F. The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study. Front Oncol 2022;12:941068. [DOI: 10.3389/fonc.2022.941068] [Reference Citation Analysis]
|
| 548 |
Gao X, Huang H, Pan C, Mei Z, Yin S, Zhou L, Zheng S. Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma. Cancers 2022;14:4715. [DOI: 10.3390/cancers14194715] [Reference Citation Analysis]
|
| 549 |
Lei Q, Yan X, Zou H, Jiang Y, Lai Y, Ung COL, Hu H. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. Discov Oncol 2022;13:95. [PMID: 36171533 DOI: 10.1007/s12672-022-00559-1] [Reference Citation Analysis]
|
| 550 |
Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, Li G, Chen F. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Front Oncol 2022;12:980214. [DOI: 10.3389/fonc.2022.980214] [Reference Citation Analysis]
|
| 551 |
Roth G, Teyssier Y, Benhamou M, Abousalihac M, Caruso S, Sengel C, Seror O, Ghelfi J, Seigneurin A, Ganne-Carrie N, Gigante E, Blaise L, Sutter O, Decaens T, Nault JC. Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization. World J Gastroenterol 2022; 28(36): 5324-5337 [DOI: 10.3748/wjg.v28.i36.5324] [Reference Citation Analysis]
|
| 552 |
Tang WW, Bauer KM, Barba C, Ekiz HA, O'Connell RM. miR-aculous new avenues for cancer immunotherapy. Front Immunol 2022;13:929677. [PMID: 36248881 DOI: 10.3389/fimmu.2022.929677] [Reference Citation Analysis]
|
| 553 |
Liu F, Gai X, Wu Y, Zhang B, Wu X, Cheng R, Tang B, Shang K, Zhao N, Deng W, Chen J, Zhang Z, Gu S, Zheng L, Zhang H. Oncogenic β-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer. Proc Natl Acad Sci U S A 2022;119:e2202157119. [PMID: 36122209 DOI: 10.1073/pnas.2202157119] [Reference Citation Analysis]
|
| 554 |
. Liver (Hepatocellular) Cancer. Fundamentals of Cancer Detection, Treatment, and Prevention 2022. [DOI: 10.1002/9783527838561.ch10] [Reference Citation Analysis]
|
| 555 |
Rizzo A, Ricci AD. Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. IJMS 2022;23:11363. [DOI: 10.3390/ijms231911363] [Reference Citation Analysis]
|
| 556 |
Tamaki N, Tada T, Kurosaki M, Yasui Y, Ochi H, Mashiba T, Sakamoto A, Marusawa H, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kobashi H, Kusakabe A, Furuta K, Arai H, Nonogi M, Ogawa C, Sato T, Tamada T, Nakamura S, Hasebe C, Tsuchiya K, Izumi N. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Invest New Drugs 2022. [PMID: 36152108 DOI: 10.1007/s10637-022-01303-w] [Reference Citation Analysis]
|
| 557 |
Müller L, Gairing SJ, Kloeckner R, Foerster F, Schleicher EM, Weinmann A, Mittler J, Stoehr F, Halfmann MC, Düber C, Galle PR, Hahn F. The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy. Cancer Imaging 2022;22. [DOI: 10.1186/s40644-022-00487-x] [Reference Citation Analysis]
|
| 558 |
Mukherji R, Debnath D, Hartley ML, Noel MS. The Role of Immunotherapy in Pancreatic Cancer. Curr Oncol 2022;29:6864-92. [PMID: 36290818 DOI: 10.3390/curroncol29100541] [Reference Citation Analysis]
|
| 559 |
Su K, Guo L, Ma W, Wang J, Xie Y, Rao M, Zhang J, Li X, Wen L, Li B, Yang X, Song Y, Huang W, Chi H, Gu T, Xu K, Liu Y, Chen J, Wu Z, Jiang Y, Li H, Zeng H, Wang P, Feng X, Chen S, Yang B, Jin H, He K, Han Y. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study. Front Immunol 2022;13:972503. [DOI: 10.3389/fimmu.2022.972503] [Reference Citation Analysis]
|
| 560 |
De Lorenzo S, Tovoli F, Trevisani F. Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers 2022;14:4616. [DOI: 10.3390/cancers14194616] [Reference Citation Analysis]
|
| 561 |
Wei F, Guo R, Yan Y, Lin R, Chen J, Lin Z. Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study. Front Immunol 2022;13:990224. [DOI: 10.3389/fimmu.2022.990224] [Reference Citation Analysis]
|
| 562 |
Luo L, Xiao Y, Zhu G, Huang A, Song S, Wang T, Ge X, Xie J, Deng W, Hu Z, Wen W, Mei H, Wan R, Shan R. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience. Front Oncol 2022;12:1004652. [DOI: 10.3389/fonc.2022.1004652] [Reference Citation Analysis]
|
| 563 |
Wang J, Zheng Z, Wu T, Li W, Wang J, Pan Y, Peng W, Hu D, Hou J, Xu L, Zhang Y, Chen M, Zhang R, Zhou Z. Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study. J Hepatocell Carcinoma 2022;9:999-1010. [PMID: 36132426 DOI: 10.2147/JHC.S379326] [Reference Citation Analysis]
|
| 564 |
Sun T, Guo Y, Sun B, Chen L, Ren Y, Zhu L, Zhang L, Liu Y, Zheng C. Association of the Pretreatment Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2083309/v1] [Reference Citation Analysis]
|
| 565 |
Cammarota A, Zanuso V, Pressiani T, Personeni N, Rimassa L. Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. J Hepatocell Carcinoma 2022;9:1011-27. [PMID: 36128575 DOI: 10.2147/JHC.S268293] [Reference Citation Analysis]
|
| 566 |
Lu S, Shi H, Zhang W, Hu B, Wang Y, Zhang Z, Mao G, Li C, Sun Y. whole-exome sequencing identifies a set of genes as markers of early hepatocellular carcinoma recurrence.. [DOI: 10.21203/rs.3.rs-2033879/v1] [Reference Citation Analysis]
|
| 567 |
Song B, Park EY, Kim KJ, Ki SH. Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics. Cancers 2022;14:4601. [DOI: 10.3390/cancers14194601] [Reference Citation Analysis]
|
| 568 |
Uchida‐kobayashi S, Kageyama K, Takemura S, Matsumoto K, Odagiri N, Jogo A, Kotani K, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Yamamoto A, Fujii H, Tanaka S, Enomoto M, Tamori A, Miki Y, Kubo S, Kawada N. Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma. JGH Open 2022. [DOI: 10.1002/jgh3.12819] [Reference Citation Analysis]
|
| 569 |
Leyh C, Heucke N, Schotten C, Büchter M, Bechmann LP, Wichert M, Dechêne A, Herrmann K, Heider D, Sydor S, Lemmer P, Ludwig JM, Pospiech J, Theysohn J, Damm R, March C, Powerski M, Pech M, Özcürümez M, Weigt J, Keitel V, Lange CM, Schmidt H, Canbay A, Best J, Gerken G, Manka PP. LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers 2022;14:4584. [DOI: 10.3390/cancers14194584] [Reference Citation Analysis]
|
| 570 |
Huang C, Chen L, Chen G, Chao T, Wang C. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. IJMS 2022;23:11092. [DOI: 10.3390/ijms231911092] [Reference Citation Analysis]
|
| 571 |
Shao YY, Feng YH, Yen CJ, Yang TS, Shen YC, Chao Y, Chen JS, Su CY, Chen WJ, Hsiang HL, Hsu CH. Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety. J Formos Med Assoc 2022:S0929-6646(22)00355-2. [PMID: 36153210 DOI: 10.1016/j.jfma.2022.09.005] [Reference Citation Analysis]
|
| 572 |
Simón Serrano S, Tavecchio M, Mallik J, Grönberg A, Elmér E, Kifagi C, Gallay P, Hansson MJ, Massoumi R. Synergistic Effects of Sanglifehrin-Based Cyclophilin Inhibitor NV651 with Cisplatin in Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36230472 DOI: 10.3390/cancers14194553] [Reference Citation Analysis]
|
| 573 |
Ling Y, Jin M, Zhu M, Wang Y, Chen Y, Peng Z. Efficacy of Different Treatments for Patients with Advanced Hepatocellular Carcinoma: A System Review and Network Meta-Analysis. IJS Oncology 2022;7:58. [DOI: 10.29337/ijsonco.140] [Reference Citation Analysis]
|
| 574 |
Ueda S, Hori S, Hori A, Makitani K, Wan K, Sonomura T. Retrospective Study of the Efficacy and Safety of Chemoembolization with Drug-Eluting Microspheres Combined with Intra-Arterial Infusion of Bevacizumab for Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:973-85. [PMID: 36117527 DOI: 10.2147/JHC.S380439] [Reference Citation Analysis]
|
| 575 |
Goyal P, Salem R, Mouli SK. Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines. Br J Radiol 2022;95:20220379. [PMID: 35867889 DOI: 10.1259/bjr.20220379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 576 |
Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer 2022;175:204-13. [PMID: 36148739 DOI: 10.1016/j.ejca.2022.08.024] [Reference Citation Analysis]
|
| 577 |
Valery M, Cervantes B, Samaha R, Gelli M, Smolenschi C, Fuerea A, Tselikas L, Klotz-Prieux C, Hollebecque A, Boige V, Ducreux M. Immunotherapy and Hepatocellular Cancer: Where Are We Now? Cancers (Basel) 2022;14:4523. [PMID: 36139683 DOI: 10.3390/cancers14184523] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 578 |
Li Y, Liang X, Li H, Chen X. Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis. Cancer. [DOI: 10.1002/cncr.34457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 579 |
Zhang J, Xia Y, Zhou X, Yu H, Tan Y, Du Y, Zhang Q, Wu Y. Current landscape of personalized clinical treatments for triple-negative breast cancer. Front Pharmacol 2022;13:977660. [DOI: 10.3389/fphar.2022.977660] [Reference Citation Analysis]
|
| 580 |
Zhang T, Wang Y, Xie M, Ji X, Luo X, Chen X, Zhang B, Liu D, Feng Y, Sun M, Huang W, Xia L. HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET. J Exp Clin Cancer Res 2022;41:275. [DOI: 10.1186/s13046-022-02475-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 581 |
Zhang Q, Ye M, Lin C, Hu M, Wang Y, Lou Y, Kong Q, Zhang J, Li J, Zhang Y, Yang T, Sun X, Yao W, Hua Y, Huang H, Xu M, Wang X, Yu X, Tao W, Liu R, Gao Y, Wang T, Wang J, Wei X, Wu J, Yu Z, Zhang C, Yu C, Bai X, Liang T. Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study. Gut 2022:gutjnl-2022-327496. [PMID: 36113977 DOI: 10.1136/gutjnl-2022-327496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 582 |
Mattingly TJ, Shetty K. The economics of advanced and unresectable hepatocellular carcinoma. Cancer. [DOI: 10.1002/cncr.34456] [Reference Citation Analysis]
|
| 583 |
Sposito C, Citterio D, Virdis M, Battiston C, Droz Dit Busset M, Flores M, Mazzaferro V. Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. World J Gastroenterol 2022; 28(34): 4929-4942 [DOI: 10.3748/wjg.v28.i34.4929] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 584 |
Ding L, Li W, Tu J, Cao Z, Li J, Cao H, Liang J, Liang Y, Yu Q, Li G. Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma. Front Immunol 2022;13:989156. [PMID: 36177029 DOI: 10.3389/fimmu.2022.989156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 585 |
Boike JR, Thornburg B, Vanwagner LB; ALTA Consortium. Reply. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00875-8. [PMID: 36113827 DOI: 10.1016/j.cgh.2022.09.003] [Reference Citation Analysis]
|
| 586 |
Yang X, Sun Y, Wang H, Li D, Xu G, Huang X. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis. Front Oncol 2022;12:914385. [DOI: 10.3389/fonc.2022.914385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 587 |
Xu Y, Fu S, Shang K, Zeng J, Mao Y. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib. Front Oncol 2022;12:958869. [DOI: 10.3389/fonc.2022.958869] [Reference Citation Analysis]
|
| 588 |
Wang H, Shi F, Zheng S, Zhao M, Pan Z, Xiong L, Zheng L. Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. Front Oncol 2022;12:896662. [DOI: 10.3389/fonc.2022.896662] [Reference Citation Analysis]
|
| 589 |
Sun B, Zhang L, Sun T, Ren Y, Cao Y, Zhang W, Zhu L, Guo Y, Gui Y, Liu F, Chen L, Xiong F, Zheng C. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. Front Oncol 2022;12:982948. [DOI: 10.3389/fonc.2022.982948] [Reference Citation Analysis]
|
| 590 |
Lee WC, Cheng CH, Lee CF, Hsu HY, Hsu PY, Wu TJ, Chan KM. Enhancement of dendritic cell immunotherapy by recalling antigens for hepatocellular carcinoma in mice. Immunotherapy 2022. [PMID: 36097695 DOI: 10.2217/imt-2021-0254] [Reference Citation Analysis]
|
| 591 |
Le Tourneau C, Becker H, Claus R, Elez E, Ricci F, Fritsch R, Silber Y, Hennequin A, Tabernero J, Jayadeva G, Luedtke D, He M, Isambert N. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open 2022;7:100576. [PMID: 36108560 DOI: 10.1016/j.esmoop.2022.100576] [Reference Citation Analysis]
|
| 592 |
Salomé B, Sfakianos JP, Ranti D, Daza J, Bieber C, Charap A, Hammer C, Banchereau R, Farkas AM, Ruan DF, Izadmehr S, Geanon D, Kelly G, de Real RM, Lee B, Beaumont KG, Shroff S, Wang YA, Wang YC, Thin TH, Garcia-Barros M, Hegewisch-Solloa E, Mace EM, Wang L, O'Donnell T, Chowell D, Fernandez-Rodriguez R, Skobe M, Taylor N, Kim-Schulze S, Sebra RP, Palmer D, Clancy-Thompson E, Hammond S, Kamphorst AO, Malmberg KJ, Marcenaro E, Romero P, Brody R, Viard M, Yuki Y, Martin M, Carrington M, Mehrazin R, Wiklund P, Mellman I, Mariathasan S, Zhu J, Galsky MD, Bhardwaj N, Horowitz A. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell 2022;40:1027-1043.e9. [PMID: 36099881 DOI: 10.1016/j.ccell.2022.08.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 593 |
Leslie J, Hunter JE, Collins A, Rushton A, Russell LG, Ramon-Gil E, Laszczewska M, McCain M, Zaki MYW, Knox A, Seow Y, Sabater L, Geh D, Perkins ND, Reeves HL, Tiniakos D, Mann DA, Oakley F. c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis. Hepatology 2022. [PMID: 36089330 DOI: 10.1002/hep.32781] [Reference Citation Analysis]
|
| 594 |
Baterdene O, Miura K, Ueno W, Watanabe S, Tsukui M, Nomoto H, Goka R, Maeda H, Yamamoto H, Morimoto N. A successful case of transarterial chemoembolization for hyperprogressive disease induced by immunotherapy in a patient with unresectable hepatocellular carcinoma. Clin J Gastroenterol 2022. [DOI: 10.1007/s12328-022-01697-3] [Reference Citation Analysis]
|
| 595 |
Liu H, Qin X, Xu Z, Wu M, Lu T, Zhou S, Yao N, Liu S, Shao Y, Han Z. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China. Front Genet 2022;13:1000448. [DOI: 10.3389/fgene.2022.1000448] [Reference Citation Analysis]
|
| 596 |
Glantzounis GK, Korkolis D, Sotiropoulos GC, Tzimas G, Karampa A, Paliouras A, Asimakopoulos AG, Davakis S, Papalampros A, Moris D, Felekouras E. Individualized Approach in the Surgical Management of Hepatocellular Carcinoma: Results from a Greek Multicentre Study. Cancers (Basel) 2022;14:4387. [PMID: 36139548 DOI: 10.3390/cancers14184387] [Reference Citation Analysis]
|
| 597 |
Sukowati C, Cabral LKD, Tiribelli C. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. Ann Hepatol 2022;27:100740. [PMID: 35809835 DOI: 10.1016/j.aohep.2022.100740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 598 |
Singh A, Zahid S, Noginskiy I, Pak T, Usta S, Barsoum M, Khan U. A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. Current Oncology 2022;29:6445-6462. [DOI: 10.3390/curroncol29090507] [Reference Citation Analysis]
|
| 599 |
Verzella D, Cornice J, Arboretto P, Vecchiotti D, Di Vito Nolfi M, Capece D, Zazzeroni F, Franzoso G. The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target. Biomedicines 2022;10. [PMID: 36140335 DOI: 10.3390/biomedicines10092233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 600 |
Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Front Immunol 2022;13:982026. [DOI: 10.3389/fimmu.2022.982026] [Reference Citation Analysis]
|
| 601 |
Kimura T, Fujiwara T, Kameoka T, Adachi Y, Kariya S. The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC). Cancers 2022;14:4383. [DOI: 10.3390/cancers14184383] [Reference Citation Analysis]
|
| 602 |
Zhao B, Li X, Kong Y, Wang W, Wen T, Zhang Y, Deng Z, Chen Y, Zheng X. Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy. Front Bioeng Biotechnol 2022;10:1010724. [DOI: 10.3389/fbioe.2022.1010724] [Reference Citation Analysis]
|
| 603 |
Sano Y, Azuma Y, Tsunenari T, Kayukawa Y, Shinozuka J, Fujii E, Amano J, Nishito Y, Maruyama T, Kinoshita Y, Sakamoto Y, Yoshida A, Miyazaki Y, Sato Y, Teramoto-Seida C, Ishiguro T, Tanaka T, Kitazawa T, Endo M. Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours. Nat Commun 2022;13:5265. [PMID: 36071036 DOI: 10.1038/s41467-022-32952-3] [Reference Citation Analysis]
|
| 604 |
Sena G, Paglione D, Gallo G, Goglia M, Osso M, Nardo B. Surgical Resection of a Recurrent Hepatocellular Carcinoma with Portal Vein Thrombosis: Is It a Good Treatment Option? A Case Report and Systematic Review of the Literature. JCM 2022;11:5287. [DOI: 10.3390/jcm11185287] [Reference Citation Analysis]
|
| 605 |
Cui C, Ren X, Cui W, Wang Y. Immune-related interstitial lung disease adverse event following immune checkpoint inhibitors and immune checkpoint inhibitors plus anti-VEGF antibody/chemotherapy: A real-world study from 2014 to 2022 based on FAERS databases.. [DOI: 10.21203/rs.3.rs-2023720/v1] [Reference Citation Analysis]
|
| 606 |
Fu J, Wang S, Li Z, Qin W, Tong Q, Liu C, Wang Z, Liu Z, Xu X. Comprehensive multiomics analysis of cuproptosis-related gene characteristics in hepatocellular carcinoma. Front Genet 2022;13:942387. [DOI: 10.3389/fgene.2022.942387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 607 |
Mishra AK, Ali A, Dutta S, Banday S, Malonia SK. Emerging Trends in Immunotherapy for Cancer. Diseases 2022;10:60. [DOI: 10.3390/diseases10030060] [Reference Citation Analysis]
|
| 608 |
Zhang T, Wang Y, Shi C, Liu X, Lv S, Wang X, Li W. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Front Pharmacol 2022;13:955701. [DOI: 10.3389/fphar.2022.955701] [Reference Citation Analysis]
|
| 609 |
Reincke M, Schultheiss M, Doppler M, Verloh N, Uller W, Sturm L, Thimme R, Goetz C, Bettinger D. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma. Hepatol Commun 2022;6:3223-33. [PMID: 36064940 DOI: 10.1002/hep4.2072] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 610 |
Hewitt DB, Aziz H, Brown ZJ, Pawlik TM. Role of genetic testing in hepatic, pancreatic, and biliary cancers. Surg Oncol 2022;44:101844. [PMID: 36116416 DOI: 10.1016/j.suronc.2022.101844] [Reference Citation Analysis]
|
| 611 |
Zhao H, Tsauo J, Zhang X, Ma H, Weng N, Yang Z, Li X. Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study. Chin Med J (Engl) 2022;135:2043-8. [PMID: 36255217 DOI: 10.1097/CM9.0000000000002034] [Reference Citation Analysis]
|
| 612 |
Yu S, Wang J, Zheng H, Wang R, Johnson N, Li T, Li P, Lin J, Li Y, Yan J, Zhang Y, Zhu Z, Ding X. Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. J Hepatocell Carcinoma 2022;9:855-67. [PMID: 36051860 DOI: 10.2147/JHC.S377768] [Reference Citation Analysis]
|
| 613 |
Mossenta M, Busato D, Dal Bo M, Macor P, Toffoli G. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. Int J Mol Sci 2022;23:10038. [PMID: 36077433 DOI: 10.3390/ijms231710038] [Reference Citation Analysis]
|
| 614 |
Gubbi S, Vijayvergia N, Yu JQ, Klubo-Gwiezdzinska J, Koch CA. Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. Horm Metab Res 2022;54:795-812. [PMID: 35878617 DOI: 10.1055/a-1908-7790] [Reference Citation Analysis]
|
| 615 |
Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson PLS Jr, Aslam F, Raupach E, Gabere M, Basnakian A, Simoes CC, Cannon MJ, Post SR, Buetow K, Chamcheu JC, Barrett MT, Duda DG, Jacobs B, Vile R, Barry MA, Roberts LR, Ilyas S, Borad MJ. Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology 2022. [PMID: 36052732 DOI: 10.1002/hep.32769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 616 |
Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol 2022;12:958720. [DOI: 10.3389/fonc.2022.958720] [Reference Citation Analysis]
|
| 617 |
Jin X, Zhang K, Fang T, Zeng X, Yan X, Tang J, Liang Z, Xie L, Zhao D. Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review. Front Oncol 2022;12:951303. [DOI: 10.3389/fonc.2022.951303] [Reference Citation Analysis]
|
| 618 |
Uchida K, Ozono Y, Uchiyama N, Hatada H, Nakamura K, Komaki Y, Iwakiri H, Hasuike S, Nagata K, Sato Y, Kawakami H. Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report. Medicine (Baltimore) 2022;101:e30486. [PMID: 36107543 DOI: 10.1097/MD.0000000000030486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 619 |
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Kajiwara M, Itano S, Moriyama E, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers 2022;14:4284. [DOI: 10.3390/cancers14174284] [Reference Citation Analysis]
|
| 620 |
Wabitsch S, McCallen JD, Kamenyeva O, Ruf B, McVey JC, Kabat J, Walz JS, Rotman Y, Bauer KC, Craig AJ, Pouzolles M, Phadke I, Catania V, Green BL, Fu C, Diggs LP, Heinrich B, Wang XW, Ma C, Greten TF. Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol 2022;77:748-60. [PMID: 35378172 DOI: 10.1016/j.jhep.2022.03.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 621 |
Eresen A, Sun C, Zhou K, Shangguan J, Wang B, Pan L, Hu S, Ma Q, Yang J, Zhang Z, Yaghmai V. Early Differentiation of Irreversible Electroporation Ablation Regions With Radiomics Features of Conventional MRI. Acad Radiol 2022;29:1378-86. [PMID: 34933803 DOI: 10.1016/j.acra.2021.11.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 622 |
Reiter FP, Ben Khaled N, Ye L, Zhang C, Seidensticker M, Op den Winkel M, Denk G, Geier A, De Toni EN. Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review. Dig Dis 2022;40:565-80. [PMID: 34644705 DOI: 10.1159/000520095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 623 |
Jia M, Jia J, Xu J, Xue H. . CMAR 2022;Volume 14:2625-38. [DOI: 10.2147/cmar.s372125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 624 |
Vogel A, Gerdes C. Von der zielgerichteten zur immunonkologischen Systemtherapie. Im Fokus Onkologie 2022;25:17-22. [DOI: 10.1007/s15015-022-3910-3] [Reference Citation Analysis]
|
| 625 |
Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). J Immunother Cancer 2022;10. [PMID: 36175037 DOI: 10.1136/jitc-2022-005413] [Reference Citation Analysis]
|
| 626 |
Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100578] [Reference Citation Analysis]
|
| 627 |
Xin B, Yang M, Wu P, Du L, Deng X, Hui E, Feng GS. Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. Hepatology 2022;76:630-45. [PMID: 34860431 DOI: 10.1002/hep.32266] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 628 |
Elshami M, Hoehn R, Hue JJ, Rothermel L, Chavin KD, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Medicaid expansion is associated with a higher likelihood of early diagnosis, resection, transplantation, and overall survival in patients with hepatocellular carcinoma. HPB (Oxford) 2022;24:1482-91. [PMID: 35370098 DOI: 10.1016/j.hpb.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 629 |
Papaconstantinou D, Tsilimigras DI, Pawlik TM. . JHC 2022;Volume 9:947-57. [DOI: 10.2147/jhc.s342266] [Reference Citation Analysis]
|
| 630 |
Van Laeken C, Taelman T, Cappuyns S, Maleux G, Vandecaveye V, Verslype C, Deroose C, Dekervel J. Clinical factors associated with early disease progression after radioembolization for hepatocellular carcinoma and feasibility of post‐progression systemic therapy. Liver Cancer International 2022;3:128-136. [DOI: 10.1002/lci2.60] [Reference Citation Analysis]
|
| 631 |
Kadono T, Yamamoto S, Kato K. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. Jpn J Clin Oncol 2022:hyac138. [PMID: 36047845 DOI: 10.1093/jjco/hyac138] [Reference Citation Analysis]
|
| 632 |
Chen H, Li Z, Qiu L, Dong X, Chen G, Shi Y, Cai L, Liu W, Ye H, Zhou Y, Ouyang J, Cai Z, Liu X. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. J Immunother Cancer 2022;10:e004389. [PMID: 36113894 DOI: 10.1136/jitc-2021-004389] [Reference Citation Analysis]
|
| 633 |
Xu Y, Fu S, Mao Y, Huang S, Li D, Wu J. Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma. Front Med 2022;9. [DOI: 10.3389/fmed.2022.919069] [Reference Citation Analysis]
|
| 634 |
Gan X, Ding D, Wang M, Yang Y, Sun D, Li W, Ding W, Yang F, Zhou W, Yuan S. DANCR deletion retards the initiation and progression of hepatocellular carcinoma based on gene knockout and patient-derived xenograft in situ hepatoma mice model. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215930] [Reference Citation Analysis]
|
| 635 |
Hao X, Zheng Z, Liu H, Zhang Y, Kang J, Kong X, Rong D, Sun G, Sun G, Liu L, Yu H, Tang W, Wang X. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biology 2022. [DOI: 10.1016/j.redox.2022.102463] [Reference Citation Analysis]
|
| 636 |
Chuah S, Lee J, Song Y, Kim HD, Wasser M, Kaya NA, Bang K, Lee YJ, Jeon SH, Suthen S, A'Azman S, Gien G, Lim CJ, Chua C, Hazirah SN, Lee HK, Lim JQ, Lim TKH, Yeong J, Chen J, Shin EC, Albani S, Zhai W, Yoo C, Liu H, Choo SP, Tai D, Chew V. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J Hepatol 2022;77:683-94. [PMID: 35430299 DOI: 10.1016/j.jhep.2022.03.039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 637 |
Cuypers A, Truong AK, Becker LM, Saavedra-garcía P, Carmeliet P. Tumor vessel co-option: The past & the future. Front Oncol 2022;12:965277. [DOI: 10.3389/fonc.2022.965277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 638 |
Zhong K, Xu Y, Cheng Y, Wen Y, Cai L, He G, Huang H, Fu S, Zhong X, Zheng Y, Chen T, Huang M, Pan M. Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy. Front Immunol 2022;13:999763. [DOI: 10.3389/fimmu.2022.999763] [Reference Citation Analysis]
|
| 639 |
Yang T, Yu Y, Li H, Huang K, Jason CC. Efficacy and Safety of Combined Targeted Therapy and Immunotherapy versus Targeted monotherapy in Unresectable Hepatocellular Carcinoma: A Systematic review and Meta- Analysis.. [DOI: 10.21203/rs.3.rs-1977814/v1] [Reference Citation Analysis]
|
| 640 |
Kye Y, Nagineni L, Gadad S, Ramirez F, Riva H, Fernandez L, Samaniego M, Holland N, Yeh R, Takigawa K, Dhandayuthapani S, Chacon J. The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy. Cancers 2022;14:4255. [DOI: 10.3390/cancers14174255] [Reference Citation Analysis]
|
| 641 |
Peng Y, Wu G, Qiu X, Luo Y, Zou Y, Wei X, Li A. Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma. Front Genet 2022;13:916024. [DOI: 10.3389/fgene.2022.916024] [Reference Citation Analysis]
|
| 642 |
Zhang G, Xiao Y, Zhang X, Fan W, Zhao Y, Wu Y, Wang H, Li J. Dissecting a hypoxia-related angiogenic gene signature for predicting prognosis and immune status in hepatocellular carcinoma. Front Oncol 2022;12:978050. [DOI: 10.3389/fonc.2022.978050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 643 |
Skorupan N, Palestino Dominguez M, Ricci SL, Alewine C. Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:4209. [DOI: 10.3390/cancers14174209] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 644 |
Decarli K, Strosberg J, Almhanna K. Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. Cancers 2022;14:4201. [DOI: 10.3390/cancers14174201] [Reference Citation Analysis]
|
| 645 |
Che Y, Wang G, Xia Q. CDK2AP1 influences immune infiltrates and serves as a prognostic indicator for hepatocellular carcinoma. Front Genet 2022;13:937310. [DOI: 10.3389/fgene.2022.937310] [Reference Citation Analysis]
|
| 646 |
Huang AC, Dodge JL, Yao FY, Mehta N. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00819-9. [PMID: 36038129 DOI: 10.1016/j.cgh.2022.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 647 |
Kamal MA, Mandour YM, Abd El-aziz MK, Stein U, El Tayebi HM. Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges. Molecules 2022;27:5537. [DOI: 10.3390/molecules27175537] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 648 |
Onuoha E, Smith AD, Cannon R, Khushman M, Kim H. Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study. J Gastrointest Cancer 2022. [PMID: 36030519 DOI: 10.1007/s12029-022-00858-4] [Reference Citation Analysis]
|
| 649 |
Luo X, Zou W, Wei Z, Yu S, Zhao Y, Wu Y, Wang A, Lu Y. Inducing vascular normalization: A promising strategy for immunotherapy. Int Immunopharmacol 2022;112:109167. [PMID: 36037653 DOI: 10.1016/j.intimp.2022.109167] [Reference Citation Analysis]
|
| 650 |
Manjunatha N, Ganduri V, Rajasekaran K, Duraiyarasan S, Adefuye M. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review. Cureus 2022. [DOI: 10.7759/cureus.28439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 651 |
Li D, Xu L, Ji J, Bao D, Hu J, Qian Y, Zhou Y, Chen Z, Li D, Li X, Zhang X, Wang H, Yi C, Shi M, Pang Y, Liu S, Xu X. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. Front Immunol 2022;13:944062. [DOI: 10.3389/fimmu.2022.944062] [Reference Citation Analysis]
|
| 652 |
Chen Y, Qiu X, Wu D, Lu X, Li G, Tang Y, Jia C, Xiong Z, Wang T. PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma. Genes 2022;13:1535. [DOI: 10.3390/genes13091535] [Reference Citation Analysis]
|
| 653 |
Chen J, Zhang D, Yuan Y. Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma. Clin Exp Med 2022. [PMID: 36018466 DOI: 10.1007/s10238-022-00873-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 654 |
Li JX, Su TS, Gong WF, Zhong JH, Yan LY, Zhang J, Li LQ, He ML, Zhang RJ, Du YQ, Wang XT, Liang SX, Xiang BD. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial. Hepatol Int 2022. [PMID: 36001228 DOI: 10.1007/s12072-022-10396-7] [Reference Citation Analysis]
|
| 655 |
Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma 2022;9:823-37. [PMID: 35996397 DOI: 10.2147/JHC.S368208] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 656 |
Muñoz NM, Dupuis C, Williams M, Dixon K, McWatters A, Zhang J, Pavuluri S, Rao A, Duda DG, Kaseb A, Sheth RA. Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Sci Rep 2022;12:14449. [PMID: 36002545 DOI: 10.1038/s41598-022-15948-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 657 |
Zhang T, Zhang C, Fu Z, Gao Q. Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy. Pharmaceutics 2022;14:1768. [DOI: 10.3390/pharmaceutics14091768] [Reference Citation Analysis]
|
| 658 |
Chon YE, Cheon J, Kim H, Kang B, Ha Y, Kim DY, Hwang SG, Chon HJ, Kim BK. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. Cancer Med 2023;12:2731-8. [PMID: 35997637 DOI: 10.1002/cam4.5161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 659 |
Carloni R, Rizzo A, Cusmai A, Palloni A, Federico AD, Marco MD, Massafra R, Fanizzi A, Palmiotti G, Brandi G. Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Med Chem 2022. [PMID: 35997677 DOI: 10.4155/fmc-2022-0045] [Reference Citation Analysis]
|
| 660 |
Nishio T, Ito T, Hata K, Taura K, Hatano E. Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma. Ann Gastroenterol Surg 2023;7:42-52. [PMID: 36643372 DOI: 10.1002/ags3.12612] [Reference Citation Analysis]
|
| 661 |
Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology 2022. [PMID: 35989535 DOI: 10.1002/hep.32740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 662 |
Khan A, Zhang X. Function of the Long Noncoding RNAs in Hepatocellular Carcinoma: Classification, Molecular Mechanisms, and Significant Therapeutic Potentials. Bioengineering 2022;9:406. [DOI: 10.3390/bioengineering9080406] [Reference Citation Analysis]
|
| 663 |
Chen C, Feng Y, Yen C, Chen S, Lin Y, Lu L, Hsu C, Cheng A, Shao Y. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatol Int. [DOI: 10.1007/s12072-022-10392-x] [Reference Citation Analysis]
|
| 664 |
Laface C, Fedele P, Maselli FM, Ambrogio F, Foti C, Molinari P, Ammendola M, Lioce M, Ranieri G. Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities. Cancers (Basel) 2022;14:4028. [PMID: 36011021 DOI: 10.3390/cancers14164028] [Reference Citation Analysis]
|
| 665 |
Lee SW, Yang SS, Lien HC, Peng YC, Tung CF, Lee TY. The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma. J Clin Med 2022;11:4874. [PMID: 36013120 DOI: 10.3390/jcm11164874] [Reference Citation Analysis]
|
| 666 |
Salem R, Greten TF. Interventional radiology meets immuno-oncology for hepatocellular carcinoma. J Hepatol 2022:S0168-8278(22)03003-3. [PMID: 35988688 DOI: 10.1016/j.jhep.2022.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 667 |
Tan S, Guo X, Bei C, Zhang H, Li D, Zhu X, Tan H. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09999-y] [Reference Citation Analysis]
|
| 668 |
Shan Y, Yu X, Yang Y, Sun J, Wu S, Mao S, Lu C. Nomogram for the Preoperative Prediction of the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:717-28. [PMID: 35974953 DOI: 10.2147/JHC.S373960] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 669 |
Bartos A, Iancu I, Ciobanu L, Onaciu A, Moldovan C, Moldovan A, Moldovan RC, Tigu AB, Stiufiuc GF, Toma V, Iancu C, Al Hajjar N, Stiufiuc RI. Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes—A Preliminary Study. Nanomaterials 2022;12:2833. [DOI: 10.3390/nano12162833] [Reference Citation Analysis]
|
| 670 |
Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E, Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Ziti-Ljajic S, Massard C. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. ESMO Open 2022;7:100562. [PMID: 35987165 DOI: 10.1016/j.esmoop.2022.100562] [Reference Citation Analysis]
|
| 671 |
Sun H, Xing C, Jiang S, Yu K, Dai S, Kong H, Jin Y, Shan Y, Yang W, Wang Z, Xiao J, Wang H, Wang W, Li Z, Shi K. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report. Front Immunol 2022;13:963031. [DOI: 10.3389/fimmu.2022.963031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 672 |
Zhang L, Chen C, Chai D, Li C, Guan Y, Liu L, Kuang T, Deng W, Wang W. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. Front Immunol 2022;13:956533. [DOI: 10.3389/fimmu.2022.956533] [Reference Citation Analysis]
|
| 673 |
Kuo Y, Huang T, Wang J, Chen Y, Tsai M, Chen Y, Lu S, Hu T, Chen C, Hung C. Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. Cancers 2022;14:3971. [DOI: 10.3390/cancers14163971] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 674 |
Sidali S, Trépo E, Sutter O, Nault JC. New concepts in the treatment of hepatocellular carcinoma. United European Gastroenterol J 2022. [PMID: 35975347 DOI: 10.1002/ueg2.12286] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 675 |
Adhoute X, De Matharel M, Mineur L, Pénaranda G, Ouizeman D, Toullec C, Tran A, Castellani P, Rollet A, Oules V, Perrier H, Si Ahmed SN, Bourliere M, Anty R. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching. World J Gastrointest Oncol 2022; 14(8): 1510-1527 [DOI: 10.4251/wjgo.v14.i8.1510] [Reference Citation Analysis]
|
| 676 |
Wang K, Yu HM, Xiang YJ, Cheng YQ, Ni QZ, Guo WX, Shi J, Feng S, Zhai J, Cheng SQ. Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase 2 trial. Future Oncol 2022. [PMID: 35968836 DOI: 10.2217/fon-2022-0188] [Reference Citation Analysis]
|
| 677 |
Uson Junior PLS, Araujo RL. Immunotherapy in biliary tract cancers: Current evidence and future perspectives. World J Gastrointest Oncol 2022; 14(8): 1446-1455 [DOI: 10.4251/wjgo.v14.i8.1446] [Reference Citation Analysis]
|
| 678 |
Lim JJ, Hooi L, Dan YY, Bonney GK, Zhou L, Chow PK, Chee CE, Toh TB, Chow EK. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors. J Exp Clin Cancer Res 2022;41:249. [DOI: 10.1186/s13046-022-02436-9] [Reference Citation Analysis]
|
| 679 |
Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, Li Q, Xu L, Zhang Y, Wei W, Chen M, Kan A, Shi M. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. Eur J Cancer 2022;174:68-77. [PMID: 35981413 DOI: 10.1016/j.ejca.2022.07.005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 680 |
Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, Kimura M, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Suzuki K, Izumi T, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Miyagishima T, Sakamoto N. Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. Cancers (Basel) 2022;14. [PMID: 36010930 DOI: 10.3390/cancers14163938] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 681 |
Tomonari T, Tani J, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Asahiro M, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Masaki T, Takayama T. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. Cancer Med 2023;12:2646-57. [PMID: 35964253 DOI: 10.1002/cam4.5145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 682 |
Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
|
| 683 |
Fulgenzi CAM, D'Alessio A, Airoldi C, Scotti L, Demirtas CO, Gennari A, Cortellini A, Pinato DJ. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials. Eur J Cancer 2022;174:57-67. [PMID: 35970037 DOI: 10.1016/j.ejca.2022.06.058] [Reference Citation Analysis]
|
| 684 |
Chen W, Zhang M, Chen C, Pang X, Pan J. Prognostic Nutritional Index and Neutrophil/Lymphocyte Ratio Can Serve as Independent Predictors of the Prognosis of Hepatocellular Carcinoma Patients Receiving Targeted Therapy. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/1389049] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 685 |
Lu Q, Xin M, Guo Q, Rothberg BS, Gamero AM, Yang L. Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells. ncRNA 2022;8:61. [DOI: 10.3390/ncrna8040061] [Reference Citation Analysis]
|
| 686 |
Ng KYY, Wong LWJ, Ang AJS, Lee AWX, Tay DSH, Tan JJE, Tan SH, Choo SP, Tai DW, Lee JJX. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter? Asia Pac J Clin Oncol 2022. [PMID: 35950298 DOI: 10.1111/ajco.13837] [Reference Citation Analysis]
|
| 687 |
Lv F, Li X, Wang Y. Lycorine inhibits angiogenesis by docking to PDGFRα. BMC Cancer 2022;22:873. [PMID: 35948939 DOI: 10.1186/s12885-022-09929-y] [Reference Citation Analysis]
|
| 688 |
Chan CY, Chiu DK, Yuen VW, Law CT, Wong BP, Thu KL, Cescon DW, Soria-Bretones I, Cheu JW, Lee D, Tse AP, Zhang MS, Tan KV, Ng IO, Khong PL, Yau TC, Bray MR, Mak TW, Wong CC. CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma. Proc Natl Acad Sci U S A 2022;119:e2119514119. [PMID: 35914158 DOI: 10.1073/pnas.2119514119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 689 |
Zou J, Qin W. Comprehensive analysis of the cancer driver genes constructs a seven-gene signature for prediction of survival and tumor immunity in hepatocellular carcinoma. Front Genet 2022;13:937948. [DOI: 10.3389/fgene.2022.937948] [Reference Citation Analysis]
|
| 690 |
Dionisi F, Scartoni D, Fracchiolla F, Giacomelli I, Siniscalchi B, Goanta L, Cianchetti M, Sanguineti G, Brolese A. Proton therapy in the treatment of hepatocellular carcinoma. Front Oncol 2022;12:959552. [DOI: 10.3389/fonc.2022.959552] [Reference Citation Analysis]
|
| 691 |
Liu J, Cheng L, El-mekkoussi H, Lee M, Jaffe D, Gavin-darby K, Morgan A, Manduchi E, Schug J, Kaestner K. Advanced HCC precision modeling reveals divergent responses to combinatorial immunotherapy.. [DOI: 10.21203/rs.3.rs-1919053/v1] [Reference Citation Analysis]
|
| 692 |
Muquith M, Espinoza M, Hsiehchen D. Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib. J Gastrointest Cancer 2022. [PMID: 35939228 DOI: 10.1007/s12029-022-00852-w] [Reference Citation Analysis]
|
| 693 |
Risaliti M, Bartolini I, Campani C, Arena U, Xodo C, Adotti V, Rosi M, Taddei A, Muiesan P, Amedei A, Batignani G, Marra F. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. World J Gastroenterol 2022; 28(29): 3981-3993 [DOI: 10.3748/wjg.v28.i29.3981] [Reference Citation Analysis]
|
| 694 |
Xin Y, Cao F, Yang H, Zhang X, Chen Y, Cao X, Zhou X, Li X, Zhou J. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front Immunol 2022;13:929141. [DOI: 10.3389/fimmu.2022.929141] [Reference Citation Analysis]
|
| 695 |
Qian B, Lin H, Lan T, Li M, Wu X, Lin S, Song Z, Shen S, Peng B. Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma. World J Surg Oncol 2022;20:252. [PMID: 35932027 DOI: 10.1186/s12957-022-02681-4] [Reference Citation Analysis]
|
| 696 |
Bang K, Casadei-Gardini A, Yoo C, Iavarone M, Ryu MH, Park SR, Kim HD, Yoon YI, Jung DH, Park GC, Ahn CS, Moon DB, Hwang S, Kim KH, Song GW, Mazzarelli C, Alimenti E, Chan SL, De Giorgio M, Ryoo BY, Lee SG. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation. Cancer Med 2023;12:2572-9. [PMID: 36812124 DOI: 10.1002/cam4.5123] [Reference Citation Analysis]
|
| 697 |
Garcia-alvarez A, Hernando J, Carmona-alonso A, Capdevila J. What is the status of immunotherapy in thyroid neoplasms? Front Endocrinol 2022;13:929091. [DOI: 10.3389/fendo.2022.929091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 698 |
Liu S. Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment. Liver Cancer - Genesis, Progression and Metastasis [Working Title] 2022. [DOI: 10.5772/intechopen.106021] [Reference Citation Analysis]
|
| 699 |
Feng MY, Chan LL, Chan SL. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Curr Oncol 2022;29:5489-507. [PMID: 36005172 DOI: 10.3390/curroncol29080434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 700 |
Duan L, Yang L, Zhang B, Liao J, Zheng X. Re: Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial: The jury is still out. Eur J Cancer 2022:S0959-8049(22)00372-0. [PMID: 35933258 DOI: 10.1016/j.ejca.2022.06.021] [Reference Citation Analysis]
|
| 701 |
Fan P, Qiang H, Liu Z, Zhao Q, Wang Y, Liu T, Wang X, Chu T, Huang Y, Xu W, Qin S. Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Front Immunol 2022;13:937924. [DOI: 10.3389/fimmu.2022.937924] [Reference Citation Analysis]
|
| 702 |
Missiaen R, Anderson NM, Kim LC, Nance B, Burrows M, Skuli N, Carens M, Riscal R, Steensels A, Li F, Simon MC. GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab 2022;34:1151-1167.e7. [PMID: 35839757 DOI: 10.1016/j.cmet.2022.06.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 703 |
Soria A, Calvo M, Casas M, Vidales Z, Muñoz-martínez S, Sapena V, Puigvehi M, Canillas L, Guardeño R, Gallego A, Mínguez B, Horta D, Clos A, Montoliu S, Roget M, Reig M, Vergara M. Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma. Front Oncol 2022;12:829483. [DOI: 10.3389/fonc.2022.829483] [Reference Citation Analysis]
|
| 704 |
Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Philipp A, Berg T, Klümpen HJ, Benckert J, Pech M, Gasbarrini A, Amthauer H, Bartenstein P, Sangro B, Malfertheiner P, Ricke J, Seidensticker M. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib. Eur J Nucl Med Mol Imaging 2022. [PMID: 35916920 DOI: 10.1007/s00259-022-05920-8] [Reference Citation Analysis]
|
| 705 |
Wang S, Wang X, Xia X, Zhang T, Yi M, Li Z, Jiang L, Yang Y, Fu J, Fang X. Identification of the immune subtype of ovarian cancer patients by integrated analyses of transcriptome and single-cell sequencing data. Sci Rep 2022;12:13296. [PMID: 35918500 DOI: 10.1038/s41598-022-17645-7] [Reference Citation Analysis]
|
| 706 |
Kim N, Cheng JC, Ohri N, Huang W, Kimura T, Zeng ZC, Lee VHF, Kay CS, Seong J. Does HCC Etiology Impact the Efficacy of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma? An Asian Liver Radiation Therapy Group Study. JHC 2022;Volume 9:707-15. [DOI: 10.2147/jhc.s377810] [Reference Citation Analysis]
|
| 707 |
Barsch M, Salié H, Schlaak AE, Zhang Z, Hess M, Mayer LS, Tauber C, Otto-Mora P, Ohtani T, Nilsson T, Wischer L, Winkler F, Manne S, Rech A, Schmitt-Graeff A, Bronsert P, Hofmann M, Neumann-Haefelin C, Boettler T, Fichtner-Feigl S, van Boemmel F, Berg T, Rimassa L, Di Tommaso L, Saeed A, D'Alessio A, Pinato DJ, Bettinger D, Binder H, John Wherry E, Schultheiss M, Thimme R, Bengsch B. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol 2022;77:397-409. [PMID: 35367533 DOI: 10.1016/j.jhep.2022.02.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 708 |
Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int 2022;42:2029-41. [PMID: 35319165 DOI: 10.1111/liv.15251] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 709 |
Awiwi MO, Elsayes KM, Mohamed YI, Altameemi L, Gjoni M, Irshad OM, Sayed Ahmed A, Kaseb AO, Salem U. . JHC 2022;Volume 9:913-27. [DOI: 10.2147/jhc.s379428] [Reference Citation Analysis]
|
| 710 |
Shindoh J, Kawamura Y, Kobayashi M, Akuta N, Okubo S, Matsumura M, Suzuki Y, Hashimoto M. Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma. J Gastrointest Surg 2022;26:1637-46. [PMID: 35715641 DOI: 10.1007/s11605-022-05388-9] [Reference Citation Analysis]
|
| 711 |
Elshami M, Hue JJ, Hoehn RS, Rothermel LD, Bajor D, Mohamed A, Selfridge JE, Chavin KD, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment. HPB (Oxford) 2022;24:1280-90. [PMID: 35063353 DOI: 10.1016/j.hpb.2021.12.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 712 |
Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2022;42:2067-79. [PMID: 34515412 DOI: 10.1111/liv.15052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 713 |
Pala L, Sala I, Oriecuia C, De Pas T, Queirolo P, Specchia C, Cocorocchio E, Ferrucci P, Patanè D, Saponara M, Pennacchioli E, Coppola S, Viale G, Giaccone G, Gelber RD, Bagnardi V, Conforti F. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5:e2226252. [PMID: 35972744 DOI: 10.1001/jamanetworkopen.2022.26252] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 714 |
Pang S, Shi Y, Xu D, Sun Z, Chen Y, Yang Y, Zhao X, Si-Ma H, Yang N. Screening of Hepatocellular Carcinoma Patients with High Risk of Early Recurrence After Radical Hepatectomy Using a Nomogram Model Based on the γ-Glutamyl Transpeptidase-to-Albumin Ratio. J Gastrointest Surg 2022;26:1-9. [PMID: 35508683 DOI: 10.1007/s11605-022-05326-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 715 |
Chen J, Chen X, Li T, Wang L, Lin G. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response. Int Immunopharmacol 2022;109:108866. [PMID: 35691273 DOI: 10.1016/j.intimp.2022.108866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 716 |
Cerniglia M, Klepadlo M, Sheneman D, Kim SS. Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC. BMJ Case Rep 2022;15:e250009. [DOI: 10.1136/bcr-2022-250009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 717 |
Ollivier-Hourmand I, Allaire M, Cervoni JP; Club Francophone pour l’Etude de l’Hypertension Portale. Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma. J Hepatol 2022;77:566-7. [PMID: 35182660 DOI: 10.1016/j.jhep.2022.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 718 |
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 Clinics in Japan (HCC 48) Group. Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. Eur J Gastroenterol Hepatol 2022;34:857-64. [PMID: 35802527 DOI: 10.1097/MEG.0000000000002398] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 719 |
Yin Z, Chen D, Liang S, Li X. . JHC 2022;Volume 9:929-46. [DOI: 10.2147/jhc.s357313] [Reference Citation Analysis]
|
| 720 |
Torimura T, Iwamoto H. Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int 2022;42:2042-54. [PMID: 34894051 DOI: 10.1111/liv.15130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 721 |
Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2022;42:2055-66. [PMID: 34780081 DOI: 10.1111/liv.15101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 722 |
Kudo M. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. Hepatobiliary Surg Nutr 2022;11:592-6. [PMID: 36016731 DOI: 10.21037/hbsn-22-143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 723 |
Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, Miyata H, Izumi N, Kudo M, Koike K. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). J Gastroenterol 2022;57:587-97. [PMID: 35788887 DOI: 10.1007/s00535-022-01893-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 724 |
Li K, Gong Y, Qiu D, Tang H, Zhang J, Yuan Z, Huang Y, Qin Y, Ye L, Yang Y. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. J Immunother Cancer 2022;10. [PMID: 36002188 DOI: 10.1136/jitc-2021-004006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 725 |
Husain A, Chiu YT, Sze KM, Ho DW, Tsui YM, Suarez EMS, Zhang VX, Chan LK, Lee E, Lee JM, Cheung TT, Wong CC, Chung CY, Ng IO. Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. J Hepatol 2022;77:383-96. [PMID: 35227773 DOI: 10.1016/j.jhep.2022.02.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 726 |
Huang J, Zhong J, Zhang J, Gong W, Ma L, Li L, Xiang B. Hepatectomy combined with targeted and immunotherapy for CNLC stage IIIb hepatocellular carcinoma: a single-arm clinical trials protocol.. [DOI: 10.1101/2022.07.29.22278175] [Reference Citation Analysis]
|
| 727 |
Marsh-Wakefield F, Ferguson AL, Liu K, Santhakumar C, McCaughan G, Palendira U. Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:17588359221113270. [PMID: 35898965 DOI: 10.1177/17588359221113270] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 728 |
Lim DH, Casadei-Gardini A, Lee MA, Lonardi S, Kim JW, Masi G, Chon HJ, Rimini M, Kim I, Cheon J, Hwang JE, Kang JH, Lim HY, Yoo C. Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib. Future Oncol 2022. [PMID: 35903991 DOI: 10.2217/fon-2022-0524] [Reference Citation Analysis]
|
| 729 |
Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? . World J Gastroenterol 2022; 28(28): 3595-3607 [DOI: 10.3748/wjg.v28.i28.3595] [Reference Citation Analysis]
|
| 730 |
da Fonseca LG, Araujo RLC. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. World J Gastroenterol 2022; 28(28): 3573-3585 [DOI: 10.3748/wjg.v28.i28.3573] [Reference Citation Analysis]
|
| 731 |
Sahai V, Griffith KA, Beg MS, Shaib WL, Mahalingam D, Zhen DB, Deming DA, Zalupski MM. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. Cancer 2022. [PMID: 35895381 DOI: 10.1002/cncr.34394] [Reference Citation Analysis]
|
| 732 |
Li L, Wen Q, Ding R. Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials. Front Oncol 2022;12:905520. [DOI: 10.3389/fonc.2022.905520] [Reference Citation Analysis]
|
| 733 |
Greten TF, Monge C. Two Milestone Studies in Liver Cancer Immunotherapy. NEJM Evidence 2022;1. [DOI: 10.1056/evide2200140] [Reference Citation Analysis]
|
| 734 |
Zhao Y, Haroun RR, Sahu S, Schernthaner RE, Smolka S, Lin MD, Hong KK, Georgiades C, Duran R. Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment? Cancers (Basel) 2022;14:3615. [PMID: 35892874 DOI: 10.3390/cancers14153615] [Reference Citation Analysis]
|
| 735 |
Brandt EF, Baues M, Wirtz TH, May J, Fischer P, Beckers A, Schüre B, Sahin H, Trautwein C, Lammers T, Berres M. Chemokine CXCL10 Modulates the Tumor Microenvironment of Fibrosis-Associated Hepatocellular Carcinoma. IJMS 2022;23:8112. [DOI: 10.3390/ijms23158112] [Reference Citation Analysis]
|
| 736 |
Digiacomo G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R, Petronini PG. CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells. Front Oncol 2022;12:942341. [DOI: 10.3389/fonc.2022.942341] [Reference Citation Analysis]
|
| 737 |
Wu K, Xia B, Zhang J, Li X, Yang S, Zhang M, Zhu L, Wang B, Xu X, Ma S, Chen X. Positive Correlation of Peripheral CD8(+) T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers (Basel) 2022;14. [PMID: 35892826 DOI: 10.3390/cancers14153568] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 738 |
Wan H, Lu S, Xu L, Yuan K, Xiao Y, Xie K, Wu H. Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:925362. [DOI: 10.3389/fonc.2022.925362] [Reference Citation Analysis]
|
| 739 |
Müller L, Gairing SJ, Kloeckner R, Foerster F, Weinmann A, Mittler J, Stoehr F, Emrich T, Düber C, Galle PR, Hahn F. Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy. Cancers 2022;14:3574. [DOI: 10.3390/cancers14153574] [Reference Citation Analysis]
|
| 740 |
Suzuki H, Iwamoto H, Shimose S, Niizeki T, Shirono T, Noda Y, Kamachi N, Yamaguchi T, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review. Front Oncol 2022;12:948293. [DOI: 10.3389/fonc.2022.948293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 741 |
Kim HS, Kim CG, Hong JY, Kim IH, Kang B, Jung S, Kim C, Shin SJ, Choi HJ, Cheon J, Chon HJ, Lim HY. The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:17588359221113266. [PMID: 35860833 DOI: 10.1177/17588359221113266] [Reference Citation Analysis]
|
| 742 |
Gairing SJ, Müller L, Penzkofer L, Stoehr F, Michel M, Shmanko K, Galle PR. Diagnostik und Therapie des primären Leberzellkarzinoms. Gastroenterologie 2022. [DOI: 10.1007/s11377-022-00636-5] [Reference Citation Analysis]
|
| 743 |
Matsumoto H, Tsuchiya K, Nakanishi H, Hayakawa Y, Yasui Y, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Ishido S, Yamada M, Keitoku T, Nobusawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Takahashi Y, Kurosaki M, Asahina Y, Okamoto R, Izumi N. Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers 2022;14:3551. [DOI: 10.3390/cancers14143551] [Reference Citation Analysis]
|
| 744 |
Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Neal JW, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol 2022;40:2295-306. [PMID: 35658002 DOI: 10.1200/JCO.22.00912] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 745 |
Pavlek G, Romic I, Juzbasic K, Alduk AM, Petrovic I, Radojkovic R, Grbavac D, Silovski H. Case report: Urgent liver pathologies: All in one. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.940856] [Reference Citation Analysis]
|
| 746 |
Leal TA, Dahlberg SE, Ramalingam SS. Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. J Clin Oncol 2022;40:2285-7. [PMID: 35658027 DOI: 10.1200/JCO.22.01035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 747 |
Feng ZH, Wang MD, Chen Z, Sun LY, Xu X, Kong QY, Chen ZX, Zeng YY, Liang YJ, Chen ZY, Wang H, Zhou YH, Chen TH, Yao LQ, Li C, Pawlik TM, Lau WY, Shen F, Yang T. Risk factors and long-term prognosis of beyond-Milan recurrence after hepatectomy for BCLC stage 0/A hepatocellular carcinoma: A large-scale multicenter study. Surgery 2022:S0039-6060(22)00408-1. [PMID: 35868902 DOI: 10.1016/j.surg.2022.05.023] [Reference Citation Analysis]
|
| 748 |
Tsilimigras DI, Aziz H, Pawlik TM. Critical Analysis of the Updated Barcelona Clinic Liver Cancer (BCLC) Group Guidelines. Ann Surg Oncol 2022. [PMID: 35854026 DOI: 10.1245/s10434-022-12242-4] [Reference Citation Analysis]
|
| 749 |
Sagmeister P, Daza J, Ofner A, Ziesch A, Ye L, Ben Khaled N, Ebert M, Mayerle J, Teufel A, De Toni EN, Munker S. Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis. J Hepatocell Carcinoma 2022;9:595-607. [PMID: 35845819 DOI: 10.2147/JHC.S356333] [Reference Citation Analysis]
|
| 750 |
Jia J, Ga L, Liu Y, Yang Z, Wang Y, Guo X, Ma R, Liu R, Li T, Tang Z, Wang J. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Front Immunol 2022;13:923031. [DOI: 10.3389/fimmu.2022.923031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 751 |
Tian Y, Zhang C, Dang Q, Wang K, Liu Q, Liu H, Shang H, Zhao J, Xu Y, Wu T, Liu W, Yang X, Safi M, Wu YS. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/4976032] [Reference Citation Analysis]
|
| 752 |
Pires Amaro C, Allen MJ, Knox JJ, Tsang ES, Lim HJ, Lee‐ying RM, Chan KW, Qian J, Meyers BM, Thawer A, Al‐saadi SMS, Hsu T, Ramjeesingh R, Karachiwala H, Abedin T, Tam VC. Dosing, efficacy and safety of lenvatinb in the real‐world treatment of hepatocellular carcinoma: Results from a Canadian database. Liver Cancer International 2022. [DOI: 10.1002/lci2.59] [Reference Citation Analysis]
|
| 753 |
Zhang Y, Pang S, Sun B, Zhang M, Jiao X, Lai L, Qian Y, Yang N, Yang W. ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:884066. [DOI: 10.3389/fonc.2022.884066] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 754 |
Menshikov KV, Sultanbaev AV, Musin SI, Rakhmatullina IR, Menshikova IA, Abdeev RR, Sultanbaeva NI, Popova EV, Serebrennikov GA. Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. Kreativnaâ hirurgiâ i onkologiâ 2022;12:139-150. [DOI: 10.24060/2076-3093-2022-12-2-139-150] [Reference Citation Analysis]
|
| 755 |
Hu X, Li R, Li Q, Zang M, Yuan G, Chen J. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. BMC Infect Dis 2022;22:614. [PMID: 35836207 DOI: 10.1186/s12879-022-07602-0] [Reference Citation Analysis]
|
| 756 |
Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice. Cancer Rep (Hoboken) 2023;6:e1679. [PMID: 35822407 DOI: 10.1002/cnr2.1679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 757 |
Hidaka Y, Tomita M, Desaki R, Hamanoue M, Takao S, Kirishima M, Ohtsuka T. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World J Surg Oncol 2022;20:228. [PMID: 35831894 DOI: 10.1186/s12957-022-02691-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 758 |
Adhoute X, Wolf T. Response to immunotherapy plus anti-angiogenic agent combination challenges hepatocellular carcinoma prognostic scores. Hepatol Commun 2022;6:3595-6. [PMID: 35819258 DOI: 10.1002/hep4.2047] [Reference Citation Analysis]
|
| 759 |
Matsumae T, Kodama T, Myojin Y, Maesaka K, Sakamori R, Takuwa A, Oku K, Motooka D, Sawai Y, Oshita M, Nakabori T, Ohkawa K, Miyazaki M, Tanaka S, Mita E, Tawara S, Yakushijin T, Nozaki Y, Hagiwara H, Tahata Y, Yamada R, Hikita H, Tatsumi T, Takehara T. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy. Cancers 2022;14:3367. [DOI: 10.3390/cancers14143367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 760 |
Zhang Z, Zeng X, Wu Y, Liu Y, Zhang X, Song Z. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol 2022;13:925618. [PMID: 35898502 DOI: 10.3389/fimmu.2022.925618] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 48.0] [Reference Citation Analysis]
|
| 761 |
Orrapin S, Udomruk S, Lapisatepun W, Moonmuang S, Phanphaisarn A, Phinyo P, Pruksakorn D, Chaiyawat P. Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review. Cancers 2022;14:3373. [DOI: 10.3390/cancers14143373] [Reference Citation Analysis]
|
| 762 |
Jomen W, Ohtake T, Akita T, Suto D, Yagi H, Osawa Y, Kohgo Y. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths. Biomed Pharmacother 2022;153:113363. [PMID: 35834989 DOI: 10.1016/j.biopha.2022.113363] [Reference Citation Analysis]
|
| 763 |
Marzi L, Mega A, Gitto S, Pelizzaro F, Seeber A, Spizzo G. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. Cancers 2022;14:3332. [DOI: 10.3390/cancers14143332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 764 |
Tanaka T, Takata K, Yokoyama K, Fukuda H, Yamauchi R, Fukunaga A, Shakado S, Sakisaka S, Hirai F. Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology 2022;29:4799-4810. [DOI: 10.3390/curroncol29070381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 765 |
Yang X, Sun Y, Li D, Xu G, Huang X. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. Front Immunol 2022;13:940009. [DOI: 10.3389/fimmu.2022.940009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 766 |
Liu S, Gao W, Ning Y, Zou X, Zhang W, Zeng L, Liu J. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:908173. [DOI: 10.3389/fimmu.2022.908173] [Reference Citation Analysis]
|
| 767 |
Marron TU, Schwartz M, Corbett V, Merad M. Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:571-81. [PMID: 35794901 DOI: 10.2147/JHC.S340935] [Reference Citation Analysis]
|
| 768 |
Xu L, Zou C, Zhang S, Chu TSM, Zhang Y, Chen W, Zhao C, Yang L, Xu Z, Dong S, Yu H, Li B, Guan X, Hou Y, Kong FM. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol 2022;15:87. [PMID: 35799264 DOI: 10.1186/s13045-022-01307-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 769 |
Liu C, Zhu S, Dong Y, Shao J, Liu B, Shen J. The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody. Front Immunol 2022;13:930096. [DOI: 10.3389/fimmu.2022.930096] [Reference Citation Analysis]
|
| 770 |
Long X, Zhang L, Wang WQ, Zhang EL, Lv X, Huang ZY. Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. Onco Targets Ther 2022;15:703-16. [PMID: 35791424 DOI: 10.2147/OTT.S365652] [Reference Citation Analysis]
|
| 771 |
Baldini C, Danlos FX, Varga A, Texier M, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A. Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. J Exp Clin Cancer Res 2022;41:217. [PMID: 35794623 DOI: 10.1186/s13046-022-02423-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 772 |
Parikh ND, Mehta N, Hoteit MA, Yang JD, John BV, Moon AM, Salgia RJ, Pillai A, Kassab I, Saeed N, Thyssen E, Nathani P, McKinney J, Chan W, Durkin C, Connor M, Alsudaney M, Konjeti R, Durand B, Nissen NN, Kim HP, Paknikar R, Rich NE, Schipper MJ, Singal AG. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer 2022. [PMID: 35796530 DOI: 10.1002/cncr.34378] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 773 |
Zhu J, Han T, Zhao S, Zhu Y, Ma S, Xu F, Bai T, Tang Y, Xu Y, Liu L. Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma. Front Oncol 2022;12:933210. [DOI: 10.3389/fonc.2022.933210] [Reference Citation Analysis]
|
| 774 |
Shah D, Kapacee ZA, Lamarca A, Hubner RA, Valle JW, McNamara MG. Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. Expert Rev Anticancer Ther 2022. [PMID: 35768183 DOI: 10.1080/14737140.2022.2096594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 775 |
Robillard L, Liao M, Nguyen M, Harding TC, Simmons AD, Dusek RL. The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models. J Immunother 2022. [PMID: 35791438 DOI: 10.1097/CJI.0000000000000427] [Reference Citation Analysis]
|
| 776 |
Kim M, Cho Y, Kim E, Choe J, Park J, Lee J, Lee J, Moon S, Kim Y, Kim S, Choi E. Cellular Prion Protein Is Closely Associated with Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma. Diagnostics 2022;12:1635. [DOI: 10.3390/diagnostics12071635] [Reference Citation Analysis]
|
| 777 |
Fan W, Zhu B, Zheng X, Yue S, Lu M, Fan H, Qiao L, Li F, Yuan G, Wu Y, Zou X, Wang H, Xue M, Li J. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization. J Cancer Res Clin Oncol 2022. [PMID: 35788728 DOI: 10.1007/s00432-022-04107-w] [Reference Citation Analysis]
|
| 778 |
Wan Y, Wang Z, Yang N, Liu F. Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review. Front Oncol 2022;12:911961. [DOI: 10.3389/fonc.2022.911961] [Reference Citation Analysis]
|
| 779 |
Schütte K, Kupčinskas J, Morkunas E, Öcal O, Schinner R, Seidensticker M, De Toni EN, Ben Khaled N, Pech M, Palmer D, Berg T, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Sangro B, Malfertheiner P, Ricke J. Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial. Front Gastroenterol 2022;1. [DOI: 10.3389/fgstr.2022.939192] [Reference Citation Analysis]
|
| 780 |
Li X, Fu Z, Chen X, Cao K, Zhong J, Liu L, Ding N, Zhang X, Zhai J, Qu Z. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. Front Oncol 2022;12:950266. [DOI: 10.3389/fonc.2022.950266] [Reference Citation Analysis]
|
| 781 |
An J, Han S, Kim HI, Shim JH. Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials. Hepatol Commun 2022. [PMID: 35785525 DOI: 10.1002/hep4.2025] [Reference Citation Analysis]
|
| 782 |
Utsumi T, Taniguchi Y, Noda Y, Fukai M, Kibata K, Murakawa T. SMARCA4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report. Thorac Cancer 2022. [PMID: 35778998 DOI: 10.1111/1759-7714.14547] [Reference Citation Analysis]
|
| 783 |
Gramantieri L, Fornari F, Giovannini C, Trerè D. MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. Biomolecules 2022;12:930. [DOI: 10.3390/biom12070930] [Reference Citation Analysis]
|
| 784 |
Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Miyazaki M, Ohkawa K, Mita E, Iio S, Nozaki Y, Yakushijin T, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatol Res 2022;52:630-40. [PMID: 35417606 DOI: 10.1111/hepr.13771] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 785 |
Teng PC, Agopian VG, Lin TY, You S, Zhu Y, Tseng HR, Yang JD. Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma. J Gastroenterol Hepatol 2022;37:1179-90. [PMID: 35543075 DOI: 10.1111/jgh.15886] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 786 |
Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib. J Viral Hepat 2022;29:543-50. [PMID: 35499194 DOI: 10.1111/jvh.13681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 787 |
Griffiths CD, Zhang B, Tywonek K, Meyers BM, Serrano PE. Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5:e2222721. [PMID: 35849393 DOI: 10.1001/jamanetworkopen.2022.22721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 788 |
Chan SL, Wong N, Lam WKJ, Kuang M. Personalized treatment for hepatocellular carcinoma: Current status and future perspectives. J Gastroenterol Hepatol 2022;37:1197-206. [PMID: 35570200 DOI: 10.1111/jgh.15889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 789 |
Kelley RK, Rimassa L, Cheng A, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo B, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00326-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 790 |
Chandra VM, Wilkins LR, Brautigan DL. Animal Models of Hepatocellular Carcinoma for Local-Regional Intraarterial Therapies. Radiology: Imaging Cancer 2022;4. [DOI: 10.1148/rycan.210098] [Reference Citation Analysis]
|
| 791 |
Luo J, Wang T, Wang X, Shi Y, Zhang Y, Tian J, Gong Y. Ficolin-3 may act as a tumour suppressor by recognising O-GlcNAcylation site in hepatocellular carcinoma. Medical Hypotheses 2022. [DOI: 10.1016/j.mehy.2022.110899] [Reference Citation Analysis]
|
| 792 |
Kuwano A, Tanaka K, Nagasawa S, Morita Y, Yada M, Masumoto A, Motomura K. Immune thrombocytopenic purpura caused by combination therapy of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A case presentation. Acta hepatologica Japonica 2022;63:335-341. [DOI: 10.2957/kanzo.63.335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 793 |
Singhal S, Patel G, Singh RB, Goyal A, Avgush K, Koka J. Atezolizumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis and Takotsubo cardiomyopathy. BMJ Case Rep 2022;15:e250662. [DOI: 10.1136/bcr-2022-250662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 794 |
Abbas D, Zhu L, Moon AM. Elevated Liver Enzymes in a Patient With Hepatocellular Carcinoma on Immune Checkpoint Inhibitor Therapy: A Diagnostic and Therapeutic Challenge. ACG Case Rep J 2022;9:e00834. [DOI: 10.14309/crj.0000000000000834] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 795 |
Saito N, Hatanaka T, Nakano S, Hazama Y, Yoshida S, Hachisu Y, Tanaka Y, Yoshinaga T, Kashiwabara K, Kubo N, Hosouchi Y, Tojima H, Kakizaki S, Uraoka T. A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.6129] [Reference Citation Analysis]
|
| 796 |
Bertaglia V, Petrelli F, Porcu M, Saba L, Pearce J, Luciani A, Solinas C, Scartozzi M. Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. Cytokine & Growth Factor Reviews 2022. [DOI: 10.1016/j.cytogfr.2022.07.009] [Reference Citation Analysis]
|
| 797 |
Zeng Q, Klein C, Caruso S, Maille P, Laleh NG, Sommacale D, Laurent A, Amaddeo G, Gentien D, Rapinat A, Regnault H, Charpy C, Nguyen CT, Tournigand C, Brustia R, Pawlotsky JM, Kather JN, Maiuri MC, Loménie N, Calderaro J. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol 2022;77:116-27. [PMID: 35143898 DOI: 10.1016/j.jhep.2022.01.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 798 |
Guan H, Wang C, Zhao Z, Han S. Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China. Adv Ther 2022;39:3334-46. [PMID: 35644019 DOI: 10.1007/s12325-022-02185-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 799 |
Jonas E, Bernon M, Robertson B, Kassianides C, Keli E, Asare KO, Alatise IO, Okello M, Blondel NO, Mulehane KO, Abubeker ZA, Nogoud AA, Nashidengo PR, Chihaka O, Tzeuton C, Dusheiko G, Sonderup M, Spearman CW. Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00042-5] [Reference Citation Analysis]
|
| 800 |
Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun 2022;6:1776-85. [PMID: 35481940 DOI: 10.1002/hep4.1927] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 801 |
Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. J Hepatol 2022;77:219-36. [PMID: 35157957 DOI: 10.1016/j.jhep.2022.01.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 802 |
Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de la Tijera F, Huitzil-melendez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. II Consenso mexicano de carcinoma hepatocelular. Parte II: tratamiento. Revista de Gastroenterología de México 2022;87:362-379. [DOI: 10.1016/j.rgmx.2022.01.006] [Reference Citation Analysis]
|
| 803 |
Serper M, Parikh ND, Thiele G, Ovchinsky N, Mehta S, Kuo A, Ho C, Kanwal F, Volk M, Asrani SK, Ghabril MS, Lake JR, Merriman RB, Morgan TR, Tapper EB. Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;76:251-74. [PMID: 34990516 DOI: 10.1002/hep.32313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 804 |
Ji F, Nguyen MH. Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00383-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 805 |
Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de la Tijera F, Huitzil-melendez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. Revista de Gastroenterología de México (English Edition) 2022;87:362-379. [DOI: 10.1016/j.rgmxen.2022.01.004] [Reference Citation Analysis]
|
| 806 |
Sessa A, Mulé S, Brustia R, Regnault H, Galletto Pregliasco A, Rhaiem R, Leroy V, Sommacale D, Luciani A, Calderaro J, Amaddeo G. Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge. JHC 2022;Volume 9:661-70. [DOI: 10.2147/jhc.s364703] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 807 |
Sclafani F, Hendlisz A. Editorial: 'All you need is immunotherapy': a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers? Curr Opin Oncol 2022;34:379-81. [PMID: 35837708 DOI: 10.1097/CCO.0000000000000856] [Reference Citation Analysis]
|
| 808 |
Hercun J, Vincent C, Bilodeau M, Lapierre P. Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. Front Immunol 2022;13:907591. [DOI: 10.3389/fimmu.2022.907591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 809 |
Reeves HL, Reicher J, Priona G, Manas DM, Littler P. Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England. Frontline Gastroenterol 2023;14:45-51. [PMID: 36561784 DOI: 10.1136/flgastro-2022-102137] [Reference Citation Analysis]
|
| 810 |
Fu J, Cao Z, Zhang J, Chen Q, Wang Y, Wang S, Fang X, Xu X. Identification of two immune-related risk score signatures through integrated analysis of multi-omics data in hepatocellular carcinoma. Gene 2022;829:146519. [PMID: 35447248 DOI: 10.1016/j.gene.2022.146519] [Reference Citation Analysis]
|
| 811 |
Lee C, Chan SL, Chon HJ. Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma? Cancers 2022;14:3213. [DOI: 10.3390/cancers14133213] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 812 |
Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Front Immunol 2022;13:896752. [PMID: 35757756 DOI: 10.3389/fimmu.2022.896752] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 813 |
Yuan G, Xie F, Song Y, Li Q, Li R, Hu X, Zang M, Cheng X, Lu G, Huang J, Fan W, Rong X, Sun J, Chen J. Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. Front Immunol 2022;13:868809. [PMID: 35757765 DOI: 10.3389/fimmu.2022.868809] [Reference Citation Analysis]
|
| 814 |
Newbury A, Ferguson C, Valero DA, Kutcher-Diaz R, McIntosh L, Karamanian A, Harman A. Interventional oncology update. Eur J Radiol Open 2022;9:100430. [PMID: 35761853 DOI: 10.1016/j.ejro.2022.100430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 815 |
Yu Y, Wang S, Su N, Pan S, Tu B, Zhao J, Shen Y, Qiu Q, Liu X, Luan J, Wang FS, Meng F, Shi M. Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. Front Oncol 2022;12:906824. [PMID: 35756643 DOI: 10.3389/fonc.2022.906824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 816 |
Rim CH, Park S, Yoon WS, Shin IS, Park HC. Radiotherapy for bone metastases of hepatocellular carcinoma: a hybrid systematic review with meta-analyses. Int J Radiat Biol 2023;99:419-30. [PMID: 35758976 DOI: 10.1080/09553002.2022.2094020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 817 |
Adetutu Adisa R, Adegboyega Sulaimon L. Hepatocellular Carcinoma. Hepatotoxicity [Working Title] 2022. [DOI: 10.5772/intechopen.105473] [Reference Citation Analysis]
|
| 818 |
Heinrich B, Ruf B, Subramanyam V, Myojin Y, Lai CW, Craig AJ, Fu J, Xie C, Kroemer A, Greten TF, Korangy F. Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. Front Immunol 2022;13:849958. [DOI: 10.3389/fimmu.2022.849958] [Reference Citation Analysis]
|
| 819 |
Shi Y, Li Y, Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Lv C, Han S, Yu Y, Xu F, Tian Y. Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. Int Immunopharmacol 2022;110:108968. [PMID: 35764018 DOI: 10.1016/j.intimp.2022.108968] [Reference Citation Analysis]
|
| 820 |
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatol Int 2022. [PMID: 35749019 DOI: 10.1007/s12072-022-10358-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 821 |
Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 [DOI: 10.5306/wjco.v13.i6.448] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 822 |
Tang M, Zhao Y, Zhao J, Wei S, Liu M, Zheng N, Geng D, Han S, Zhang Y, Zhong G, Li S, Zhang X, Wang C, Yan H, Cao X, Li L, Bai X, Ji J, Feng XH, Qin J, Liang T, Zhao B. Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. Sci Adv 2022;8:eabn5683. [PMID: 35731873 DOI: 10.1126/sciadv.abn5683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 823 |
Zhang Z, Shang J, Hu B, Shi H, Cao Y, Li J, Jiao T, Zhang W, Lu S. Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature. Front Immunol 2022;13:836576. [DOI: 10.3389/fimmu.2022.836576] [Reference Citation Analysis]
|
| 824 |
Maki H, Hasegawa K. Advances in the surgical treatment of liver cancer. Biosci Trends 2022. [PMID: 35732434 DOI: 10.5582/bst.2022.01245] [Reference Citation Analysis]
|
| 825 |
Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-saccà M, Bon G. Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Front Oncol 2022;12:877380. [DOI: 10.3389/fonc.2022.877380] [Reference Citation Analysis]
|
| 826 |
Pu Z, Liu Z, Chen J, Inoue K, Ruan Z, Zhu L, Kikuchi H, Matsui A, Huang P, Duda DG. Inflammasome targeting with an NLRP3 agonist therapy is feasible but ineffective in murine hepatocellular carcinoma models with liver damage.. [DOI: 10.1101/2022.06.23.497362] [Reference Citation Analysis]
|
| 827 |
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 2022. [PMID: 35739268 DOI: 10.1038/s41591-022-01868-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 828 |
Chen X, Lin L, Chen G, Yan H, Li Z, Xiao M, He X, Zhang F, Zhang Y. High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma. Front Oncol 2022;12:900671. [DOI: 10.3389/fonc.2022.900671] [Reference Citation Analysis]
|
| 829 |
Pan S, Yu Y, Wang S, Tu B, Shen Y, Qiu Q, Liu X, Su N, Zuo Y, Luan J, Zhang JY, Shi M, Meng F, Wang FS. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy. Front Immunol 2022;13:892618. [PMID: 35711409 DOI: 10.3389/fimmu.2022.892618] [Reference Citation Analysis]
|
| 830 |
Wang G, Zhang W, Chen J, Luan X, Wang Z, Wang Y, Xu X, Yao S, Guan Z, Tian J, Lu S, Xu B, Ma G. Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. Front Oncol 2022;12:884372. [PMID: 35719917 DOI: 10.3389/fonc.2022.884372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 831 |
Su K, Gu T, Xu K, Wang J, Liao H, Li X, Wen L, Song Y, Zhong J, He B, Liu X, He J, Liu Y, Li Q, Feng X, Chen S, Yang B, Huang W, Jin H, Luo X, Hu T, Chen J, Wu Z, Lu S, Zhang J, Rao M, Xie Y, Wang J, Zhu X, Chen L, Li B, Su S, Yang X, Wang J, Zeng H, Wang P, Yan M, Chen X, He K, Han Y. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Hepatol Int 2022. [PMID: 35729469 DOI: 10.1007/s12072-022-10339-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 832 |
Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23): 2561-2568 [DOI: 10.3748/wjg.v28.i23.2561] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 833 |
Li L, Yang S, Chen Y, Tian L, He Y, Wu B, Dong D. Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. Front Pharmacol 2022;13:891008. [PMID: 35721168 DOI: 10.3389/fphar.2022.891008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 834 |
Melo V, Bremer E, Martin JD. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment. Front Cell Dev Biol 2022;10:908389. [PMID: 35712656 DOI: 10.3389/fcell.2022.908389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 835 |
Menshikov KV, Sultanbaev AV, Musin SI, Menshikova IA, Abdeev RR, Sultanbaeva NI, Nigmatullin VG, Popova EV. Immunotherapy of advanced hepatocellular carcinoma: case report and literature review. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-9-31-39] [Reference Citation Analysis]
|
| 836 |
Brossard C, Vlach M, Jacquet L, Vène E, Dorcet V, Loyer P, Cammas-Marion S, Lepareur N. Hepatotropic Peptides Grafted onto Maleimide-Decorated Nanoparticles: Preparation, Characterization and In Vitro Uptake by Human HepaRG Hepatoma Cells. Polymers (Basel) 2022;14:2447. [PMID: 35746020 DOI: 10.3390/polym14122447] [Reference Citation Analysis]
|
| 837 |
Ouyang T, Kan X, Zheng C. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Front Oncol 2022;12:898964. [DOI: 10.3389/fonc.2022.898964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 838 |
Yasui Y, Kurosaki M, Tsuchiya K, Hayakawa Y, Hasebe C, Abe M, Ogawa C, Joko K, Ochi H, Tada T, Nakamura S, Furuta K, Kimura H, Tsuji K, Kojima Y, Akahane T, Tamada T, Uchida Y, Kondo M, Mitsuda A, Izumi N; Japanese Red Cross Liver Study Group. Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers (Basel) 2022;14:2975. [PMID: 35740647 DOI: 10.3390/cancers14122975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 839 |
Abdelhamed W, El-Kassas M. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event. World J Gastrointest Oncol 2022; 14(6): 1103-1114 [DOI: 10.4251/wjgo.v14.i6.1103] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 840 |
Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, Voloshin T, Tzchori I, Haber A, Giladi M, Kinzel A, Weinberg U, Palti Y. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers (Basel) 2022;14. [PMID: 35740624 DOI: 10.3390/cancers14122959] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 841 |
Charonpongsuntorn C. Systemic Therapy in Hepatocellular Carcinoma. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.100257] [Reference Citation Analysis]
|
| 842 |
Aryan M, Altshuler E, Qian X, Zhang W. Treatment of Advanced Hepatocellular Carcinoma. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.99837] [Reference Citation Analysis]
|
| 843 |
Ozeki Y, Kanogawa N, Ogasawara S, Ogawa K, Ishino T, Nakagawa M, Fujiwara K, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Nakamura M, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Muroyama R, Tawada A, Chiba T, Arai M, Kato J, Ikeda JI, Takiguchi Y, Kato N. Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis. Int J Clin Oncol 2022. [PMID: 35704154 DOI: 10.1007/s10147-022-02195-9] [Reference Citation Analysis]
|
| 844 |
Cabezas-Camarero S, Pérez-Alfayate R, García-Barberán V, Polidura MC, Gómez-Ruiz MN, Casado-Fariñas I, Subhi-Issa IA, Hernández JCP, Garre P, Díaz-Millán I, Pérez-Segura P. Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome-associated glioma. Ther Adv Med Oncol 2022;14:17588359221100863. [PMID: 35694191 DOI: 10.1177/17588359221100863] [Reference Citation Analysis]
|
| 845 |
Lefler DS, Snook AE, Bashir B. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1. Immunotherapy 2022. [PMID: 35694998 DOI: 10.2217/imt-2022-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 846 |
Fan W, Zhu B, Yue S, Zheng X, Zou X, Li F, Qiao L, Wu Y, Xue M, Wang H, Tang Y, Li J. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis. Cancer Med 2023;12:61-72. [PMID: 35698292 DOI: 10.1002/cam4.4937] [Reference Citation Analysis]
|
| 847 |
Kobeissi JM, Hilal L, Simone CB 2nd, Lin H, Crane CH, Hajj C. Proton Therapy in the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:2900. [PMID: 35740567 DOI: 10.3390/cancers14122900] [Reference Citation Analysis]
|
| 848 |
Xu Y, Yang Y, Li L, Ye F, Zhao X. The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy. Front Oncol 2022;12:905260. [PMID: 35686094 DOI: 10.3389/fonc.2022.905260] [Reference Citation Analysis]
|
| 849 |
Li JX, Deng WX, Huang ST, Lin XF, Long MY, Zhang J, Su TS, Li LQ, Pang YD, Liang CF, Zhou HM, Lu HY, Liang SX, Xiang BD. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study. Radiat Oncol 2022;17:106. [PMID: 35690773 DOI: 10.1186/s13014-022-02075-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 850 |
Shi C, Kwong DL, Li X, Wang X, Fang X, Sun L, Tang Y, Guan XY, Li SS. MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. Cancers (Basel) 2022;14:2880. [PMID: 35740546 DOI: 10.3390/cancers14122880] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 851 |
Toshida K, Itoh S, Tomiyama T, Morinaga A, Kosai Y, Tomino T, Kurihara T, Nagao Y, Morita K, Harada N, Yoshizumi T. Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients. JGH Open. [DOI: 10.1002/jgh3.12777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 852 |
Rizzo A, Cusmai A, Massafra R, Bove S, Comes MC, Fanizzi A, Rinaldi L, Acquafredda S, Gadaleta-Caldarola G, Oreste D, Zito A, Giotta F, Lorusso V, Palmiotti G. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. Cells 2022;11:1857. [PMID: 35740985 DOI: 10.3390/cells11121857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 853 |
Abou-alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang Y, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng A, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence. [DOI: 10.1056/evidoa2100070] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 854 |
O’sullivan DE, Boyne DJ, Syed IA, Shephard C, Clouthier DL, Yoshida EM, Spratlin JL, Batra A, Rigo R, Hannouf M, Yang Hu X, Jarada T, Brenner DR, Cheung WY. Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma. CanLivJ 2022. [DOI: 10.3138/canlivj-2022-0001] [Reference Citation Analysis]
|
| 855 |
Fu J, Lei X. Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data. Front Immunol 2022;13:868325. [DOI: 10.3389/fimmu.2022.868325] [Reference Citation Analysis]
|
| 856 |
Chakraborty E, Sarkar D. Emerging Therapies for Hepatocellular Carcinoma (HCC). Cancers (Basel) 2022;14. [PMID: 35681776 DOI: 10.3390/cancers14112798] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 28.0] [Reference Citation Analysis]
|
| 857 |
Zhang W, Wu L, Chen L, Ren Y, Sun T, Sun B, Zhu L, Liu Y, Zheng C. The Efficacy and Safety of Transarterial Chemoembolization Plus Iodine 125 Seed Implantation in the Treatment of Hepatocellular Carcinoma With Oligometastases: A Case Series Reports. Front Oncol 2022;12:828850. [PMID: 35656512 DOI: 10.3389/fonc.2022.828850] [Reference Citation Analysis]
|
| 858 |
Zheng Z, Liu Z, Zhang H, Guo X, Jia X, Wang J, Meng L, Xin Y, Jiang X. Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. Front Pharmacol 2022;13:894016. [PMID: 35656302 DOI: 10.3389/fphar.2022.894016] [Reference Citation Analysis]
|
| 859 |
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib. Cancer Med 2023;12:325-34. [PMID: 35666040 DOI: 10.1002/cam4.4854] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 860 |
Shirono T, Iwamoto H, Niizeki T, Shimose S, Kajiwara A, Suzuki H, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatsu R, Murotani K, Koga H, Torimura T. Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Commun 2022. [PMID: 35656864 DOI: 10.1002/hep4.2016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 861 |
Naruto K, Kawaoka T, Kodama K, Ogawa Y, Amioka K, Yoshikawa Y, Kikukawa C, Suehiro Y, Yamaoka K, Ando Y, Kosaka Y, Uchikawa S, Nakahara T, Murakami E, Ono A, Uchida T, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chosa K, Awai K, Kubo K, Nagata Y, Chayama K, Aikata H. Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02359-x] [Reference Citation Analysis]
|
| 862 |
Tella SH, Kommalapati A, Mahipal A, Jin Z. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines 2022;10. [PMID: 35740326 DOI: 10.3390/biomedicines10061304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 863 |
Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattan S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillén-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Delord JP. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res 2022;41:189. [PMID: 35655320 DOI: 10.1186/s13046-022-02383-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 864 |
Chapin WJ, Hwang WT, Karasic TB, McCarthy AM, Kaplan DE. Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Med 2023;12:189-99. [PMID: 35652419 DOI: 10.1002/cam4.4906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 865 |
Huang J, Kang W, Pan S, Yu C, Jie Z, Chen C, Ciccarone F. NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. Oxidative Medicine and Cellular Longevity 2022;2022:1-17. [DOI: 10.1155/2022/6891155] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 866 |
Yu JI, Kang W, Yoo GS, Goh MJ, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Hong JY, Lim HY, Park B, Park HC. Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis. Front Oncol 2022;12:888755. [PMID: 35646674 DOI: 10.3389/fonc.2022.888755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 867 |
Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal YI, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron T. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer 2022;10:e004205. [PMID: 35710293 DOI: 10.1136/jitc-2021-004205] [Reference Citation Analysis]
|
| 868 |
Yang Y, Lu Y, Pei T, Guo B, Li J, Wang H, Ba Q. Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms. Pharmacological Research - Modern Chinese Medicine 2022;3:100108. [DOI: 10.1016/j.prmcm.2022.100108] [Reference Citation Analysis]
|
| 869 |
Yang Z, Sun JQ, Wang S, Zhuang L, Zheng SS. Response to pretransplant downstaging therapy predicts patient outcome after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Hepatobiliary Pancreat Dis Int 2022;21:295-8. [PMID: 34696977 DOI: 10.1016/j.hbpd.2021.09.012] [Reference Citation Analysis]
|
| 870 |
Sanmamed MF, Berraondo P, Rodriguez-ruiz ME, Melero I. Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat Cancer 2022;3:665-680. [DOI: 10.1038/s43018-022-00401-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 871 |
Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology 2022;75:1604-26. [PMID: 35253934 DOI: 10.1002/hep.32447] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 872 |
Yasutomi E, Yano Y, Yamamoto A, Kitadai J, Asaji N, Yoshida R, Hatazawa Y, Matsuura T, Shiomi Y, Ueda Y, Kodama Y. Cerebral hemorrhage during systemic chemotherapy with atezolizumab and bevacizumab for hepatocellular carcinoma. Acta hepatologica Japonica 2022;63:297-300. [DOI: 10.2957/kanzo.63.297] [Reference Citation Analysis]
|
| 873 |
Ayoub WS, Jones PD, Yang JD, Martin P. Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2022. [PMID: 35642526 DOI: 10.1080/14728214.2022.2083107] [Reference Citation Analysis]
|
| 874 |
Aimar G, Marino D, Zichi C, Gamba T, Caglio A, De Vita F, Sperti E, Di Maio M. Advanced hepatocellular carcinoma: Impact of systemic treatments on health‐related quality of life and patient‐reported outcomes. Liver Cancer International 2022;3:90-98. [DOI: 10.1002/lci2.50] [Reference Citation Analysis]
|
| 875 |
Su Y, Liu Y, Hsiao C, Hsu C, Chen L. Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. JHC 2022;Volume 9:517-36. [DOI: 10.2147/jhc.s220978] [Reference Citation Analysis]
|
| 876 |
Zhao L, Chang N, Shi L, Li F, Meng F, Xie X, Xu Z, Wang F. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study. Heliyon 2022;8:e09538. [PMID: 35706954 DOI: 10.1016/j.heliyon.2022.e09538] [Reference Citation Analysis]
|
| 877 |
Guo L, Zhang J, Liu X, Liu H, Zhang Y, Liu J. Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report. OTT 2022;Volume 15:629-36. [DOI: 10.2147/ott.s346635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 878 |
Brown ZJ, Gregory S, Hewitt DB, Iacono S, Choe J, Labiner HE, Pawlik TM. Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surgical Oncology 2022;42:101748. [DOI: 10.1016/j.suronc.2022.101748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 879 |
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. Eur J Gastroenterol Hepatol 2022;34:698-706. [PMID: 35170529 DOI: 10.1097/MEG.0000000000002356] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 880 |
Shen Y, Huang C, Zhu X, Xu M, Chen Z, Tan C, Zhou J, Fan J, Sun H. The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma. Annals of Surgery Open 2022;3:e163. [DOI: 10.1097/as9.0000000000000163] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 881 |
Di Carlo E, D'alessio A, Cammarota A, Zanuso V, Pressiani T, Bozzarelli S, Ferrillo G, Vatteroni G, Pedicini V, Giordano L, Personeni N, Rimassa L. Tumour burden score and immune‐related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. Liver Cancer International 2022;3:63-71. [DOI: 10.1002/lci2.51] [Reference Citation Analysis]
|
| 882 |
Siciliano M, Caridà G, Ciliberto D, d’Apolito M, Pelaia C, Caracciolo D, Riillo C, Correale P, Galvano A, Russo A, Barbieri V, Tassone P, Tagliaferri P. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. ESMO Open 2022;7:100465. [DOI: 10.1016/j.esmoop.2022.100465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 883 |
Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2022;10:e004779. [PMID: 35738801 DOI: 10.1136/jitc-2022-004779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 884 |
Zhuravleva E, O'Rourke CJ, Andersen JB. Mutational signatures and processes in hepatobiliary cancers. Nat Rev Gastroenterol Hepatol 2022;19:367-82. [PMID: 35273358 DOI: 10.1038/s41575-022-00587-w] [Reference Citation Analysis]
|
| 885 |
Bejjani AC, Finn RS. Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations. J Clin Oncol 2022;:JCO2102605. [PMID: 35649192 DOI: 10.1200/JCO.21.02605] [Reference Citation Analysis]
|
| 886 |
Driggers KE, Sadowski BW, Shagla E, Kwok RM. Care of the Hepatology Patient in the COVID-19 Era. Curr Hepatology Rep 2022;21:9-20. [DOI: 10.1007/s11901-021-00581-x] [Reference Citation Analysis]
|
| 887 |
Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol 2022;76:1348-61. [PMID: 35589255 DOI: 10.1016/j.jhep.2022.01.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 888 |
Nong C, Guan P, Li L, Zhang H, Hu H. Tumor immunotherapy: Mechanisms and clinical applications. MedComm – Oncology 2022;1. [DOI: 10.1002/mog2.8] [Reference Citation Analysis]
|
| 889 |
Chen X, Li W, Wu X, Zhao F, Wang D, Wu H, Gu Y, Li X, Qian X, Hu J, Li C, Xia Y, Rao J, Dai X, Shao Q, Tang J, Li X, Shu Y. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. Front Oncol 2022;12:909035. [DOI: 10.3389/fonc.2022.909035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 890 |
Fu J, Qin W, Tong Q, Li Z, Shao Y, Liu Z, Liu C, Wang Z, Xu X. A novel DNA methylation-driver gene signature for long-term survival prediction of hepatitis-positive hepatocellular carcinoma patients. Cancer Med 2022;11:4721-35. [PMID: 35637633 DOI: 10.1002/cam4.4838] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 891 |
Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. Int J Clin Oncol 2022. [PMID: 35633441 DOI: 10.1007/s10147-022-02174-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 892 |
Qiu H, Ke S, Cai G, Wu Y, Wang J, Shi W, Chen J, Peng J, Yu B, Chen Y. An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma. Cancer Med 2023;12:213-22. [PMID: 35633045 DOI: 10.1002/cam4.4900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 893 |
Yano Y, Yamamoto A, Minami A, Momose K, Mimura T, Kim SK, Hayashi H, Kado T, Hirano H, Hirohata S, Yoon S, Nishi K, Tei H, Tanaka H, Oouchi S, Matsuura T, Yasutomi E, Hatazawa Y, Shiomi Y, Ueda Y, Kodama Y; Kobe Liver Conference (KLC). Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma. JGH Open. [DOI: 10.1002/jgh3.12772] [Reference Citation Analysis]
|
| 894 |
Morise Z, Aldrighetti L, Belli G, Ratti F, Cheung TT, Lo CM, Tanaka S, Kubo S, Okamura Y, Uesaka K, Monden K, Sadamori H, Hashida K, Kawamoto K, Gotohda N, Chen K, Kanazawa A, Takeda Y, Ohmura Y, Ueno M, Ogura T, Suh KS, Kato Y, Sugioka A, Belli A, Nitta H, Yasunaga M, Cherqui D, Halim NA, Laurent A, Kaneko H, Otsuka Y, Kim KH, Cho HD, Lin CC, Ome Y, Seyama Y, Troisi RI, Berardi G, Rotellar F, Wilson GC, Geller DA, Soubrane O, Yoh T, Kaizu T, Kumamoto Y, Han HS, Ekmekcigil E, Dagher I, Fuks D, Gayet B, Buell JF, Ciria R, Briceno J, O'Rourke N, Lewin J, Edwin B, Shinoda M, Abe Y, Hilal MA, Alzoubi M, Tanabe M, Wakabayashi G. An International Retrospective Observational Study of Liver Functional Deterioration after Repeat Liver Resection for Patients with Hepatocellular Carcinoma. Cancers (Basel) 2022;14:2598. [PMID: 35681578 DOI: 10.3390/cancers14112598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 895 |
Xiao LS, Hu CY, Cui H, Li RN, Hong C, Li QM, Huang CY, Dong ZY, Zhu HB, Liu L. Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer Med 2022;11:4880-8. [PMID: 35599583 DOI: 10.1002/cam4.4818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 896 |
Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Front Immunol 2022;13:913464. [DOI: 10.3389/fimmu.2022.913464] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 897 |
Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Karp SJ, Moriyama M, Kogure H. Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. Cancers 2022;14:2549. [DOI: 10.3390/cancers14102549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 898 |
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M. C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Sci Rep 2022;12:8421. [PMID: 35589772 DOI: 10.1038/s41598-022-12058-y] [Reference Citation Analysis]
|
| 899 |
Xu Q, Chen G, Chen G, Wu H, Yang Y, Mai Z, Sun R, Luan P, Guo C, Yu M, Peng Z, Yu Z. NO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performance. J Control Release 2022;347:389-99. [PMID: 35569586 DOI: 10.1016/j.jconrel.2022.05.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 900 |
Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 901 |
Alvarez M, Benhammou JN, Darci-Maher N, French SW, Han SB, Sinsheimer JS, Agopian VG, Pisegna JR, Pajukanta P. Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival. Genome Med 2022;14:50. [PMID: 35581624 DOI: 10.1186/s13073-022-01055-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 902 |
Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
|
| 903 |
Kothari G. Role of radiomics in predicting immunotherapy response. J Med Imaging Radiat Oncol 2022. [PMID: 35581928 DOI: 10.1111/1754-9485.13426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 904 |
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. J Immunother Cancer 2022;10. [PMID: 35577503 DOI: 10.1136/jitc-2021-004076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 905 |
Huge N, Reinkens T, Buurman R, Sandbothe M, Bergmann A, Wallaschek H, Vajen B, Stalke A, Decker M, Eilers M, Schäffer V, Dittrich-Breiholz O, Gürlevik E, Kühnel F, Schlegelberger B, Illig T, Skawran B. MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF. Cancer Cell Int 2022;22:192. [PMID: 35578240 DOI: 10.1186/s12935-022-02582-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 906 |
Rizzo A, Ricci AD. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Expert Review of Precision Medicine and Drug Development 2022;7:50-7. [DOI: 10.1080/23808993.2022.2075724] [Reference Citation Analysis]
|
| 907 |
Bang YH, Lee C, Yoo C, Chon HJ, Hong M, Kang B, Kim H, Park SR, Choi W, Choi J, Lee D, Shim JH, Kim KM, Lim Y, Lee HC, Ryu M, Ryoo B. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Ther Adv Med Oncol 2022;14:175883592210979. [DOI: 10.1177/17588359221097934] [Reference Citation Analysis]
|
| 908 |
Qu G, Wang D, Xu W, Guo W. Comprehensive Analysis of the Correlation Between Pyroptosis-Related LncRNAs and Tumor Microenvironment, Prognosis, and Immune Infiltration in Hepatocellular Carcinoma. Front Genet 2022;13:867627. [PMID: 35559014 DOI: 10.3389/fgene.2022.867627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 909 |
Sasaki R, Fukushima M, Haraguchi M, Honda T, Miuma S, Miyaaki H, Nakao K. Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e29289. [PMID: 35583540 DOI: 10.1097/MD.0000000000029289] [Reference Citation Analysis]
|
| 910 |
Jethwa KR, Hallemeier CL. Hepatobiliary Cancers. Principles and Practice of Particle Therapy 2022. [DOI: 10.1002/9781119707530.ch19] [Reference Citation Analysis]
|
| 911 |
Qian Y, Gong L, Li S, Mao K, Li X, Liao G. Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. Front Oncol 2022;12:879454. [DOI: 10.3389/fonc.2022.879454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 912 |
Machida K, Tahara SM. Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. Cancers (Basel) 2022;14. [PMID: 35625986 DOI: 10.3390/cancers14102381] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 913 |
Kim J, Byun HK, Kim TH, Kim SI, Kim BK, Kim SU, Park JY, Kim DY, Seong J. Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2022;14:2396. [PMID: 35626001 DOI: 10.3390/cancers14102396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 914 |
Falette Puisieux M, Pellat A, Assaf A, Ginestet C, Brezault C, Dhooge M, Soyer P, Coriat R. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Cancers (Basel) 2022;14:2357. [PMID: 35625962 DOI: 10.3390/cancers14102357] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 915 |
Zhang JX, Chen YX, Zhou CG, Liu J, Liu S, Shi HB, Zu QQ. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center. Can J Gastroenterol Hepatol 2022;2022:7982118. [PMID: 35586608 DOI: 10.1155/2022/7982118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 916 |
Zhou T, Zhang Y, Chen Y, Shan J, Wang J, Wang Y, Chang J, Jiang W, Chen R, Wang Z, Shi X, Yu Y, Li C, Li X. ROBO1 p.E280* Loses the Inhibitory Effects on the Proliferation and Angiogenesis of Wild-Type ROBO1 in Cholangiocarcinoma by Interrupting SLIT2 Signal. Front Oncol 2022;12:879963. [DOI: 10.3389/fonc.2022.879963] [Reference Citation Analysis]
|
| 917 |
Kudo M. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. Int J Clin Oncol. [DOI: 10.1007/s10147-022-02166-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 918 |
Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;:1-11. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Reference Citation Analysis]
|
| 919 |
Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Curr Oncol 2022;29:3259-71. [PMID: 35621656 DOI: 10.3390/curroncol29050266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 920 |
Huang PH, Yu J, Chu YY, Lin YH, Yeh CT. Child-Pugh Score and ABCG2-rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib. J Clin Med 2022;11. [PMID: 35566676 DOI: 10.3390/jcm11092550] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 921 |
Salman S, Meyers DJ, Wicks EE, Lee SN, Datan E, Thomas AM, Anders NM, Hwang Y, Lyu Y, Yang Y, Jackson W, Dordai D, Rudek MA, Semenza GL. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. Journal of Clinical Investigation 2022;132:e156774. [DOI: 10.1172/jci156774] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 922 |
Kurebayashi Y, Matsuda K, Ueno A, Tsujikawa H, Yamazaki K, Masugi Y, Kwa WT, Effendi K, Hasegawa Y, Yagi H, Abe Y, Kitago M, Ojima H, Sakamoto M. Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments. Hepatology 2022;75:1139-53. [PMID: 34657298 DOI: 10.1002/hep.32201] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 923 |
Dai X, Li X, Liu Y, Yan F. Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy. Materials & Design 2022;217:110656. [DOI: 10.1016/j.matdes.2022.110656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 924 |
Rushakoff JA, Shek L. Hepatocellular Carcinoma with Extensive Macrovascular Invasion. J Gen Intern Med 2022;37:1789-90. [PMID: 35031948 DOI: 10.1007/s11606-021-07346-8] [Reference Citation Analysis]
|
| 925 |
D'Avola D, Granito A, Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol 2022;76:1185-98. [PMID: 34793869 DOI: 10.1016/j.jhep.2021.11.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 926 |
Thompson SM, Suman G, Torbenson MS, Chen ZE, Jondal DE, Patra A, Ehman EC, Andrews JC, Fleming CJ, Welch BT, Kurup AN, Roberts LR, Watt KD, Truty MJ, Cleary SP, Smoot RL, Heimbach JK, Tran NH, Mahipal A, Yin J, Zemla T, Wang C, Fogarty Z, Jacobson M, Kemp BJ, Venkatesh SK, Johnson GB, Woodrum DA, Goenka AH. PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68) Ga-PSMA-11 PET Using Cyclotron-Produced (68) Ga. Hepatol Commun 2022;6:1172-85. [PMID: 34783177 DOI: 10.1002/hep4.1861] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 927 |
Carroll HK, Duffy AG, O'Farrelly C. Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink? Semin Liver Dis 2022;42:212-24. [PMID: 35263795 DOI: 10.1055/s-0042-1744143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 928 |
Narahara S, Watanabe T, Nagaoka K, Fujimoto N, Furuta Y, Tanaka K, Tokunaga T, Kawasaki T, Yoshimaru Y, Setoyama H, Oniki K, Saruwatari J, Tateyama M, Naoe H, Tanaka M, Tanaka Y, Sasaki Y. Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma. Hepatol Commun 2022;6:1198-212. [PMID: 34837478 DOI: 10.1002/hep4.1872] [Reference Citation Analysis]
|
| 929 |
Zhang S, Wang X, Gu H, Liu J. Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study. CMAR 2022;Volume 14:1715-27. [DOI: 10.2147/cmar.s359482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 930 |
Agirrezabal I, Brennan VK, Colaone F, Shergill S, Pereira H, Chatellier G, Vilgrain V. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. Adv Ther 2022;39:2035-51. [PMID: 35279814 DOI: 10.1007/s12325-022-02099-0] [Reference Citation Analysis]
|
| 931 |
Guiard E, Baldini C, Pobel C, Assi T, Bernard-tessier A, Martin-romano P, Hollebecque A, Verlingue L, Geraud A, Michot J, Armand J, Soria J, Massard C, Ammari S. Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. European Journal of Cancer 2022;167:42-53. [DOI: 10.1016/j.ejca.2022.02.024] [Reference Citation Analysis]
|
| 932 |
Castven D, Czauderna C, Becker D, Pereira S, Schmitt J, Weinmann A, Shah V, Hajduk J, Keggenhoff F, Binder H, Keck T, Heilmann-Heimbach S, Wörns MA, Thorgeirsson SS, Breuhahn K, Galle PR, Marquardt JU. Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes-Associated Protein 1 Activation and Transient Expansion of Stem-Like Cancer Cells. Hepatol Commun 2022;6:1140-56. [PMID: 34817932 DOI: 10.1002/hep4.1869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 933 |
Zhang X, Zhu XJ, Zhong Z, Du JC, Fang GX, Cui XL, Guan LT, Hu YY, Wang HY, Zhang PL. Small Molecule-Induced Differentiation As a Potential Therapy for Liver Cancer. Adv Sci (Weinh) 2022;9:e2103619. [PMID: 35343115 DOI: 10.1002/advs.202103619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 934 |
Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 935 |
Grinspan LT, Villanueva A. Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. Semin Liver Dis 2022;42:188-201. [PMID: 35738257 DOI: 10.1055/s-0042-1748924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 936 |
Sun G, Liu H, Shi X, Tan P, Tang W, Chen X, Sun G, Yang W, Kong X, Zheng Z, Cao H, Shao G. Treatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review). Int J Oncol 2022;60:74. [PMID: 35485291 DOI: 10.3892/ijo.2022.5364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 937 |
Trifylli E, Koustas E, Papadopoulos N, Sarantis P, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Karamouzis MV. An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. Life 2022;12:665. [DOI: 10.3390/life12050665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 938 |
Li L, Chen W, Wu G, Zhang Y. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study. Disease Markers 2022;2022:1-10. [DOI: 10.1155/2022/4322404] [Reference Citation Analysis]
|
| 939 |
Wu WC, Lin TY, Chen MH, Hung YP, Liu CA, Lee RC, Huang YH, Chao Y, Chen SC. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs 2022. [PMID: 35477812 DOI: 10.1007/s10637-022-01248-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 940 |
Tan X, Bednarsch J, Rosin M, Appinger S, Liu D, Wiltberger G, Garcia Vallejo J, Lang SA, Czigany Z, Boroojerdi S, Gaisa NT, Boor P, Bülow RD, De Vos-Geelen J, Valkenburg-van Iersel L, Clahsen-van Groningen MC, de Jong EJM, Groot Koerkamp B, Doukas M, Rocha FG, Luedde T, Klinge U, Sivakumar S, Neumann UP, Heij LR. PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. Cancers (Basel) 2022;14:2190. [PMID: 35565318 DOI: 10.3390/cancers14092190] [Reference Citation Analysis]
|
| 941 |
Salani F, Latarani M, Casadei-Gardini A, Gangadharannambiar P, Fornaro L, Vivaldi C, Pecora I, Massa V, Marisi G, Canale M, Ulivi P, Scartozzi M, Eccleston M, Masi G, Crea F. Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. Epigenomics 2022. [PMID: 35473355 DOI: 10.2217/epi-2021-0383] [Reference Citation Analysis]
|
| 942 |
Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Clark W, Gilroy K, Hedley A, Nixon C, Luli S, Laszczewska M, Pinyol R, Esteban-Fabró R, Willoughby CE, Haber PK, Andreu-Oller C, Rahbari M, Fan C, Pfister D, Raman S, Wilson N, Müller M, Collins A, Geh D, Fuller A, McDonald D, Hulme G, Filby A, Cortes-Lavaud X, Mohamed NE, Ford CA, Raffo Iraolagoitia XL, McFarlane AJ, McCain MV, Ridgway RA, Roberts EW, Barry ST, Graham GJ, Heikenwälder M, Reeves HL, Llovet JM, Carlin LM, Bird TG, Sansom OJ, Mann DA. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 2022;71:2093-106. [PMID: 35477863 DOI: 10.1136/gutjnl-2021-326259] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 31.0] [Reference Citation Analysis]
|
| 943 |
Fujiwara Y, Horita N, Harrington M, Namkoong H, Miyashita H, Galsky MD. Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03203-7] [Reference Citation Analysis]
|
| 944 |
Tsai YT, Li CY, Huang YH, Chang TS, Lin CY, Chuang CH, Wang CY, Anuraga G, Chang TH, Shih TC, Lin ZY, Chen YL, Chung I, Lee KH, Chang CC, Sung SY, Yang KH, Tsui WL, Yap CV, Wu MH. Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts. Oncogene 2022. [PMID: 35459781 DOI: 10.1038/s41388-022-02309-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] |
